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ABSTRACT 
Girls Clustering Epilepsy is the second most common developmental and epileptic 
encephalopathy. GCE is due to variants in the X chromosome gene PCDH19 and is 
underpinned by cellular mosaicism due to X-chromosome inactivation (XCI) in females 
or somatic variant in males. The hallmark feature is that seizures occur in clusters and 
mainly affect females. At the time of thesis submission, GCE was re-named “X-linked 
clustering epilepsy” (XCE) to accommodate the growing number of affected male cases. 
Seizures typically present as generalized tonic-clonic and/or focal, which may evolve to 
bilateral, tonic-clonic. The clinical profile includes variable cognitive impairment and 
psychiatric features. The prevalence of these comorbidities and cause of the variable 
clinical expressivity is unknown.    
We performed a systematic review and meta-analysis to identify the comorbidities 
associated with PCDH19 variants and examine phenotype- and genotype-phenotype 
associations. Data from 38 peer-reviewed original articles were used and included 271 
individual cases. We found that seizure onset ≤ 12 months was significantly associated (p 
= 4.127 x 10-7) with more severe intellectual disability compared with onset > 12 months. 
We identified two recurrent variants p.Asn340Ser and p.Tyr366Leufs*10, occurring in 25 
(20 unrelated) and 30 (11 unrelated) cases, respectively. PCDH19 variants were 
associated with psychiatric comorbidities in approximately 60% females, 80% affected 
mosaic males, and reported in nine hemizygous males. Executive dysfunction, and 
hyperactive, autistic, and obsessive-compulsive features were most frequently associated 
with PCDH19 variants. 
We developed a PCDH19 survey to systematically examine the comorbidities identified 
in our review using standardized neuropsychiatric assessments. The survey was 
completed by 122/186 (66%) participants diagnosed with GCE or with a confirmed likely 
pathogenic PCDH19 variant. Executive functions were measured using the Behavior 
Rating Inventory of Executive Function. Psychiatric comorbidities were assessed via the 
Social Responsiveness Scale or Social Communication Questionnaire, the Strengths and 
Difficulties Questionnaire, and the Dimensional Obsessive-Compulsive Scale. Genetic, 
seizure, and developmental information were also collected. Of the 112 evaluated 
participants (15 males), there were 70 unique variants. Thirty-five variants were novel 
ABSTRACT 
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and included a newly identified recurrent variant Ile781Asnfs*3. There were no 
phenotypic differences between published and unpublished cases. Seizures occurred in 
clusters in 94% individuals, with seizures resolving in 28% at an average age of 17.5 
years. Developmental delay prior to seizure onset occurred in 18% of our cohort. 
Executive dysfunction and autism spectrum disorder (ASD) occurred in approximately 
60% of individuals. The ASD profile included features of attention-deficit hyperactivity 
disorder. Obsessive-compulsive symptomology was observed in 21% individuals. There 
were no phenotypic differences between heterozygous females and mosaic males. We 
describe a mosaic male and two hemizygous males with atypical clinical profiles. Earlier 
seizure onset age and increased number of seizures within a cluster were associated with 
more severe clinical outcomes. No clinical profile was observed for transmitting males. 
The penetrance of GCE is incomplete; estimated to be around 80-90%, and might be 
explained by cellular interference. Cellular interference postulates that the coexistence of 
PCDH19 wild-type and variant cells would be pathogenic, whereas a homogenous cell 
population would be tolerated; an idea supported by the presence of asymptomatic 
PCDH19-negative hemizygous and symptomatic PCDH19-mosaic males. The cellular 
interference hypothesis was tested through analyses of GCE penetrant and non-penetrant 
female fibroblast cell lines using assays to determine XCI patterns and relative PCDH19 
cDNA expression. Specifically, we hypothesized that XCI and PCDH19 cDNA 
expression will be skewed towards complete wild-type or variant expression in non-
penetrant females.  
We have shown that XCI patterns do not correlate with relative PCDH19 cDNA 
expression in fibroblasts, thus invalidating use of this assay to infer PCDH19 expression. 
No clear association was observed between penetrance in XCE and the degree of variant 
and wild-type PCDH19 mRNA expression in skin fibroblasts. Although we were able to 
identify three non-penetrant females with 100% wild-type PCDH19 expression, we were 
unable to provide support for the mechanism of cellular interference through our finding 
clinical phenotypes in individuals with markedly skewed XCI. Neuropsychiatric disorders 
can be very responsive to early intervention; therefore, a better understanding of these 
comorbidities may help to inform treatment and ultimately lead to better developmental 
outcomes for individuals affected by GCE. We show that both seizure onset age and 
activity are associated with clinical outcomes. Clinicians can use this information to 
ABSTRACT 
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1.1 Navigation 
This thesis incorporates a combination of published work (Chapters 2, 3, 4, and 5), material 
submitted for publication (Chapter 6), and prepared for submission (Chapter 7). Each 
chapter is formatted as a stand-alone peer-reviewed article and thus some repetition exists 
with respect to background information across chapters in order to contextualize each 
study. To minimize repetition, the systematic review and meta-analysis forms the thesis 
introduction (Chapter 2) and thus provides a ‘big picture’ overview of the history of GCE 
and gaps in the knowledge base. The reader is directed to the individual manuscripts for 
specific literature review and methodologies employed. Formatting of each manuscript has 
been adjusted to maintain consistency throughout the thesis. Tables and figures appear 
within each chapter and all references relevant to all chapters are at the end of the thesis. 
1.2 Overview 
This research explored the heterogeneity associated with GCE. It was observed that 
variation existed within families with respect to the penetrance or clinical presentation 
associated with an identical genetic variant. GCE is caused by PCDH19 pathogenic variants 
and is expressed in a unique X-linked fashion whereby heterozygous females and mosaic 
males are affected and hemizygous males are unaffected. The aim of this work was to 
characterize and identify the cause of the variable penetrance and clinical expressivity 
associated with PCDH19 variants. It was also noted that, although seizures were refractory 
to medication, families describe the cognitive and behavioral problems as the most 
challenging aspects. A characterization of the cognitive and behavioral deficits associated 
with PCDH19 variants had yet to be established. We aimed to characterize the 
neuropsychiatric profile of GCE and provide an avenue for clinicians and families to access 
information about PCDH19 and GCE in real-time.  
This research represents the first to systematically characterize the neuropsychiatric profile 
of GCE using standardized assessments and utilizing a large international cohort. Further, 
this research is the first to establish a link between seizure frequency within a cluster, the 
timing of seizure onset, and clinical outcome. Individuals with a PCDH19 variant were 
eligible to participate in this research. Our work incorporated findings from both 
symptomatic and asymptomatic males and females of all ages. This represents a novel 
approach to understanding GCE, as previous research typically focused on penetrant 
      CHAPTER 1 
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individuals. Research exploring the clinical outcomes of GCE focused primarily on electro-
clinical features and intellectual disability (ID). There was no research into the specific 
areas of cognition affected nor was a broad-scale approach to identifying associated 
psychiatric comorbidities employed. Research in this area focused solely on symptoms 
associated with ASD. The key strengths of this study are 1) the use of a large international 
cohort, which grants the power to statistically examine differences between the various 
symptom presentation subgroups; 2) the use of standardized assessments to target a broad 
range of neuropsychiatric comorbidities and; 3) the use of patient fibroblast cells from both 
penetrant and non-penetrant females, which allows for targeted molecular comparisons.  
The aim of Study 1 (Chapter 2) was to identify the comorbidities frequently associated 
with GCE in the literature and examine potential associations of clinical and molecular 
factors with neuropsychiatric outcomes. I was interested in examining the prevalence of 
each profile, with a view to identifying the most appropriate neuropsychiatric assessments 
to validate these findings. Associations were tested using a linear regression model, 
factorial analysis of variance (ANOVA), and Student’s t tests. For the binary categorical 
outcome variable, chi-squared tests of independence were performed. Due to the nature of 
reported data (i.e., raw data not available), certain variables were re-classified to aid the 
analyses.  
In Study 2, (Chapters 3 and 6) I conducted similar analyses to that of Study 1, but with a 
difference in the way data were collected. I developed an online survey in three languages 
(English, Italian, and French). I collected demographic and clinical information via the 
Epilepsy Questionnaire (EQ), which was developed based on literature review and 
discussion with health professionals. I administered the following standardized 
neuropsychiatric assessments: the Behavior Rating Inventory of Executive function 
(BRIEF) for the assessment of executive dysfunction; the extended version of the Strengths 
and Difficulties Questionnaire (SDQ) for the assessment of behavioral difficulties, 
including ADHD; the Dimensional Obsessive-Compulsive Scale (DOCS) for the 
assessment of symptoms related to obsessive-compulsive disorder (OCD); and the Social 
Responsiveness Scale, second edition (SRS-2) for the assessment of symptoms related to 
ASD. As a French translation of the SRS-2 was not available, I also utilized the Social 
Communication Questionnaire (SCQ). Using a linear regression model, I validated the 
      CHAPTER 1 
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associations from Study 1 and identified an additional association. A characterization of 
the clinical profile associated with GCE was established and formed the basis for Study 3.  
In study 3 (Chapter 4) I used the data collected from Study 1 and 2, as well as information 
gleaned directly from health professionals to develop a PCDH19 gene page as part of the 
Human Disease Genes Website Series. This is an international library of websites for 
professional information about genes and copy number variances and their clinical 
consequences. The PCDH19 page will provide a platform for clinicians and families to 
share information and learn more about PCDH19. 
Study 4 (Chapter 5) explores the effectiveness of the anti-epileptic medication 
Levetiracetam. As seizures in GCE are refractory to treatment, the identification of 
efficacious treatments is crucial. Through clinical practice, we noted remarkable seizure 
control with Levetiracetam for several girls with drug resistant GCE. Here, I report the 
impact of Levetiracetam on girls with GCE in two cohorts: a research cohort obtained 
through our collaborators in which detailed historical clinical information was available 
and an international cohort of individuals with PCDH19 variants who were surveyed via 
the PCDH19 survey from Study 2.   
The final study (Chapter 7) explores biological factors associated with penetrance in GCE. 
I analyzed skin fibroblasts of 13 penetrant and non-penetrant GCE females to determine 
XCI patterns, relative wild-type to variant PCDH19 cDNA expression, and protein levels. 
Where available, biological data were compared to clinical information obtained from the 
PCDH19 survey in Study 2. 
The thesis concludes with a general discussion (Chapter 8) which summarises the main 
findings, incorporates these with recent research in the field, discusses clinical implications, 
considers study limitations, and presents suggestions for future research.  
      CHAPTER 2 
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2.1 Preamble 
This thesis explores the variable clinical and molecular expressivity associated with 
PCDH19 variants. To date, there have been no factors identified to explain the variable 
clinical expression observed among related individuals with identical variants. Further, no 
biological factors have been identified to explain the variable penetrance. An exploration 
of such factors could not be undertaken without first characterizing the clinical profile 
associated with PCDH19 variants. A challenge for researchers is accessing a cohort that 
is spread around the world. Trying to evaluate each individual via a face-to-face 
assessment would not only be time-consuming and costly, it would be near impossible. 
Moreover, research settings are often constrained by available resources and time, 
therefore highlighting the need for tools that can be administered quickly and easily. 
Standardized assessments can be systematically administered by different researchers in 
different contexts. They can also be administered online, which makes them a quick and 
easy way to obtain information, particularly if respondents are spread geographically. All 
the assessments that were incorporated into the PCDH19 survey demonstrated excellent 
validity and reliability, as well as adequate sensitivity and specificity – some comparable 
to gold standard clinical assessment. Through the survey, I was able to reach 112 
individuals from countries such as the USA, New Zealand, Canada, Italy, France, and 
Denmark. 
The aim of this introduction is to provide an overview of the PCDH19 literature to 
support the research questions and aims explored in the subsequent chapters. The 
introduction is a systematic review and meta-analysis that has been published in the peer-
review journal Molecular Psychiatry. I begin by describing GCE and discuss the limited 
information available with relation to the comorbidities associated with GCE. I highlight 
the importance of establishing a clinical profile to assist with diagnosis, treatment, and 
our ability to identify potential associations. This is followed by a systematic review of 38 
peer-reviewed original articles and a meta-analysis incorporating studies that included 
information regarding cognitive function or the degree of impairment, or the presence or 
type of psychiatric comorbidity. Findings from this work form the basis for the 
subsequent studies. 
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Abstract  
Epilepsy and Mental Retardation Limited to Females (EFMR) is an infantile onset disorder 
characterized by clusters of seizures. EFMR is due to variants in the X chromosome gene 
PCDH19 and is underpinned by cellular mosaicism due to XCI in females or somatic 
variant in males. This review characterizes the neuropsychiatric profile of this disorder and 
examines the association of clinical and molecular factors with neuropsychiatric outcomes. 
Data were extracted from 38 peer-reviewed original articles including 271 individual cases. 
We found that seizure onset ≤ 12 months was significantly associated (p = 4.127 x 10-7) 
with more severe ID compared with onset > 12 months. We identified two recurrent variants 
p.Asn340Ser and p.Tyr366Leufs*10, occurring in 25 (20 unrelated) and 30 (11 unrelated) 
cases, respectively. PCDH19 variants were associated with psychiatric comorbidities in 
approximately 60% of females, 80% of affected mosaic males, and reported in nine 
hemizygous males. Hyperactive, autistic, and obsessive-compulsive features were most 
frequently reported. There were no genotype-phenotype associations in the individuals with 
recurrent variants or the group overall. Age at seizure onset can be used to provide more 
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Introduction 
Epilepsy and Mental Retardation Limited to Females (EFMR; OMIM #300088) was first 
described in 1971 by Juberg and Hellman as an early onset seizure disorder triggered by 
febrile illness, and with female-limited expression.1 The causative gene was identified in 
2008 by Dibbens et al. in a study that involved six new EFMR families, as well as the 
original EFMR family reported by Juberg and Helman.2 In the same year EFMR was further 
characterized as a neurological disorder with a markedly varied neuropsychiatric profile 
including ID, and aggressive, autistic, or obsessive features.3 In 2009 Depienne et al. 
identified PCDH19 variants in sporadic cases with an infantile developmental and epileptic 
encephalopathy resembling Dravet Syndrome (DS).4 Males have since been identified who 
are cellular mosaics for the PCDH19 gene with a similar clinical profile to affected 
females,4-6 thus challenging the dogma that this is a disorder limited exclusively to females. 
The hallmark feature of PCDH19-associated epilepsy is that seizures occur in clusters. We 
therefore proposed “Girls Clustering Epilepsy” (GCE) as a name to facilitate clinical 
identification of this disorder.7 Seizures typically present as generalized tonic-clonic and/or 
focal seizures, which may evolve to bilateral, tonic-clonic seizures. An additional unifying 
feature of GCE is cellular mosaicism, either due to XCI in females or early somatic variant 
and, as such, somatic mosaicism in males.  
GCE is associated with a reduction or remission of seizures during adolescence.3, 8, 9 
Unfortunately, neuropsychiatric dysfunction remains, often exacerbating with age and 
becoming the most prominent and disabling feature in some patients.10-12 ID ranging from 
mild to profound is present in approximately 70% of cases.13 The prevalence of psychiatric 
comorbidities is unknown, however, reports suggest that ASD is a common feature in both 
females14-16 and males.17 Intriguingly, no association has been established between the 
severity of epilepsy and ID.9, 10 Here we conduct a comprehensive and systematic review of 
the GCE literature, specifically focusing on the neuropsychiatric profile and examine if 
associations exist between age at seizure onset, variant type, variant location, or mode of 
inheritance and cognitive function or psychiatric comorbidity. Determining factors that 
contribute to clinical outcome will be useful for prognostic counseling. 
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Method 
Inclusion Criteria 
Studies were included if they met the following criteria: 1) reported the cDNA or protein 
change, 2) were peer-reviewed and written in English, and 3) were original cases only. To 
be included in the meta-analysis, information regarding cognitive function or the degree of 
impairment, or the presence of or type of psychiatric comorbidity was also required.  
Search Strategy 
A computerized search of public databases Embase, PubMed, Google Scholar, and Scopus 
from January 2008 to August 2017 was conducted. Search terms were as follows: pcdh19, 
pcdh 19, protocadherin19, and protocadherin 19. Full text articles of abstracts were then 
selected, retrieved, and assessed for eligibility considering established criteria detailed 
above. Inclusion was based on final consensus between two authors. Authors were contacted 
via email if further information or clarification was required. The reference lists of all 
articles selected for review and the full texts of potentially relevant studies were also 
examined.  
Data Extraction 
All relevant data were extracted from selected articles and imported into a Statistical 
Program for the Social Sciences (SPSS) dataset. Data were cleaned and cross-checked to 
ensure that no individual was recorded more than once.  
Excluding Duplicates 
To minimise bias through the reporting of the same individual from multiple publications, 
we used the following information to identify duplicates: variant (cDNA or protein change) 
and age at seizure onset. As additional measures, we also used the age at study and 
inheritance information to further confirm the likelihood that a case was the same across two 
or more publications. The supplementary file “raw data” lists all reviewed cases with a 
double asterisk against cases identified as duplicates. Once a potential duplicate was 
identified, the most recent duplicated information for that individual was included in the 
review and all references were assigned to that individual. For example, case 68 and 172 in 
the raw data are flagged as potential duplicates. Both cases are reported as having a de novo 
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c.2097dupA variant and an age at seizure onset of 7 months. In addition, the age of the 
individual when reported satisfies the expected change based on publication dates (11 
months; 2010 and 2 years 2 months; 2012). If there was a slight discrepancy between 
suspected duplicates, caution was taken, and the suspected duplicate was removed. For 
example, case 110 and 187 in the raw data file are flagged as potential duplicates. Both 
cases are reported as having the c.1298T>C variant, however with an age at seizure onset of 
9 months and 7 months, respectively. As additional information such as age at study and 
inheritance satisfies the assumption of a duplicate, the case was only included once in this 
review. 
Data Coding 
Initially, certain variables were re-classified to aid analyses. Seizure onset was classified as 
follows: (0) “early” (≤ 12 months) or (1) “late” (> 12 months). Variant type was classified 
as follows: (0) “truncating” or (1) “missense”. Other variants were too infrequent and, as 
such, were excluded from the analyses. Variant location was classified as (0) “early” (EC1 
to EC3) or (1) “late” (EC4 to cytoplasmic) and inheritance as (0) “sporadic” or (1) 
“familial”. The first dependent variable (cognitive function) was scored on a scale: (0) 
“normal”, (1) “borderline”, (2), “mild ID”, (3) “moderate ID”, or (4) “severe/profound 
ID”, with higher scores indicating increased ID severity. Information regarding the degree 
of ID was extracted from reports only if explicitly stated and where a report indicated a 
range, i.e., moderate to severe ID, classification was based on the more severe category. 
Given that the number of levels of cognitive function exceeded four, this variable was 
upgraded to continuous.18 The second dependent variable (psychiatric comorbidity) was 
scored as follows: (0) “no psychiatric features reported”, (1) “psychiatric features 
reported”. Reports that did not cover this aspect of the clinical profile were coded “N/A” 
and excluded from the analyses. 
Missing Data 
Full-scale intelligence quotient (FSIQ) scores were rarely reported. Generally, reports 
involved reference to the classification of normal, borderline, mild ID, moderate ID, severe 
ID, or profound ID. As such, this classification was adopted for analytical purposes. There 
were some instances where developmental quotients were provided. Although early 
developmental quotient testing has been shown to correlate with later IQ,19 they are not the 
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same. Therefore, a classification could not be attributed to these cases and, as such, they 
were excluded from the analysis. If data were missing from any of the other variables in the 
meta-analysis, the case was excluded to prevent an over or under-estimation of the true 
nature of any association. In total, 131 cases were represented in the meta-analysis. 
Data Analyses 
Continuous data were analyzed using SPSS version 24 and followed significant effects (p ≤ 
.05) using a linear regression model, factorial ANOVA, and Student’s t tests. For the binary 
categorical outcome variable, chi-squared tests of independence were performed. 
Descriptive statistics, scatterplots, and histograms were generated for all variables used in 
the analyses to ensure data met criteria for the use of parametric tests. While the normality 
assumption within the levels of certain independent variables was not met, there were more 
than 30 cases in each group and, as such, parametric tests could be utilized.20 Furthermore, 
non-parametric tests yielded the same results for all parametric tests performed. 
PCDH19 Reference Sequences 
All PCDH19 cDNA and protein were based on the following reference sequences, which 
represent the longest isoform of the PCDH19 mRNA and protein: NM_001184880 and 
NP_001171809 (https://www.ncbi.nlm.nih.gov/). 
Results 
Thirty-eight studies, with a total of 297 cases met inclusion criteria. After excluding 
duplicates, there were a total of 271 individuals comprising 12 (4.4%) males and 259 
(95.6%) females. Two males were excluded from the meta-analysis as they harbored 
hemizygous PCDH19 variants and exhibited a phenotype that was not characteristic of 
GCE. All ten mosaic males are included in all descriptive and statistical analyses and did not 
differ significantly from females on the outcome measures tested (cognitive function: t(193) = 
-0.33, p = .745; psychiatric comorbidity: χ2(1, n=230) = 1.99, p = .158). The mean age at time 
of study (n = 235) was 13.0 years (SD = 12.1, range = 1 to 79 years). The average age at 
seizure onset (n = 219) was 11.9 months (SD = 9.0, median = 10 months, range = 1 to 70 
months, see Supplementary Fig. 2.1), with seizure onset precipitated by fever in 81.1% of 
cases where this information was available (see Supplementary Table 2.1). 
PCDH19 Variant 
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The PCDH19 gene is located at Xq22.1, and its coding sequence consists of six exons. The 
gene encodes a 1,148 amino acid protein with typical features of the δ2-protocadherin sub-
family, with 23 amino acid signal peptides, six conserved cadherin repeats in the 
extracellular cadherin domain (EC), a transmembrane domain, and conserved motifs (CM1-
CM2) in the C-terminal region.2, 21 The first exon encodes the EC and transmembrane 
domains, as well as a small portion of the C-terminal region. While the rest of the C-
terminal region is encoded by exons 2-6, the second, and likely third, exon is subjected to 
alternative splicing. Exon 5 and 6 encode for CM1 and CM2, respectively. The majority of 
reported GCE variants were observed in the EC domain of the protein encoded by exon 1 
(86.7%; Fig. 2.1). Of the reported variants in this region, almost half were located in the 
EC3 and EC4 domains (20.3% and 23.2%, respectively; see Supplementary Table 2.2). 
Missense variants were the most frequently reported type of GCE variant (45.4%), followed 
by frameshift (27.3%), and nonsense (19.6%; see Supplementary Table 2.3). In total, 145 
unique germline PCDH19 variants were identified in GCE, both in large families as well as 
singleton cases (see Supplementary Table 2.4 for a complete list). 
 
Figure 2.1 Lollipop plot illustrating all reviewed GCE variants (n = 271). Lollipop size is exponentially proportional to the 
number of times the variant has been observed. Recurrent (i.e., seen more than once in unrelated individuals) variants are 
located above the protein and labelled if they occur more than twice. 
Mode of inheritance. GCE was originally recognized as a familial disorder.1, 3, 22 However, 
in recent years a significant number of sporadic cases have been identified due to next 
generation sequencing, with over half of reported GCE cases arising de novo (50.2%; 
Supplementary Table 2.5). Interestingly, there were a considerable number of maternally 
inherited variants (18.7%). The penetrance of GCE has been estimated as greater than 90%, 
however, recent reports of asymptomatic carrier mothers11, 12, 23 would suggest this is 
somewhat lower. The difficulty in determining penetrance lies in the definition. Some 
studies define unaffected individuals by a complete absence of symptoms,10, 11 while others 
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refer to an individual as being unaffected if they only had a brief history of infantile 
seizures.3, 11, 24 Based on the inclusion of all reports where a variant has been maternally 
inherited, we estimated the penetrance of GCE to be 80%. This may still be conservative 
given this number is based only on reported cases in which mothers have been tested.  
Recurrent variants. Previous reports have identified p.Asn340Ser to be a recurrent 
variant.5, 22 The present study has validated and extended this further by identifying 25 (20 
unrelated) GCE cases (Table 2.1). Another recurrent variant (p.Tyr366Leufs*10) reported in 
30 (11 unrelated) GCE cases was also identified (Table 2.2). Of the 25 patients with a 
p.Asn340Ser variant, almost half (40.0%, 10/25) had normal or borderline cognitive 
function, 28.0% (7/25) had mild or moderate ID, with the remaining 32.0% either unclear 
(6/25) or not reported (2/25; Figure 2.2a). Further, psychiatric comorbidities primarily 
included autistic or hyperactive features, or both, with over half of cases reported as having 
no psychiatric comorbidity (55.0%, 11/20). Psychiatric reports were not specified for five 
cases. Of the 30 patients with a p.Tyr366Leufs*10 variant, just over a quarter (26.7%, 8/30) 
had normal cognitive function, 23.3% (7/30) had mild or moderate ID, and 26.7% (8/30) 
had severe or profound ID, with the remaining 23.3% either not reported (5/30) or not 
specifying the degree of ID (2/30; Figure 2a). Psychiatric comorbidities were predominantly 
hyperactive (36.7%, 11/30), with one third of cases reported as having no psychiatric 
comorbidity (33.3%, 10/30). Psychiatric reports were not specified for three cases. 
Neuropsychiatric Profile 
Cognitive function. The cognitive profile associated with GCE (n = 195) was found to be 
highly heterogeneous, ranging from normal cognitive function (28.2%), to borderline 
(5.1%), mild (27.2%), moderate (22.1%), or severe to profound (17.4%) ID (see 
Supplementary Table 2.6). We observed that development prior to the onset of seizures was 
reported to be delayed in approximately 15% of cases.  
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Table 2.1 PCDH19 variant: p.Asn340Ser (c.1019A>G) 
# Age at 
study 











 Age Type Fever+/- 
____________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
1 3.5y 9m GTCS + FS, SE + Controlled De novo + Mild None 4 
2 6y 8m FS NS GTCS + Ongoing De novo + Mild BD 4 
3 44y 8m TCS NS - NS 17y Unknown NS Normal NS 8a 
4 16y 6m FS + TCS, SE + NS Maternal NS Mild No autistic traits* 8, 25a 
5 11y 10m FS + - + NS De novo + Moderate No autistic traits* 8, 25 
6 7.5y 12m FBTCS + - + Ongoing De novo NS Normal None 9 
7 6y 13m TCS NS NS NS Ongoing #Maternal NS Moderate Autism 11b 
8 3y 17m TCS NS NS NS NS #Maternal + NS NS 11b 
9 NS 12m NS NS NS NS 14y De novo NS Normal None 11b 
10 5y 13m FS NS FBTCS + Ongoing De novo NS Normal None 26c 
11 5y 25m GTCS - None - 25m De novo NS Normal None 26c 
12 NS NS NS NS NS NS NS Unknown NS NS NS 22 
13 32y 15m NS - FS, GTCS, SE - NS Unknown NS Mild ASD 27 
14 5.5y 10m FS NS - NS NS De novo NS Borderline Psychosis, EtD, no autistic traits* 25 
15 10y 5m FS NS - NS NS De novo NS DQ 72 (NS) Autistic traits* 25 
16 8y 12m FS NS - NS NS #Maternal NS Normal No autistic traits* 25 
17 8y 11m CS + NS + 5.5y #Maternal - Normal None 23d 
18 NS N/A N/A N/A N/A N/A N/A NS - Normal None 23d 
19 6y 15m HCS + TCS, FS, TS, SE + Ongoing Unknown NS Moderate Autistic, hyperactive 16 
20 8y 5m FS, TS + - + Ongoing De novo NS DQ 44 (7y4m) NS 28 
21 5.5y 8m TCS, FS + - + Ongoing Maternal NS DQ 38 (4y7m) Autistic, hyperactive 28 
22 NS NS NS + NS + NS De novo NS NS NS 5^ 
23 9y 7m GTCS NS FS + Ongoing De novo NS Yes Autism, aggression 24 
24 3y 8m GTCS NS FS, MCS + Ongoing Maternal NS Yes Autism, aggression 24 
25 7y 18m GTCS NS - + Ongoing De novo NS Normal None 24 
____________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
Abbreviations: GTCS, generalized tonic-clonic seizure; FS, focal seizure; SE, status epilepticus; BD, behavioral disturbances; NS, not specified; TCS, tonic-clonic seizure; FBTCS, focal-to-bilateral seizure; ASD; 
autism spectrum disorder; MCS, myoclonic seizure; EtD, eating disorder; CS, clonic seizure; N/A, not applicable; HCS, hemiclonic seizure; TS, tonic seizure 
#asymptomatic female; abcdfamilial relationships (amother/daughter; bmother/daughters; ctwins; dmother/daughter) 
*Information obtained from the author 
^Reported as p.Asn370Ser___________________________________________________________________________________________________________________________________ 
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Table 2.2 PCDH19 variant: p.Tyr366Leufs*10 (c.1091dupC or c.1091_1092insC) 
# Age at 
study 













Age Type Fever+/- 
_______________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
1 23y 18m TCS NS NS NS NS Paternal NS Profound Hyperactive 1, 2, 29a 
2 22y NS NS NS NS NS NS Paternal NS Normal*** None 1, 2, 29a 
3 21y NS NS NS NS NS NS Paternal NS Normal*** None 1, 2, 29a 
4 20y NS NS NS NS NS NS Paternal + Mild Hyperactive 1, 2, 29a 
5 22y NS NS NS NS NS NS Paternal NS Normal*** None 1, 2, 29a 
6 18y NS NS NS NS NS NS Paternal NS Normal*** None 1, 2, 29a 
7 8y NS NS NS NS NS NS Paternal NS Normal*** None 1, 2, 29a 
8 14y NS NS NS NS NS NS Paternal NS Severe** Hyperactive 1, 2, 29a 
9 12y NS FS NS AS, GTCS NS NS Paternal NS Normal*** None 1, 2, 29a 
10 11y NS NS NS NS NS NS Paternal NS Normal None 1, 2, 29a 
11 14y NS NS NS FS, GTCS NS NS Paternal NS Profound Hyperactive 1, 2, 29a 
12 8y NS NS NS NS NS NS Paternal NS Moderate Hyperactive 1, 2, 29a 
13 6y NS NS NS NS NS NS Paternal NS Moderate** Hyperactive 1, 2, 29a 
14 6y NS NS NS NS NS NS Paternal NS Severe Hyperactive 1, 2, 29a 
15 5y NS NS NS NS NS NS Paternal NS Severe Hyperactive 1, 2, 29a 
16 2y NS NS NS NS NS NS Maternal NS Mild None 1, 2a 
17 2y NS NS NS NS NS NS Maternal NS NS None 1, 2a 
18 ≥5y 4m GTCS - AS, FS, SE NS Ongoing Maternal + Severe BD, hyperactive, impulsive 2, 29, 30a 
19 NS 7m NS NS NS NS NS Maternal NS NS NS 2, 29, 30a 
20 NS 14m NS + NS NS NS Paternal NS NS NS 2, 29, 30a 
21 14y 7m GTCS NS - + 11y Paternal + Severe Hyperactive 26^ 
22 NS NS NS NS NS NS NS De novo NS NS NS 22 
23 7.5y 17m FS NS - NS NS De novo NS Mild Autistic traits* 25 





NS - - Ongoing 
De novo + Normal AD, hyperactive, No ASD* 25, 31 
26 13y 17m TCS - - + 12y De novo NS Moderate Autistic traits 16 
27 8y 5m FS + TS + Ongoing Unknown NS Mild Impulsive 28^ 
28 1y 6m FS NS GTCS + Ongoing De novo NS Yes None 24 
29 4y 11m GTCS, FS NS FS + Ongoing De novo NS Yes AD 24 
30 7y 7m NS NS GTCS, SE + NS Unknown NS Severe Autistic traits* 32 
__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
Abbreviations: FBTCS, Focal to bilateral seizure; FS, focal seizure; NS, not specified; AD, attention-deficit; GTCS, generalized tonic-clonic seizure; AS, absence seizure; DB, destructive behavior; SE, 
status epilepticus; TS, tonic seizure; TCS, tonic-clonic seizure 
aOriginal EFMR family 
*Information obtained from author; **Reliable observer reports; ***Based on level of education attained; ^Reported as c.1300_1301insC 
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Psychiatric comorbidities. Of the 213 cases where psychiatric information was provided, 
autistic features were most prominent (19.7%) followed by hyperactive and/or attention-
deficit (11.7%), and behavioral disturbances (6.1%). Many reports described individuals 
with multiple psychiatric comorbidities (21.6%) that predominantly included combinations 
of autistic, aggressive, hyperactive, and/or obsessive features (see Supplementary raw data 
https://www.nature.com/articles/s41380-018-0066-9#Sec23 for a complete list). 
Genotype-Phenotype Association 
To determine if age at seizure onset, variant type, variant location, and mode of inheritance 
were associated with cognitive function, a linear regression was performed. Age at time of 
study was also included in the model as a covariate to control for any confounding effects 
that age may have on the severity of reported ID.33 Of all the variables tested in the model, 
only age at seizure onset was significantly associated with cognitive function (p = 4.127 x 
10-7; Figure 2.2b). Specifically, individuals with an early seizure onset had an average ID 
severity that was 1.3 units greater than individuals with a late seizure onset, holding other 
predictors in the model constant (estimate = 1.30, 95% CI: 0.80, 1.80; Table 2.3). A 
factorial ANOVA was then performed to ascertain whether variant type or variant location 
were associated with seizure onset. No significant associations were found (Table 2.4).    
 
Figure 2.2 Genotype-phenotype association. (a) Circos plot illustrating the variable cognitive profile of GCE (n = 155) 
against age at seizure onset: ≤12 months (n = 124) and >12 months (n = 48). Recurrent variants p.Asn340Ser (n = 17) and 
p.Tyr366Leufs*10 (n = 23) are highlighted in red and blue, respectively. Axes show the number of individuals in each 
category. Illustration is representative of cases where relevant information was available. (b) Bar graph (±SEM) illustrating 
the association of age at seizure onset and ID severity (values from unadjusted linear model) ***p = 3.090 x 10-7. 
a 
b 
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Table 2.3 Estimated marginal means (controlling for covariates) 
Age at seizure onset Mean ID severity Standard Error 
_________________________________________________________________________________________________________ 
≤12 months (“early”) 2.2 0.1 
>12 months (“late”) 0.9 0.2 
NB: Scale: (0) “normal”, (1) “borderline”, (2), “mild ID”, (3) “moderate ID”, and (4) “severe/profound ID” 
Non-Significant Associations 
To determine if any predictor variable was associated with the presence of a psychiatric 
comorbidity a series of Pearson’s chi-squared tests of independence were performed. There 
was a trend towards earlier seizure onset being associated with the presence of a psychiatric 
comorbidity, χ2(1, n=205) = 3.01, p = .083, however this was not statistically significant. All 
other tested associations were non-significant (Table 2.4).  
Table 2.4 Non-significant associations 
 Psychiatric comorbidity Age at seizure onset 
________________________________________________________________________________________________________________________________________________ 
Variant Type  
Truncating versus missense 
 
χ2 (1, n=210) = 0.46, p = .497 
 
F(195) = 0.41, p = .523 
Variant Location  
Early versus late 
 
χ2 (1, n=216) = 0.08, p = .778 
 
F(195) = 0.49, p = .487 
Inheritance  
Sporadic versus familial 
 




PCDH19 Mosaic Males 
There have been ten reported cases of PCDH19 variants causing a GCE-like phenotype in 
males. PCDH19 variants were initially thought to only affect females, however, in 2009 
Depienne and colleagues4 described a SCN1A-negative male diagnosed with DS as having a 
de novo deletion on chromosome Xq22.1 that spanned the entire PCDH19 gene. Using 
fluorescence in situ hybridization, the mosaic status of this PCDH19-variant male was 
confirmed, with a “normal” PCDH19 allele detected in 53% of skin fibroblasts. A second 
case was described by Thiffault et al., (2016).6 Sanger sequencing revealed an exon 1 
protein truncating variant in a mosaic status that was associated with focal myoclonic as 
well as TCS, at the age of 9 months. Two additional mosaic males were recently reported by 
Terracciano et al. (2016).5 The first, a 4-year-old boy, presented with an afebrile hypotonic 
seizure at the age of 9 months. The second, a 3.5-year-old boy, presented with a 24 h cluster 
of febrile seizures at the age of 10 months. Multigene panel revealed an exon 1 nonsense 
and missense substitution in each case, respectively. Recently, a male mosaic for a PCDH19 
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missense variant believed to affect the canonical splice donor site in the first intron 
(c.2147+2 T>C) was reported34, as well as an additional five males.17 All six males 
exhibited a clinical profile corresponding to the female phenotype. Nine of the ten reported 
PCDH19 mosaic males have been described as having comorbid psychiatric features.4-6, 17, 34 
For example, the case described by Thiffault and colleagues6 involved a young boy with 
behavioral disturbances (i.e., aggression and rigidity) that became evident by the age of 3 
years. At the time of the study he had been diagnosed with ADHD, anxiety, OCD, and 
oppositional defiant disorder. All cases of affected males with a normal complement of sex 
chromosomes have arisen de novo, suggesting that a somatic PCDH19 variant during early 
development resulted in a mixed population of PCDH19 variant and wild-type cells, and 
therefore cellular expression resembling that of an affected female.  
PCDH19 Transmitting Males 
It is generally considered that hemizygous or “transmitting” males are unaffected or 
asymptomatic.1, 2, 29 While epilepsy has not been reported in these males, there is some 
evidence to suggest that there is a mild phenotype associated with this transmitting status in 
males. The first indication of such arose from the observations of Scheffer et al. in 2008.3 In 
this study, five males were all described as inflexible, having rigid, controlling personalities, 
and obsessive interests and traits (e.g., obsessively repeating details in conversation). Such 
characteristics are particularly common in ASD (e.g., inflexibility) and OCD (e.g., repetitive 
behaviors). In addition, some transmitting fathers of affected daughters have varying 
degrees of ID.4, 16 Lastly, PCDH19 variants have been reported in a male with autism35, a 
male with Asperger’s syndrome16, and two males with ID.36 These reports suggest that a 
psychiatric profile may be evident in some transmitting males and that PCDH19 is involved 
in other neurodevelopmental disorders. 
Discussion 
This review is the first to systematically characterize the reported neuropsychiatric profile of 
GCE and examine any associations between clinical and molecular factors and 
neuropsychiatric outcomes. We have demonstrated that an earlier seizure onset is 
significantly associated with more severe ID. We have also shown that there is no 
association between the type and location of a PCDH19 variant and seizure onset and 
confirmed that onset is often precipitated by fever. Although the association of early seizure 
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onset with more severe ID may simply reflect the underlying severity of the disorder in that 
individual, it is also possible that the early seizure activity may be contributing to adverse 
cognitive and behavioral outcomes. There are “critical periods” of development during 
which the brain undergoes changes that are crucial to the formation of certain behaviors and 
various cognitive processes.37, 38 Functional changes in frontal cortical brain regions, in 
particular, coincide with cognitive and behavioral alterations known to occur during early 
development.37, 39 We have observed that a majority of first seizures in GCE occur at a 
median age of 10 months. It is at this time that the frontal cortex shows an increase in 
glucose metabolism,40 with total brain volume increasing by 101% in the first year of life.41 
There is also a rapid elaboration of new synapses in the first 2 years of life that corresponds 
to an increase in cortical grey matter.42, 43 The frontal cortex is involved in a diverse range of 
functions that can be broadly referred to as “cognition”.44 Injury to this region has been 
associated with deficits in executive functions (i.e., attention), as well as psychiatric 
conditions including schizophrenia, depression, and OCD.44 It is therefore reasonable to 
speculate that seizure activity within the first 12 months of life may be more likely to disrupt 
neural development and lead to cognitive dysfunction.  
Given the clinical similarities involving age at seizure onset and fever sensitivity shared by 
GCE and DS, we investigated whether a similar association between ID severity and age at 
seizure onset has been demonstrated in the Dravet literature. Brunklaus et al., (2012) 
demonstrated an association between early focal seizures with impaired awareness ≤24 
months (yes/no) and worse developmental outcome.33 Patients with DS with the highest 
seizure burden are reported to also suffer from more comorbidities.45 Recently it has been 
shown that, in children with SCN1A variants, early seizure onset related to DS rather than 
GEFS+.46 Conversely, we recently defined a new profound SCN1A developmental and 
epileptic encephalopathy far more severe than DS, that is associated with an even earlier (6-
12 weeks) seizure onset.47 
Considering this question from a different perspective, McIntosh et al., 2010 investigated 
whether seizure onset in DS triggered by vaccination (called vaccination proximate) had a 
more severe clinical outcome than patients whose seizure onset was not related to 
vaccination (vaccination distal). The two groups differed significantly in the average age at 
seizure onset, with onset being earlier by approximately 8 weeks in the vaccination 
proximate group.48 As there are anecdotal reports of vaccination triggering seizures in GCE, 
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it would be interesting to ascertain whether GCE demonstrates a similar association between 
vaccination and age at seizure onset. 
We also identified two recurrent variants, p.Asn340Ser and p.Tyr366Leufs*10. Both 
recurrent variants are found at a similar location within the PCDH19 gene, suggesting that 
this region may be vulnerable to or selected for genetic variant. Recurrent variants provide 
some scope for determining a genotype-phenotype association. We have been able to utilize 
the recurrence of these two variants to demonstrate for the first time that there is no 
association between these specific PCDH19 variants and the type and/or severity of 
symptoms, at least at a qualitative level. However, it is feasible to postulate that a milder 
phenotype may be associated with the p.Asn340Ser variant. Additional cases would help 
draw a more definitive conclusion. Heterogeneity is typically observed among related 
individuals, suggesting that other mechanisms, such as hormones49, 50, XCI51 or other 
genetic or environmental factors may be the underlying explanation for the variable clinical 
expressivity associated with GCE. One interesting finding that emerged was the absence of 
any paternally inherited p.Asn340Ser variants. Complete pedigree information regarding 
these cases will help determine if this is, in fact, a true observation. Additionally, the 
annotation of p.Tyr366Leufs*10 varied in the literature. As such, there may be additional 
variants that have been reported across multiple individuals and families that have not been 
correctly identified. Such additional recurrent cases will allow for more detailed quantitative 
analyses. 
This review has revealed that the neuropsychiatric profile of GCE varies considerably across 
individuals and within families. Current reports concerning psychiatric comorbidities in 
GCE are incomplete. This review provides some insight into the type of psychiatric 
comorbidities that likely exist in association with PCDH19 variants. In line with previous 
reports11, 14, 52 we observed that autistic features were most prominent. A novel finding to 
emerge was that hyperactivity was frequently observed. This finding is reflected in a recent 
animal model study showing that heterozygous female Pcdh19 knockout mice show 
hyperactivity in social interactions, under stress and with advancing age.53 Overall, features 
associated with ADHD, ASD, and OCD were observed in GCE at rates much higher than 
those observed in the general population.54 Although these rates are comparable to those 
reported among individuals with ID55, 25% of reviewed cases had normal cognitive function 
in association with psychiatric comorbidities. These results should be considered formative 
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due to limited data specifically targeting the presence and/or severity of psychiatric 
symptomatology. As over 60% of reviewed cases are associated with some form of 
psychiatric comorbidity, a comprehensive and standardized assessment of the psychiatric 
profile associated with PCDH19 variants is warranted.31 
There were no reported psychiatric comorbidities in over 75% of individuals with normal 
cognitive function. Determining what factors are unique to this group might shed some light 
on what causes the clinical variability observed in GCE. Previous reports suggest that ID 
becomes apparent sometime after seizure onset8, 9, 14, suggesting that seizure and epileptic 
activity may contribute to cognitive deficits. However, we observed that development prior 
to the onset of seizures was delayed for 15% of individuals indicating that PCDH19 variants 
produce a developmental encephalopathy as well as an epileptic encephalopathy in some 
cases. Given that prior development was not reported, unclear, or unknown in 130 cases, 
and that obtaining such information retrospectively or prior to the onset of seizures is often 
challenging; previous reports are likely underestimating the proportion of individuals 
showing signs of delay prior to seizure onset. It was also noted that dysfunction specific to 
executive functions was reported, such as problems with planning and organization56, 
abstract reasoning52, or lack of inhibitory control.31 Therefore, executive functions may be 
compromised in GCE. Moreover, definitions of ID now include deficits in adaptive 
behavior, with the severity of ID based on adaptive behavior impairment rather than 
exclusively on IQ score.57 
Conclusion 
Given the limited information in the literature concerning comorbid symptomatology, there 
is a need to formally characterize the neuropsychiatric profile of GCE. Neuropsychiatric 
disorders can be very responsive to early intervention58-60; therefore, a better understanding 
of these comorbidities may help to inform treatment and ultimately lead to better 
developmental outcomes for individuals affected by GCE. In addition, transmitting males 
may exhibit mild neuropsychiatric features. An assessment of these males may identify a 
clinical profile unique to this group, which may lead to carrier testing and has implications 
for genetic counseling. We have shown that seizure onset within the first 12 months is 
significantly associated with more severe ID. Therefore, knowledge of an individual’s 
seizure onset will aid prognostic counseling, providing valuable information for clinicians 
managing affected individuals and their families. 
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3.1 Preamble 
The aim of the second study is to use the information gleaned from the first study to 
systematically characterize the neuropsychiatric profile associated with PCDH19 variants 
using standardized assessments. I also validate the findings from the meta-analysis using 
more sophisticated methods. This was possible due to the nature of the data collection and 
an a priori understanding of the variables to be tested. Additional predictive variables 
were also evaluated. I begin by illustrating the importance of characterizing the 
neuropsychiatric profile associated with PCDH19 variants. Knowledge of comorbidities 
will assist families and individuals affected by GCE by expanding diagnostic criteria and 
tailoring treatment. Previous work in this area is limited and focused only on females. 
Here, I describe the neuropsychiatric profile for both females and males. Findings from 
this work form the basis of the detailed analysis of treatment efficacy and PCDH19-





















   CHAPTER 3 
 
P a g e  | 28 
3.2 Statement of authorship   
Title of Paper A standardized patient-centered characterization of the phenotypic 





Unpublished and Unsubmitted work written in 
manuscript style  
Publication Details Kolc, K. L., Sadleir, L. G., Depienne, C., Marini, C., Scheffer, I. E., 
Møller, R. S.., Trivisano, M., Specchio, N., Pham, D. H., Kumar, R., 
Roberts, R., & Gecz, J. (2020). A standardized patient-centered 
characterization of the phenotypic spectrum of PCDH19 girls clustering 
epilepsy. Translational psychiatry. 
Principal author 
Name of Principal Author 
(Candidate) 
Kristy Kolc 
Contribution to the Paper 
 
 
Major contribution to the research question. Designed study, performed 
data collection, analysis, and interpretation, prepared manuscript, and 
performed all required revisions. 
Overall percentage (%) 80% 
Certification: This manuscript reports on original research I conducted during the 
period of my Higher Degree by Research candidature and is not subject 
to any obligations or contractual agreements with a third party that would 




 Date Feb 14 2020 
Co-Author contributions 
By signing the Statement of Authorship, each author certifies that: 
i. the candidate’s stated contribution to the publication is accurate (as detailed above); 
ii. permission is granted for the candidate in include the publication in the thesis; and 
iii. the sum of all co-author contributions is equal to 100% less the candidate’s stated contribution.  
   CHAPTER 3 
 
P a g e  | 29 
Name of Co-Author Professor Lynette Sadleir 






Date Feb 13 2020 
 
Name of Co-Author Dr Christel Depienne 






Date Feb 13 2020 
 
Name of Co-Author Dr Carla Marini 






Date Feb 13 2020 
 
Name of Co-Author Laureate Professor Ingrid Scheffer 










   CHAPTER 3 
 
P a g e  | 30 
Name of Co-Author Dr Rikke Møller 





Date Feb 13 2020 
 
Name of Co-Author Dr Marina Trivisano 
Contribution to the Paper Assisted with data collection and manuscript editing. 
Signature 
 
 Date Feb 13 2020 
 
Name of Co-Author Dr Nicola Specchio 
Contribution to the Paper Assisted with data collection. 
Signature 
 
 Date Feb 13 2020 
 
Name of Co-Author Dr Duyen Pham 
Contribution to the Paper Assisted with data interpretation. 
Signature 
 
 Date  
 
Name of Co-Author Dr Raman Kumar 









   CHAPTER 3 
 
P a g e  | 31 
Name of Co-Author Associate Professor Rachel Roberts 
Contribution to the Paper Supervised development of work, assisted with design, data 





Date Feb 15 2020 
 
Name of Co-Author Professor Jozef Gecz 
Contribution to the Paper Supervised development of work, assisted with design, data 





Date Feb 13 2020 
    CHAPTER 3 
 
 
P a g e  | 32 
3.3 Accepted manuscript 
Title: A standardized patient-centered characterization of the phenotypic spectrum of 
PCDH19 girls clustering epilepsy. 
Running Title: CHAPTER 3 
List of Authors: Kristy L Kolc1, Lynette G Sadleir2, Christel Depienne3,4, Carla Marini5, 
Ingrid E Scheffer6,7,8, Rikke S Møller9,10, Marina Trivisano11, Nicola Specchio11, Duyen 
Pham1,12, Raman Kumar1,12, Rachel Roberts13, and Jozef Gecz1,12,14 
Affiliations: 1Adelaide Medical School, the University of Adelaide, SA, Australia, 2Department of 
Paediatrics and Child Health, University of Otago, Wellington, New Zealand, 3Institute of Human Genetics, 
University Hospital Essen, University Duisburg-Essen, Essen, Germany, 4Inserm U 1127, CNRS UMR 
7225, Sorbonne Universités, UPMC Univ Paris, 06 UMR S 1127, Institut du Cerveau et de la Moelle 
épinière, ICM, F-75013, Paris, France, 5Child Neurology and Psychiatric unit, Pediatric Hospital G. Salesi, 
Ospedali Riuniti Ancona, Ancona, Italy, 6Department of Medicine, Epilepsy Research Centre, The 
University of Melbourne, Austin Health, Melbourne, VIC, Australia, 7Department of Paediatrics, Royal 
Children's Hospital, The University of Melbourne, VIC, Australia, 8The Florey and Murdoch Institutes, 
Melbourne, VIC, Australia, 9Department of Epilepsy Genetics and Personalized Medicine, The Danish 
Epilepsy Centre, Dianalund, Denmark, 10Department for Regional Health Research, University of Southern 
Denmark, Odense, Denmark, 11Rare and Complex Epilepsy Unit, Department of Neuroscience, Bambino 
Gesù Children's Hospital, IRCCS, Rome, Italy, 12Robinson Research Institute, the University of Adelaide, 
SA, Australia, 13School of Psychology, The University of Adelaide, SA, Australia, 14Women and Kids, 
South Australian Health and Medical Research Institute, SA, Australia. 
Conflict of Interest 
I.E.S serves on the editorial boards of Neurology® and Epileptic Disorders; may accrue 
future revenue on a pending patent re: Therapeutic compound; has received speaker 
honoraria from Athena Diagnostics, UCB, GSK, Eisai, and Transgenomics; has received 
scientific advisory board honoraria from Nutricia, UCB, and GSK; and receives/has 
received research support from the NHMRC, ARC, NIH, Health Research Council of 
New Zealand, March of Dimes, CURE, US Department of Defense, and the Perpetual 
Charitable Trustees. The remaining authors declare no conflict of interest. 
 
 
    CHAPTER 3 
 
 
P a g e  | 33 
Acknowledgements 
We thank the patients and their families for their time to complete this survey. The 
authors wish to thank Alison Gardner for performing the in silico analysis, Alison, Urwah 
Nawaz, and Atma Ivancevic for assisting with the lollipop plot, and Suzanne Edwards for 
statistical support. We thank Francesca Squillante, Maria Avellino, and Fabio Cec for 
their assistance with the Italian translations. Thank you Bri Boljonis, Katja Boysen, 
Francesca Darra, Arjen van Erkelens, Georgie Hollingsworth, Ditte Kjelgaard, Janneke 
Schuurs-Hoeijmakers, and Amy Schneider for providing clinical information. Thank you 
also to Hilde Braakman, Delphine Breuillard, Elisabetta Cesaroni, Tiziana Granata, David 
Koolen, Eric Leguern, Shane McKee, Mathieu Milh, Kenneth Myers, Rima Nabbout, 
Caroline Nava, Lisa Ouss, Maria Paola Canevini, Annapurna Poduri, and Federico Sicca 
for disseminating the survey to their patients. A special thanks to Gataen Lesca for his 
assistance with the French translations and providing clinical information, Lacey Smith 
for providing clinical information and sharing the survey with a PCDH19 Registry, to the 
PCDH19 Alliance Board of Directors (Julie Walters, Leslie Henkel, Susan Taylor, and 
Karin Wells-Kilpatrick), Insieme per la Ricerca PCDH19 – ONLUS (especially 
Francesca Squillante), and the PCDH19 France Association (especially Denis Dumas) for 
their valued feedback regarding survey items and for advertising the survey among their 
groups, and to all the health professionals and researchers who have been integral in 









    CHAPTER 3 
 
 
P a g e  | 34 
Abstract 
PCDH19 pathogenic variants cause an early-onset seizure disorder called GCE. GCE is 
an X chromosome disorder that affects heterozygous females and mosaic males, however 
hemizygous “transmitting” males are spared. We aimed to define the neuropsychiatric 
profile associated with PCDH19 pathogenic variants and determine if a clinical profile 
exists for transmitting males. We also examined genotype- and phenotype-phenotype 
associations. We developed an online PCDH19 survey comprising the following 
standardized assessments: The BRIEF; the SRS-2; the SDQ; and the DOCS. Genetic, 
seizure, and developmental information were also collected. The survey was completed 
by patients or by caregivers on behalf of patients. Of the 112 individuals represented (15 
males), there were 70 unique variants. Thirty-five variants were novel and included a 
newly identified recurrent variant Ile781Asnfs*3. There were no significant differences in 
phenotypic outcomes between published and unpublished cases. Seizures occurred in 
clusters in 94% of individuals, with seizures resolving in 28% at an average age of 17.5 
years. Developmental delay prior to seizure onset occurred in 18% of our cohort. 
Executive dysfunction and ASD occurred in approximately 60% of individuals. The ASD 
profile included features of ADHD. In addition, 21% of individuals met criteria for OCD 
that appeared to be distinct from ASD. There were no phenotypic differences between 
heterozygous females and mosaic males. We describe a mosaic male and two hemizygous 
males with atypical clinical profiles. Earlier seizure onset age and increased number of 
seizures within a cluster were associated with more severe ASD symptoms (p = .001), 
with seizure onset also predictive of executive dysfunction (p = 4.69 × 10−4) and prosocial 
behavior (p = .040). No clinical profile was observed for transmitting males. This is the 
first patient-derived standardized assessment of the neuropsychiatric profile of GCE. 






    CHAPTER 3 
 
 
P a g e  | 35 
Introduction 
PCDH19 pathogenic variants cause an infantile onset seizure disorder called GCE. GCE 
is an X chromosome disorder with a unique expression pattern where heterozygous 
females and males with postzygotic somatic variants (“mosaic males”) are affected, but 
hemizygous (“transmitting”) males are unaffected. The hallmark of GCE is clusters of 
focal seizures, often coinciding with fever.25 While the seizure semiology associated with 
GCE has been characterized,3, 25, 61, 62 the neuropsychiatric profile has not been well 
established.  
PCDH19 pathogenic variants are frequently associated with ID and psychiatric 
disturbances.14, 31, 61, 63 These neuropsychiatric comorbidities are highly heterogeneous, 
with ID ranging from mild to profound, and combinations of autistic, attention-
deficit/hyperactive, obsessive, or aggressive features. The natural history of GCE shows 
that seizures become less frequent with age and cognition plateaus over time.9, 31 
Psychiatric symptoms often increase with age and become the most disabling feature in 
some patients.9, 61 The specific cognitive deficits, and the severity and prevalence of 
comorbidities remain unknown.  
In our systematic review and meta-analysis, we identified that executive dysfunction and 
hyperactive, autistic, and obsessive-compulsive features were most frequently reported in 
individuals with PCDH19 pathogenic variants. We also showed that individuals with 
seizure onset before 12 months of age had more severe ID than those with seizure onset 
after 12 months.64 A recent retrospective study validated this finding and also showed an 
association between earlier seizure onset and the presence of ASD.62 Reviewed studies 
were typically based on small samples, lacked systematized approaches, and focused on 
only one clinical outcome. 
Here we aim to define the neuropsychiatric profile associated with PCDH19 pathogenic 
variants using standardized assessments that specifically target executive functions and 
symptoms associated with ASD, ADHD, and OCD, and interrogate which factors predict 
the severity of these neuropsychiatric comorbidities. 
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Method 
Study design and participants 
The PCDH19 survey was developed in English, Italian, and French using Survey Monkey 
(www.surveymonkey.com/) and was available from April 2017 through March 2019. 
Invited participants (n = 186) were parents or caregivers responding on behalf of 
individuals aged 2 years and over with a PCHD19 variant or individuals over 10 years of 
age with a PCDH19 variant who were able to self-report. Exclusion was based on our 
determination that the PCDH19 variant was likely benign based on frequency in the 
general population and in silico assessment.  
Outcomes 
We collected demographic and clinical information using the EQ, which we developed 
based on literature review and discussion with health professionals (Appendix A6). We 
assessed ASD using the SRS-2 (Appendix A1).65 As a French translation of the SRS-2 
was not available, we also utilized the SCQ (Appendix A2).66 Behavioral difficulties were 
assessed via the SDQ (Appendix A3).67 We used the four-band categorization cut-off 
scores to assess symptoms of depression and anxiety (emotional problems scale), 
aggression (conduct problems and prosocial scales), ADHD (hyperactivity-inattention 
scale), and social deficits (peer problems and prosocial scales).68 SDQ categories were re-
classified from “close to average” to “average”, “slightly raised/lowered” to “mild”,  
“high/low” to “moderate”, and “very high/very low” to “severe” to align our analysis with 
other assessed constructs. Executive dysfunction was assessed using the BRIEF 
(Appendix A4).69 BRIEF inconsistency, negativity, and infrequency scales were included 
to assist in detecting bias associated with rating scales. We assessed OCD using the 
DOCS (Appendix A5).70 The internal consistency of all assessments was acceptable: 
SRS-2 (Cronbach’s alpha = .97), SCQ (α = .86), SDQ scales (M = 0.73; Supplementary 
Table 3.1), BRIEF forms (M = 0.98), and DOCS (α = .96). 
Translation of the EQ, survey scripts, and study material were performed and checked by 
either a professional translator or by an individual familiar with GCE and fluent in the 
relevant languages. Published authorized translations of the SRS-2, SCQ, SDQ, BRIEF, 
and DOCS were utilized. License agreements were obtained to reproduce assessments in 
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an online format. The project was approved by the University of Adelaide Human 
Research Ethics Committee (H-2016-184). Electronic informed consent was obtained 
from all participants.  
Statistical analysis 
All genetic variants were mapped to the longest isoform of the PCDH19 mRNA 
(NM_001184880.1) and protein (NP_001171809.1) reference sequences 
(https://www.ncbi.nlm.nih.gov/). Variant annotation was based on nomenclature for the 
description of sequence variants (http://www.hgvs.org/mutnomen/). We identified 
whether the PCDH19 variant had been previously reported, then assessed the 
pathogenicity of all novel variants based on gnomAD (http://gnomad.broadinstitute.org/) 
frequency and in silico prediction tools through the web-based ANNOVAR 
(http://wannovar.wglab.org/). Data were analyzed using SPSS version 25. ID severity was 
coded as previously described.64 To test associations, we used a linear regression model 
and set statistical significance at p = .05. We used a deductive category analytical 
approach to evaluate qualitative data.71 
Results 
Of the 122 completed surveys, 7 participants were excluded prior to, and 3 following, in 
silico PCDH19 variant assessment (Supplementary Table 3.2). Seven individuals reported 
secondary variants in other genes, which were not predicted to be likely pathogenic 
(Supplementary Table 3.3), so these participants remained in the analysis. Following 
exclusions, 112 individuals remained; including 97 heterozygous females (90 affected, 7 
unaffected) and 15 males (6 hemizygous, 9 mosaic). The mean age at time of study (n = 
112) was 17.6 years (SD = 15.6, range = 1.5 to 70 years). 
The characteristic phenotype for PCDH19 heterozygous females and mosaic males is 
epilepsy. Individuals without epilepsy were classified as “non-penetrant”. Of the 106 
heterozygous females and mosaic males, there were eight non-penetrant individuals 
(seven females). Therefore, the penetrance of GCE in our cohort was 92%. The non-
penetrant mosaic male (#63) was ascertained as they were the father of an affected female 
(#28). Of the seven non-penetrant females (#49, #56, #58, #62, #93, #97, #99), two (#58, 
#93) had a single febrile seizure.72 Interestingly, our cohort included two symptomatic 
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hemizygous males, one with epilepsy (#39) and one with ASD and no epilepsy (#47). The 
remaining four hemizygous males were classified as “transmitting”, as they were the 
asymptomatic fathers of affected females. 
PCDH19 DNA Variants 
There were 70 unique PCDH19 variants, of which 35 were novel. Variants included 25 
frameshift, 14 nonsense, 60 missense, 3 in-frame duplications (Fig. 3.1), 6 whole gene 
deletions, and 4 splicing. Almost half (54/112) arose de novo, with 18 paternal, 21 
maternal, or 19 of unknown origin. There were four recurrent variants: p.Arg886* (2), 
p.Ile781Asnfs*3 (2), p.Asn340Ser (3), and p.Tyr366Leufs*10 (6). The p.Ile781Asnfs*3 
variant is newly identified as recurrent (Supplementary Table 3.4). 
 
Figure 3.1 Lollipop plot illustrating all PCDH19 variants in our cohort (n = 102) excluding whole gene deletions and 
splicing variants. Lollipop size is exponentially proportional to the number of times the variant has been observed in 
unrelated individuals (recurrent). At a given locus, the number of lollipops represents the number of related individuals 
with that variant, with the exception of Asn340Ser (2 unrelated families and one sporadic case) where this is illustrated 
in text. Unpublished (novel) variants (n = 34) are located above the protein and published variants (n = 32) are below 
the protein. 
Development 
Early development was ascertained only for surveys completed by a parent or caregiver 
(n = 83; Supplementary Table 3.5a). Developmental delay occurred in 50/83 (60%). The 
average age of first developmental concern was 12.8 months (SD = 11.1, range = 1 to 48 
months). All developmental domains were affected, however, communication (24/50) and 
motor skills (22/50) were most affected. Delay prior to the onset of seizures occurred in 
15/49 individuals (31%). For one individual (#47), developmental delay was noted at 12 
months in the absence of seizures. Regression occurred in 37/83 (46%), and regression 
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following a seizure cluster occurred in 30/37 (81%). 
The intellect of the entire cohort was based on pre-existing diagnosis. Information 
regarding the degree of ID was not available for one individual (#22), therefore they were 
excluded from this analysis. Normal intellect was reported in 62/111 (56%), borderline in 
4/111 (3.5%), mild ID in 20/111 (18%), moderate ID in 9/111 (8%), severe ID in 14/111 
(12.5%), and profound ID in 2/111 (2%) of our patient cohort (Supplementary Table 
3.5b). 
Seizures 
Age at seizure onset for heterozygous females (n = 90) ranged from 1.5 to 60 months (M 
= 12.2, SD = 9.27, median = 10 months) and for mosaic males (n = 8) from 5 to 96 
months (M = 20.6, SD = 30.9, median = 9 months). The most common age at onset was 8 
months (14%, n = 98). Cluster duration (n = 93) ranged from 1 to 24 days (M = 4.61, SD 
= 4.29) and the average number of seizures within a cluster ranged from 2 to 100 (M = 
15.53, SD = 13.99), with most clusters lasting for 2 days and averaging 10 seizures per 
cluster (Fig. 3.2; see also Supplementary Table 3.6).  
Seizure offset for individuals aged 11 years and over (based on the youngest reported 
seizure offset age) had occurred in 28% of our cohort. Age at seizure offset ranged from 
11 to 38 years (M = 17.6, SD = 7.43). Epilepsy is classified as resolved when an 
individual has been seizure free for 10 years, with the last five years free from 
antiepileptic medication.72 Sixteen individuals (16%), aged 22 to 52 years (M = 32.8, SD 
= 8.55) were seizure-free for at least 10 years. Eleven of the 16 were taking antiepileptic 
medication. For the five individuals who were seizure-free without medication, age at 
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Figure 3.2 Seizure characteristics: a) proportion of individuals with seizure clusters and number of clusters in the last 
12 months; b) proportion of individuals with isolated seizures and the frequency of isolated seizures (infrequent refers 
to less than yearly and frequent to occurrence ranging from daily to yearly); and c) proportion of individuals with 
episodes of status epilepticus and type of status epilepticus. 
Neuropsychiatric comorbidities  
Autism Spectrum Disorder. All participants completed either the SRS-2 (n = 104) or the 
SCQ (n = 8). Total average SRS-2 scores fell in the normal range for transmitting males 
and non-penetrant females and in the clinical range for all other groups (Fig. 3.3). Total 
SRS-2 scores were in the clinical range in 68% of females (56/82) including one non-
penetrant female (#58), 75% of mosaic males (6/8) including the non-penetrant male 
(#63), and both hemizygous males (#39, #47). There was no sex difference in severity of 
ASD (p = .781; Supplementary Fig. 3.1). The SCQ average total score ranged from 8 to 
32 (M = 18.5, SD = 8.1), and fell in the clinical range for five individuals (63%). 
 
Figure 3.3 Average (±2 SEM) SRS-2 total and DSM-5 domain t scores by group. Darkening shades of red correspond 
to increasing degrees of severity. SCI, social communication and inhibition; RRB, restricted interests and repetitive 
behavior. 
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Behavioral assessment. The SDQ was completed by parents/caregivers of individuals 
aged between 2 and 17 years (n = 73). Elevated scores were observed across all SDQ 
domains, with the hyperactivity-inattention, peer problems, and prosocial behavior 
domains most severely affected (Supplementary Table 3.7). Impact scores were in the 
very high range for approximately 75% of participants (Supplementary Table 3.7). This 
was further supported by 65% of respondents endorsing behavior as the most challenging 
aspect each day. 
Executive dysfunction. One participant (#87) was excluded due to missing data (n = 
111). For individuals aged between 2-4 years (n = 17), BRIEF total global executive 
composite t scores (GECt) fell within the clinical range for heterozygous females (M = 
68.1) and mosaic males (M = 62.5). Inhibit (M = 68.5) and working memory (M = 70.9) 
domains were the most affected for females, with working memory also elevated for 
males (M = 72.5). For individuals aged between 5-17 years (n = 57), GECt scores fell 
within the clinical range for heterozygous females (M = 73.2) and mosaic males (M = 
67.0), and within the normal range for one hemizygous male (#39). Elevation in all 
domains were observed for females, with the exception of organization of materials. 
Shift, working memory and plan/organize were elevated for males. For individuals aged 
18 and over (n = 37), GECt scores fell in the normal range for all but one hemizygous 
male (#47).  
Average scores in the shift domain were elevated for most groups, including one 
hemizygous male (#47) and the non-penetrant mosaic male (#63; Supplementary Fig. 
3.2). Overall, executive dysfunction was observed in 72% of heterozygous females 
(64/89), 50% of mosaic males (4/8), one non-penetrant female (1/7) and one hemizygous 
male (1/2). Again, no difference was observed between males and females (p = .482; 
Supplementary Fig. 3.1). Inconsistency, negativity, and infrequency scores were in the 
acceptable range. Figure 3.4 summarizes the neuropsychiatric profile of our cohort.  
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Figure 3.4 The percentage of each comorbidity associated with PCDH19 variants. ID, intellectual disability; ASD, 
autism spectrum disorder (severity based on SRS-2 t scores only). Severe ID included two individuals with profound 
ID. DOCS scores omitted as no cutoff exists for severity. 
Obsessive Compulsive Disorder. The DOCS was administered only to individuals who 
could complete the assessment themselves (n = 29). One participant (#56) was excluded 
due to missing responses (n = 28). Six individuals (21%), attained a total score that was 
consistent with a possible OCD diagnosis. All six were heterozygous females, including 
one non-penetrant female (#58). All transmitting males scored in the normal range 
(Supplementary Table 3.8). 
Predicting the severity of neuropsychiatric comorbidities 
Five outliers (#39, #50, #58, #64, & #112) were removed prior to statistical analyses due 
to seizure onsets 2 standard deviations above the mean. There was a significant negative 
association between age at seizure onset and ID for novel variants (p = .007) as well as 
for the entire cohort (p = .010). For every one month increase in seizure onset age, there 
was a 0.07 decrease in average ID severity, controlling for age at time of study (estimate 
= -0.07, 95% CI: -0.12, -0.02). There was a significant negative association between age 
at seizure onset and executive dysfunction for novel variants (p = .044) as well as the 
entire cohort (p = 4.69 × 10−4; Fig. 7a). On average, increasing seizure onset age by 1 
month was associated with a 0.82 decrease in average GECt scores, controlling for age at 
time of study (estimate = -0.82, 95% CI: -1.27, -0.37). For the ASD analysis, SRS-2 and 
SCQ total scores were converted to z scores and combined. Seizure onset age was 
significantly associated with ASD (p = .001; Fig. 7b) and prosocial behavior (p = .040). 
On average, increasing seizure onset age by 1 month was associated with a 0.50 decrease 
in SCQ/SRS-2 combined scores (estimate = -0.50, 95% CI: -0.08, -0.02) and a 0.13 
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increase in prosocial behavior scores (estimate = 0.13, 95% CI: 0.01, 0.25), controlling 
for age at time of study. No significant association was observed for the hyperactivity-
inattention and peer problems scales.  
 
 
Figure 3.5 Circos and scatterplot illustrating phenotype-phenotype association: a) The variable cognitive profile of 
GCE (n = 95) against age at seizure onset: ≤12 months, represented by grey links (n = 66) and >12 months, represented 
by black links (n = 29); b) The variable ASD profile of GCE (n = 88) against age at seizure onset: ≤12 months, 
represented by orange links (n = 62) and >12 months, represented by purple links (n = 26). Axes show the number of 
individuals in each category; c) A moderate negative association between age at seizure onset and clinical outcome, as 
measured by the BRIEF (n = 93) and SRS-2 (n = 86). 
We hypothesized that seizure activity (operationalized as the average number of seizures 
per day in a cluster) combined with onset would strengthen these associations. An 
additional outlier (#26) was removed from this analysis. For a one-way ANOVA, seizure 
onset was categorized as “early” (≤12 months) or “late” (>12 months)64 and seizure 
activity was categorized as “mild” (≤15 seizures/day in a cluster) or “severe” (>15 
seizures/day in a cluster) based on the group average. Seizure activity was associated with 
executive dysfunction, F3,81 = 4.71, p = .004, ASD, F3,81 = 7.45, p = 1.82 x 10
-4, and 
prosocial behavior, F3,66 =  3.10, p = .033. We predicted that the greatest phenotypic 
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difference would be observed between individuals with late onset/mild seizure activity 
and individuals with early onset/severe seizure activity. Our prediction was supported for 
all outcomes: executive dysfunction (Supplementary Fig. 3a; t81 = -3.45, p = .001), ASD 
(Supplementary Fig. 3b; t81 = -4.66, p = 1.2 x 10
-5), and prosocial behavior (t66 = -2.92, p 
= .005), with an earlier age at seizure onset combined with severe seizure activity being 
associated with more severe outcomes. An examination of the means revealed that seizure 
onset was more strongly associated with cognitive outcomes whereas seizure activity was 
more strongly associated with psychiatric outcomes (Supplementary Table 3.9). 
Given that 50% of our cohort had novel variants, we wanted to exclude that the clinical 
outcome for published cases would be more severe than that of unpublished cases due to 
selection or admission bias.73 We investigated this via t tests and found no statistically 
significant difference for either executive dysfunction (Mpublished = 67.5; Munpublished = 62.2) 
or standardized ASD symptom severity (Mpublished = 0.14; Munpublished = -0.24). The SDQ 
and DOCS were excluded, as fewer individuals had scores on these measures. Consistent 
with our previous finding, there were no notable genotype-phenotype associations 
(Supplementary Table 3.10). 
Discussion 
We performed the first comprehensive patient-derived standardized assessment of 
PCDH19-variant individuals, including males (both germline and mosaic) and non-
penetrant females. Females with GCE are typically described as having normal early 
development and regressing in infancy.8-10 We found that delayed development prior to 
seizure onset occurred in 18% of individuals, replicating observations in two smaller 
studies.3, 61 This may provide scope for early detection, especially for siblings of affected 
individuals. Seizures occurred in clusters in 94% of individuals. We believe the hallmark 
features of GCE to be threefold: 1) focal seizure clusters with affective semiology,25 often 
triggered by fever; 2) seizure onset at 8 months of age; and 3) predominantly affecting 
females. The molecular diagnosis for many infantile neurodevelopmental disorders 
including epilepsy occurs at a mean age of 3 years, which represents delays of months to 
years for patients with pathogenic variants.74 Early clinical identification of GCE will 
result in earlier molecular diagnosis and may impact outcome by allowing optimization of 
both seizure management and developmental progress. 
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Overall, 69/112 (62%) individuals met criteria for ASD. GCE has previously been 
associated with ASD,3, 14 suggesting that this genetic etiology underlies epilepsy, ASD, 
and ID. The frequency of ASD in our cohort was lower than previous estimates, but may 
be more accurate given the much smaller sample sizes and lack of systemized approaches 
in these studies.14, 31, 61, 62 We found that executive dysfunction occurs in 70/111 (63%) 
individuals. Of these, 62 (89%) individuals also met criteria for ASD. It has been posited 
that the social and non-social deficits observed in ASD stem from deficits in executive 
functions and might explain the co-occurrence of these disorders.75  
The SDQ revealed that peer problems and prosocial behavior were the most affected 
domains. This is expected given the high proportion of individuals meeting criteria for 
ASD. Most individuals who met criteria for ASD, also scored high on the BRIEF inhibit 
and shift subscales. The inhibit domain is relatively preserved in ASD, yet impaired in 
ADHD whereas shift domain deficits are characteristic of ASD rather than ADHD.76 The 
ASD group with elevated inhibit (ADHD-like) and shift (ASD-like) scores also scored 
very high on hyperactivity-inattention (see Supplementary output). This may represent an 
ASD profile with features of ADHD or a general deficit in executive functions that 
underlies these comorbidities. SDQ impact assesses chronicity, distress, social 
impairment, and burden for others. Most (75%) scores were in the very high range. This 
finding, combined with qualitative accounts, supports reports that psychiatric 
comorbidities become the most concerning feature in GCE.  
Consistent with a recent report,61 21% of our cohort had obsessive-compulsive 
symptomatology revealed by the DOCS. This may be an accurate estimate or may reflect 
the similarities between OCD and other disorders, such as ASD. Only one of the six 
individuals meeting criteria for OCD also met criteria for ASD in conjunction with a 
moderately elevated shift score (#58), suggesting that OCD is distinct from ASD in GCE. 
We demonstrated that the clinical profile for heterozygous females and mosaic males is 
the same. We describe seven non-penetrant females and one male. This non-penetrance 
may reflect absence of mosaicism in the brains of these individuals, consistent with the 
cellular interference model.2, 4 We confirmed there is no clinical profile for transmitting 
males, although identified two hemizygous males with ASD in addition to executive 
dysfunction (#42) or seizures (#39). If their phenotypes are due to their PCDH19 variants, 
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these findings will expand the phenotypic spectrum; however, they may be due to 
additional genetic or environmental factors.  
Consistent with our previous meta-analysis, earlier seizure onset age was associated with 
more severe ID. We also showed that earlier seizure onset age predicted greater executive 
dysfunction, prosocial behavior, and ASD severity, and that increased seizure activity 
strengthened these associations. It could be that earlier and more frequent seizures cause 
more adverse outcomes,77 or the PCDH19 variant is enhanced by polygenic or epigenetic 
burden.51    
Although the frequency of comorbid ASD in the GCE population is likely to be correct, 
we are limited by inherent difficulties in delineating ASD from other impairments. For 
example, parent reports are not entirely reliable in discriminating children with ASD from 
those with language impairment.78 An assessment of language was beyond the scope of 
this study. As language delay may be associated with GCE,64 future work should 
incorporate a formal assessment of ASD and language impairment.  
Biases also exist with self-reported data.79 Validity checks within the BRIEF addressed 
these biases to some extent. Retrospective accounts are inherently less reliable than direct 
observation of behavior or events. However, standardized assessments are particularly 
useful in contexts such as these, as they minimize any potential confounds that are likely 
to emerge as a result of subjectivity and different administrators or methodology.80 
GCE is a distinctive epilepsy with early onset of seizure clusters, with or without ID. We 
show that individuals with PCDH19 pathogenic variants may have associated executive 
dysfunction, ASD, ADHD, and OCD, thus characterizing the neuropsychiatric profile of 
GCE. Our data show that approximately 20% of individuals have developmental delay 
prior to seizure onset. We confirm the association between earlier seizure onset age and 
more severe ID and demonstrate that the association with earlier seizure onset age 
extends to neuropsychiatric comorbidities. We also demonstrate an association between 
increased seizure frequency and poorer clinical outcomes. We show that the clinical 
profile for heterozygous females and mosaic males is the same and describe seven non-
penetrant females and one male. We also show that there is no clinical profile for 
transmitting males, but identify two affected hemizygous males. These phenotypic 
insights will lead to better diagnosis and management of GCE. 
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4.1 Preamble 
Based on the findings from the first two studies, I developed a PCDH19 website as part of 
the Human Disease Genes website series https://humandiseasegenes.nl/pcdh19/. The 
Human Disease Genes website series is an international library of websites for 
professional information about genes and copy number variances and their clinical 
consequences. Through discussions with individuals and families affected by PCDH19 
variants and GCE we discovered that having access to information was extremely 
important, as well as being able to connect with PCDH19 researchers, clinicians, and 
other families affected by this disorder. The PCDH19 website provides clinical and 
genetic information about patients with disease-causing changes in the PCDH19 gene. 
We are dedicated to ensuring access to new information about PCDH19 as soon as it 
becomes available. The PCDH19 website will provide a platform for clinicians, 
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Gene Specific Homepage 
This website provides clinical and genetic information about patients with disease-
causing changes in the PCDH19 gene.  
Abnormalities in the PCDH19 gene are usually associated with epilepsy in girls. The 
seizures often start at 8 months (median onset = 10 months), most girls having seizure 
onset by 3 years of age. Commonly, girls have clusters of many seizures over several 
days followed by periods where they are seizure free. This distinctive pattern has led to 
the disorder being often referred to as GCE to assist in earlier recognition of PCDH19 
epilepsies. Affected girls often have behavioral difficulties, learning problems, or ID that 
may not be apparent until after the seizures start. 
The PCDH19 gene is located on the X chromosome, and was first implicated in epilepsy 
in 2008. Changes that affect a gene’s ability to function are referred to as pathogenic 
variants or mutations. Many different pathogenic variants in the PCDH19 gene are 
associated with GCE. The PCDH19 gene is important because it encodes a protein that is 
involved in how brain cells (neurons) communicate with other cells and move in forming 
the brain. 
GCE typically affects females, but not all females with PCDH19 pathogenic variants are 
affected. The penetrance (the extent to which the condition is present with the pathogenic 
variant) of GCE is estimated to be 90%. Males who inherit a PCDH19 pathogenic variant 
from their mother are generally not affected; they do not have seizures or learning 
difficulties.  
However, in rare cases, males have a PCDH19 pathogenic variant in some, but not all, of 
their cells (called mosaicism). These males usually have similar features to females with 
GCE. Mosaicism can result from a pathogenic variant occurring in the male during early 
development (post fertilization of the sperm and egg).   
This website was created to facilitate the collection and sharing of information about 
PCDH19-associated conditions. Our aim is to enhance the understanding of these 
disorders and improve treatment of individuals with PCDH19 pathogenic variants 
through PCDH19 research.  
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Professionals – General Information 
GCE is a condition caused by pathogenic variants in the X chromosome gene PCDH19. 
PCDH19 encodes the protocadherin-19 protein. This protein is important in individual 
cell function, cell-cell adhesion, and cell-cell communication. Due to the normal X-
chromosome inactivation in females or the development of a somatic (postzygotic) 
pathogenic variant in males, individuals with pathogenic variation in this gene are cellular 
mosaics. That is, they have some cells that express functional protocadherin-19 protein 
and some cells that do not express protocadherin-19 protein or express its non-functional 
form. 
Main clinical features. PCDH19 pathogenic variants cause a distinctive phenotype for 
which the name GCE has been proposed to aid in early recognition of the distinguishing 
phenotypic features. Although GCE can show marked inter-individual variation in 
severity, it is readily identifiable clinically. Typically developing girls present with 
clusters of frequent seizures usually in the first year of life, often triggered by fever. 
Seizures are typically focal, although bilateral tonic-clonic (BTCS) and tonic seizures 
may occur. Clusters may be difficult to abort and the epilepsy is often pharmaco-resistant. 
During the second decade of life (mean 18 years) the epilepsy can improve, with many 
girls becoming seizure free in adolescence. Developmental course is varied, with many 
girls showing developmental slowing during childhood. Although some girls have 
abnormal development from birth (approx. 20%). There may be developmental regression 
with clusters of seizures. Approximately half of affected individuals have ID ranging 
from mild to profound. Comorbid psychiatric disorders are common, most frequently 
ASD and behavioral problems; later onset psychosis occurs in approximately 20% of 
females. These features also have a significant impact on the quality of life for these 
individuals and their families.  
Prevalence. PCDH19 is considered one of the most clinically relevant genes in epilepsy, 
second only to SCN1A. The prevalence of GCE is estimated to be 1 in 15,000. To date, 
over 300 individuals with pathogenic variants in PCDH19 are reported in the literature.  
Inheritance. PCDH19 pathogenic variants can be de novo or inherited. Females may 
present as sporadic cases or with a striking family history in which only women have 
seizures, ID, or ASD. The X-chromosome-linked inheritance pattern observed in families 
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is unique: only females with heterozygous pathogenic variants are affected, whereas 
males with hemizygous pathogenic variants are unaffected. A hemizygous or 
“transmitting” male must pass the pathogenic variant onto all his daughters who are likely 
to be affected. The penetrance (the extent to which the condition is present with the 
pathogenic variant) is estimated to be 90%.  
Sporadic cases are generally the result of a de novo (“new”) pathogenic variant and are 
observed in approximately half of the reported PCDH19 cases. However, in rare 
instances, the unaffected father may be mosaic thus increasing the recurrence risk of 
having another girl with GCE in those families. 
Males with a de novo somatic pathogenic variant are mosaic, that is, some of their cells 
express PCDH19 and others do not. These males exhibit a similar clinical profile (with 
seizures and ID) to heterozygous affected females. No significant clinical differences 
have been observed among individuals with inherited or de novo pathogenic variants. 
There are two frequent recurrent variants: p.Asn340Ser and p.Tyr366Leufs*10 that have 
been identified in 25 (20 unrelated) and 30 (11 unrelated) cases, respectively. There are 
no marked similarities among individuals with the same variant. 
Professionals – Clinical Characteristics 
Clinical characteristics of affected females with a PCDH19 pathogenic variant 
The clinical spectrum of GCE varies significantly, even amongst individuals in the same 
family ((including mother-daughter, sister-sister, and monozygotic (MZ) twin pairs)) and 
non-related individuals with the same PCDH19 variant. 
Epilepsy. The median age of seizure onset is 10 months (range 1 to 70 months), with 
95% of cases beginning before 25 months of age.  
Seizures are often focal and include FIAS, FMS and FBTCS but can progress quickly to 
BTCS. Ictal fear is an initial feature in ~80% of seizures with screaming reported in 
~60%. FIAS are prominent in the first few years and can have subtle semiology with a 
fearful expression, behavioral arrest accompanied by an arrest, loss of muscle tone, 
hypopnea, cyanosis, and desaturation. The motor semiology is often tonic and more 
common in older girls. Seizures can arise independently from either hemisphere. TCS are 
common in infancy, occurring in clusters and often triggered by fever. Generalised 
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absence, myoclonic, and atonic seizures are rare but there are no reports of epileptic 
spasms. The more severe cases have a developmental and epileptic encephalopathy.  
For 95% of individuals, seizures cluster and are often triggered by fever and illness, and, 
less commonly, by vaccination. Clusters typically comprise of many seizures per day over 
several days for up to a week. The severity of the clusters varies from several brief 
seizures per day with normal interictal state to hourly seizures, or status epilepticus 
requiring intensive care management. Video monitoring shows that most (71%) seizures 
occur during sleep. Although girls can have months of seizure freedom between clusters, 
the epilepsy is often pharmaco-resistant and it can be difficult to both abort a cluster of 
seizures and prevent clusters and sporadic seizures from occurring in the first decade of 
life. In adolescence, seizures often improve, with at least 30% of girls becoming seizure 
free. The age of seizure onset does not predict seizure outcome.  
Intellectual disability. Infants are usually developmentally normal at seizure onset, 
although some are delayed from birth. Regression often occurs with seizure clusters. 
Initially, development subsequently improves with a return to normal between clusters. 
Over time, with subsequent clusters, return to previous levels of function may not occur. 
Intellectual outcome varies from normal (~30%) to severe or profound ID (~15%), with 
most individuals having mild to moderate cognitive difficulties (~55%) with predominant 
language impairment.  
Early seizure onset (≤ 12 months of age) is associated with more severe ID. As delayed 
development prior to the onset of seizures is observed in ~15% of infants and seizure 
persistence is not correlated with intellectual outcome, it is likely that PCDH19 
pathogenic variants have an independent effect on seizures and cognition, which may be 
additive. In a set of identical twins with the same variant, the sister who had more 
frequent, intense, and longer clusters had a significantly worse cognitive and behavioral 
outcome than the sister who had fewer seizures. This is consistent with a developmental 
and epileptic encephalopathy. Although the association of early seizure onset with more 
severe ID may reflect the underlying severity of the disorder in that individual, it is likely 
that the early, frequent seizure activity also contributes to poorer cognitive outcomes.  
Psychiatric comorbidities. Many females with PCDH19 pathogenic variants develop 
significant mental health disorders. ASD is often diagnosed in childhood. Although 
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seizures typically improve by the second decade of life, behavioral difficulties become 
the main feature in adolescence and significantly impact the quality of life for both the 
individual and their family. These difficulties affect over half of females and males and, 
in addition to autistic features, include aggression, obsessions, depression, hyperactivity, 
panic attack, hysteria/somatoform disorder, anxiety, impulsivity, disinhibition, and 
dysexecutive syndrome. Autistic features and executive dysfunction are the most 
prominent, occurring in approximately 60% of individuals. Reports describe that 22% of 
individuals have multiple psychiatric comorbidities that predominantly include 
combinations of autistic, aggressive, hyperactive, and/or obsessive features. Psychosis 
occurs in about 20% of women, beginning in adolescence or adult life. 
More research is required to further characterize the psychiatric aspects of the clinical 
profile associated with PCDH19 pathogenic variants. Currently, research in this area is 
being led by Professor Jozef Gecz at the University of Adelaide, Australia. Further details 
can be found under “Ongoing Research” on the “Parents” page.  
EEG and neuroimaging findings: EEGs are often normal between seizure clusters but 
may show focal slowing and interictal focal or multifocal epileptiform discharges 
between and, more frequently, during seizure clusters. Focal discharges are typically 
located in the frontal and temporal regions. Focal discharges can have a diffuse field in up 
to 25% of EEGs with true generalized spike wave or polyspike wave occurring 
infrequently and in patients who also have focal discharges.  
The ictal EEG shows seizures arise from the temporal (83%), frontal (6%), parieto-
occipital (6%), or central (5%) regions. Within a cluster, seizures can start independently 
from either hemisphere or have bilateral onset. In 20% of seizures, interhemispheric 
asynchrony is observed with seizures originating in one hemisphere and migrating to 
involve only the other hemisphere.  
Neuroimaging is usually normal, although there is a report of focal cortical malformation 
in 5 individuals with PCDH19 pathogenic variants.  
Differential diagnosis. At presentation, the main differential diagnoses include a self-
limited infantile epilepsy syndrome, focal structural epilepsy, and DS. There is some 
clinical overlap between GCE and DS, as both syndromes present at a similar age, with 
seizures often triggered by fever. However, the syndromes are quite distinguishable: a 
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younger age of onset in DS (mean 5 months) comparted with GCE (mean 14 months); 
often presenting with hemiclonic SE in DS compared to clusters of brief FIAS or TCS 
with ictal fear in GCE; and generalized spike wave often seen later in DS but uncommon 
in GCE.  
It can be difficult to differentiate GCE from self-limited focal infantile epilepsy at 
presentation. For example, sporadic or familial proline rich transmembrane protein 2 
(PRRT2) self-limited focal infantile epilepsy presents at a similar age with clusters of 
brief FS. With time, the features of the syndromes diverge with continuing normal 
development and seizure resolution in most PRRT2 epilepsies and developmental slowing 
and continuing seizure clusters in GCE.  
Clinical characteristics of “mosaic” males with a de novo PCDH19 pathogenic variant 
At least ten males have been reported with de novo PCDH19 pathogenic variants. All had 
a normal complement of sex chromosomes. It was confirmed that each male was mosaic, 
with some cells containing the PCDH19 pathogenic variant and some containing wild-
type PCDH19. This mixed population of PCDH19 variant and wild-type cells is termed 
cellular mosaicism and arises from a pathogenic variant that occurs after fertilisation, but 
during early development. The mosaic cellular expression resembles an affected 
heterozygous female who has two X chromosomes, one with variant and one with wild-
type PCDH19.   
These mosaic males have a similar clinical profile to heterozygous females. Nine of the 
ten reported mosaic males have comorbid psychiatric features including behavioral 
disturbances (i.e., aggression and rigidity), ADHD, anxiety, OCD, and oppositional 
defiant disorder. 
An additional five males have recently been described, with intellectual function ranging 
from normal to severely impaired. Executive dysfunction, autistic features, hyperactivity, 
and social problems were also common. 
Clinical characteristics of hemizygous males with a germline PCDH19 pathogenic 
variant  
As transmitting males do not have epilepsy or significant cognitive difficulties, they are 
considered unaffected. However, it has been noted that they may exhibit behavioral 
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features reminiscent of a broader autism-like phenotype or obsessive-compulsive features. 
Five transmitting males have been described with inflexible, rigid personalities, and 
obsessive traits. 
Professionals – Management 
Management and Surveillance. Currently, there is no known cure for GCE. Epilepsy 
should be managed by a pediatric neurologist or a pediatrician with expertise in epilepsy. 
Early developmental and behavioral diagnosis and intervention with education programs 
can maximize cognitive and social potential.  
Parents should be encouraged to promptly discuss concerns about possible seizures, 
learning difficulties, or behavioral problems with their child’s pediatrician or pediatric 
neurologist so that these symptoms can be appropriately diagnosed and managed. 
Table 4.1 Management and surveillance 
Possible health risk Suggested surveillance 
____________________________________________________________________________________________________________________________________________ 
Seizure control/management Epilepsy should be managed by a pediatric neurologist or a pediatrician with 
expertise in epilepsy. 
Learning (including speech 
and language) 
Developmental surveillance by a pediatrician with appropriate referral for early 
cognitive assessment, intervention (including speech therapy), and ongoing 
support at school and on leaving school. 
Behavioral problems Developmental surveillance by a pediatrician with appropriate referral for early 
intervention and ongoing support by a psychologist or psychiatrist, if required. 
For more severely affected individuals, behavioral medications may be required. 
 
Genetic counseling. Individuals and their families with a PCDH19 pathogenic variant 
should be referred to a geneticist and for genetic counseling. This is especially important 
given the unusual X-linked dominant pattern of inheritance with male sparing. 
Approximately half of the individuals with GCE have a family history of epilepsy. 
However, the expression pattern is unusual given only females are affected and daughters 
can inherit the variant from their unaffected fathers or affected or unaffected mothers 
(Fig. 4.1). The expression pattern in GCE is the “inverse” of typical X-linked inheritance, 
where males are affected, and females are unaffected carriers (Fig. 4.2). 
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Figure 4.1 X-linked dominant inheritance with male sparing and expression pattern in GCE. Note that all daughters of 
an unaffected (transmitting) male inherit the PCDH19 pathogenic variant and most are affected. A female with a 
PCDH19 pathogenic variant will transmit this to 50% of her daughters. 
 
Figure 4.2 Typical X-linked recessive inheritance 
Males inherit an X chromosome from their mother and a Y chromosome from their 
father. Males who inherit an X chromosome with an abnormal PCDH19 gene are 
unaffected and are therefore considered transmitting carriers of GCE. Females have two 
X chromosomes; one inherited from their mother and one from their father. Each X 
chromosome has a PCDH19 gene. However, while females have two X chromosomes in 
each of their cells, only one X chromosome is generally active. This is due to an 
evolutionarily old molecular process called XCI (see also below), which prevents the two 
X chromosomes from being expressed in one cell. Females who have a pathogenic variant 
in one of their PCDH19 genes are called heterozygotes and are generally affected (90% 
penetrance).  
Around half of the females with GCE are sporadic, with no family history of the disorder. 
The majority of these have a de novo PCDH19 pathogenic variant. However, in a small 
percentage germline mosaicism can occur where the genetic change occurs later in the 
parents’ early development. The pathogenic variant is not present in the mother or 
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father’s brain, so they are unaffected. The variant is present in their germline cells. 
Therefore, the chance that they may have another affected child is lower than for a 
heterozygous female carrier (50% chance of transmission to daughters) or a transmitting 
male (100% chance of transmitting to daughters). However, the risk of having another 
affected child for individuals with gonadal mosaicism is not negligible. Due to the 
complex nature of GCE inheritance, it is important that families are offered 
comprehensive genetics counseling, especially if they are planning another pregnancy. 
Their children should also be offered counseling when they grow up. The sons of a 
mother with a PCDH19 pathogenic variant have a 50% chance of inheriting the 
pathogenic variant and then a high risk of having affected daughters. 
What are the chances of a female with a PCDH19 pathogenic variant having a child with 
GCE? 
Females with a PCDH19 pathogenic variant who are on the mild end of the disease 
spectrum or asymptomatic carriers may want to have children. Females with a PCDH19 
pathogenic variant, regardless of their disease penetrance, have a 50% chance of passing 
on the X chromosome with the working PCDH19 gene and a 50% chance of passing on 
















*X chromosome with the PCDH19 pathogenic variant 

















Figure 4.3 Transmission of the PCDH19 gene from the mother. 
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What are the chances of a male (hemizygous or mosaic) with a PCDH19 pathogenic variant having 
a child with GCE? 
Males pass on their X chromosome to all their daughters and a Y chromosome to all their 
sons. A carrier male will pass on the X chromosome with the PCDH19 pathogenic variant 
to all his daughters. This means all their daughters will be at high (due to ~90% penetrance) 
risk of developing GCE. As a male with a PCDH19 pathogenic variant passes on his Y 













*X chromosome with the PCDH19 gene pathogenic variant 
  X chromosome with a normal copy of the PCDH19 gene 
 
Professionals – Molecular Characteristics 
The PCDH19 gene is located at Xq22.1 and consists of six exons. The gene encodes a 
1148 amino acid protein with typical features of the δ2-protocadherin sub-family, with 23 
amino acid signal peptides, six conserved cadherin repeats in the EC domain, a 
transmembrane domain, and conserved motifs (CM1-CM2) in the C-terminal region. The 
first exon encodes the EC and transmembrane domains, as well as a small portion of the 
C-terminal region. While the rest of the C-terminal region is encoded by exons 2–6, the 
second, and likely the third exon are subject to alternative splicing. Exons 5 and 6 encode 
for CM1 and CM2 domains, respectively. More than 80% of the reported GCE 
All daughters will inherit 
the pathogenic variant 
and likely develop GCE 
No sons will inherit the 
pathogenic variant and will 





Figure 4.4 Transmission of the PCDH19 gene from the father. 
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pathogenic variants are observed in the EC domain of the protein encoded by exon 1. Of 
the reported variants in this region, almost half are in the EC3 and EC4 domains (20% 
and 23%, respectively). Missense variants are most frequently reported (45%), followed 
by frameshift (27%), and nonsense variants (20%). In total, 145 unique germline 
PCDH19 pathogenic variants have been identified in GCE, both in large families as well 
as singleton cases. Most PCDH19 variants are non-recurrent (exclusive to that individual 
or family) with the exception of p.Asn340Ser and p.Tyr366Leufs*10, which have been 
reported in 25 and 30 individuals, respectively.  
Several mechanisms have been suggested to account for the unusual mode of inheritance. 
Of these, cellular interference has received the most support. Cellular interference is a 
mechanism reminiscent of metabolic interference and postulates that random inactivation 
of one X chromosome in females with a PCDH19 pathogenic variant generates cellular 
mosaicism in PCDH19-expressing tissue (i.e. co-existence of PCDH19-normal or 
PCDH19-abnormal cells). Such cellular mosaicism causes the condition by altering cell-
cell interactions, function, and therefore neural networks in the brain. Cellular 
interference is consistent with the clinical finding that males hemizygous for a PCDH19 
pathogenic variant in all their cells are typically unaffected as they have only one 
population of cells albeit with the pathogenic variant, whereas males with somatic 
mosaicism are affected similarly to heterozygous females.  
The identification of affected males who are mosaic for PCDH19, and therefore have a 
mixture of PCDH19-normal and PCDH19-abnormal cells, strongly supports the 
hypothesis of cellular interference as the main pathogenic mechanism associated with 
PCDH19 pathogenic variants. The co-existence of normal and abnormal cells and the 
proportion of each population in the brain of these males cannot, however, be 
extrapolated from available tissues i.e., skin fibroblasts or lymphocytes. To establish that 
cellular interference is the pathogenic mechanism, it is necessary i) to demonstrate that 
neuronal cells are mosaic, but also that ii) females who are homozygous for PCDH19 
pathogenic variants or deletions are also unaffected, akin to hemizygous males. Some 
support for the first point lies in the findings from a Pcdh19 knockout mouse model. 
Simultaneous labelling of wild-type Pcdh19 and null Pcdh19 cells in Pcdh19 
heterozygous mice revealed a striking pattern of alternating Pcdh19 +ve and Pcdh19 -ve 
regions. This pattern was particularly obvious in the developing cortex where it 
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resembled “tiger stripes”. Although pathogenesis in cells that express the abnormal allele 
corresponds to a loss-of-function, cellular interference would result in a gain-of-function 
at the tissue level, because of abnormal interactions between normal and abnormal cells. 
This hypothesis supposes that the loss of PCDH19 is compensated for, but by a 
mechanism that is relatively independent of gender. For the latter, there is yet to be a 
report of a female homozygous for loss of function pathogenic variant in PCDH19. 
Molecular diagnosis 
Testing for GCE requires sequencing of the PCDH19 gene, either by traditional Sanger 
sequencing or massively parallel sequencing methodology (panel testing, exome, or 
genome). If no pathogenic variants are identified, then microarrays for copy number 
testing i.e., deletions or duplications should be performed in individuals presenting with 
the typical phenotype or inheritance pattern. 
Determining the pathogenicity of novel variants requires the use of in silico tools and 
segregation in additional family members. In some cases, molecular/functional studies 
may be required to build evidence that a detected variant is causal of the individual’s 
condition. Whether the phenotype is consistent with the disease should also be 
considered. 
Repository of the variant and levels of evidence for causality in publicly available 
international databases like ClinVar https://www.ncbi.nlm.nih.gov/clinvar/ or 
DECIPHER https://decipher.sanger.ac.uk/ is recommended to aid interpretation of novel 
variants. 
Professionals – Publications 
Juberg RC et al. A new familial form of convulsive disorder and mental retardation 
limited to females. J Pediatr. 1971;79:726–32. PMID: 5116697 
Ryan SG et al. Epilepsy and mental retardation limited to females: an X-linked dominant 
disorder with male sparing. Nat Genet. 1997;17:92–95. PMID: 9288105 
Scheffer IE et al. Epilepsy and mental retardation limited to females: an under-recognized 
disorder. Brain. 2008;131:918–27. PMID: 18234694 
Dibbens LM et al. X-linked protocadherin 19 pathogenic variants cause female-limited 
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pathogenic variants in PCDH19 resembles Dravet syndrome but mainly affects females. 
PLoS Genet. 2008;5(2):e1000381. PMID: 19214208 
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pathogenic variants can present de novo or in single generation families. J Med Genet. 
2010;47(3):211–216. PMID: 19752159 
Dibbens LM et al. Recurrence risk of epilepsy and mental retardation in females due to 
parental mosaicism of PCDH19 pathogenic variants. Neurology. 2011;76(17):1514–1519. 
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Professionals – Research Collaboration 
Ongoing Research  
1. Understanding individual differences associated with PCDH19 pathogenic 
variants (H-2016-184) 
This research, led by Professor Jozef Gecz at the University of Adelaide, aims to 
understand the symptoms associated with PCDH19 pathogenic variants. The project also 
aims to provide a clear picture of how these symptoms change over time. This 
information will help us to better understand PCDH19-related disorders. 
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Participants for this project are individuals with a PCDH19 pathogenic variant or their 
caregivers who can report on behalf of someone with a PCDH19 pathogenic variant. 
Participation involves responding to an online PCDH19 survey. 
For more details and to participate, please contact Kristy Kolc 
Kristy.kolc@adelaide.edu.au  
2. PCDH19 Registry 
With funding provided by the PCDH19 Alliance, researchers at UCSF Benioff Children’s 
Hospital and Boston Children’s Hospital have created a registry for individuals with 
PCDH19-Related Epilepsy. The registry is an important tool to help researchers gain a 
better understanding of PCDH19-Related Epilepsy and ultimately develop more effective 
treatment options. The registry is open to any individual who has been diagnosed with 
PCDH19-Related Epilepsy. 
For more information visit https://www.pcdh19info.org/pcdh19-patient-registry  
Support Organisations 
There are several organisations around the world that provide support, information, and 
fund research related to PCDH19. 
USA: PCDH19 Alliance 
http://pcdh19info.org/ 
France: PCDH19 France 
http://www.pcdh19france.fr/  
Italy: ONLUS Insieme per la Ricerca PCDH19 
www.pcdh19research.org 
Caregivers – General Information 
The PCDH19 gene is an important gene contributing to brain function. Genetic changes 
(called pathogenic variants or mutations) in the PCDH19 gene cause disease. This 
predominantly occurs in girls and the characteristic feature of this disease is seizures 
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occurring in clusters, hence the name GCE. Some girls (20%) with a PCDH19 pathogenic 
variant have no clinical features. Affected females with pathogenic variants vary in the 
severity of their illness, ranging from mild epilepsy, to mild epilepsy with learning 
difficulties to a severe treatment-resistant epilepsy accompanied by ID and mental health 
disorders, such as ASD and behavioral problems. How much this condition affects an 
individual varies significantly, even amongst individuals in the same family with the 
same pathogenic variant. 
The first symptoms are usually epileptic seizures that often begin in the first year of life, 
but may begin up to 3 years of age. The seizures come in clusters, that is, many seizures 
occur over several days followed by periods of time (up to months) without seizures. 
Girls may have slow development and behavioral problems, and sometimes lose their 
skills. The more severely affected will develop ID, ranging from mild to profound. 
Individuals with GCE are otherwise healthy, with normal functioning of the rest of their 
bodies.  
The PCDH19 gene lies on the X chromosome, which is one of the sex chromosomes. 
Males have a single X chromosome and a Y chromosome, while females have two X 
chromosomes. GCE can be passed down (inherited) within a family or found in an 
individual with no family history of the disorder. Females with a pathogenic variant have 
a high likelihood of being affected, but males with the pathogenic variant typically do not 
have seizures and have normal intelligence.  
Only a small number of males have been reported who are affected by PCDH19 
pathogenic variants. This is due to a situation called “somatic mosaicism”, where the 
affected males have a mixture of normal and abnormal copies of the PCDH19 gene in 
their brains. 
Pathogenic variants in PCDH19 are a common genetic cause of epilepsy. As the gene was 
only identified in 2008, we are rapidly learning about this condition as more people are 
being diagnosed.   
It is crucial that we capture as many individuals as possible with PCDH19 pathogenic 
variants (including those not reported in the medical literature). This includes females as 
well as males, so we can build a more comprehensive understanding of this condition. 
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Caregivers – Clinical Characteristics 
Features of GCE. Not all individuals with a pathogenic variant in the PCDH19 gene 
have clinical features. How much a pathogenic variant results in symptoms (e.g. seizures, 
learning difficulties) in an individual varies, even amongst affected individuals in the 
same family. The main clinical features of this disorder are seizures, abnormal 
development, and behavioral problems.  
Seizures. The most common age of seizure onset is 8 months, but children can develop 
seizures anytime between 1.5 and 70 months of age. The first seizures often occur in the 
setting of a fever. Most seizures occur in clusters and girls can have many seizures in a 
day for several days. The types of seizures are most commonly focal seizures, but tonic-
clonic convulsive seizures can also occur. During a seizure, girls appear fearful and may 
scream. They are not aware of what is going on around them. They may have stiffening or 
jerking of one limb, which can sometimes spread to involve the entire body. Most 
seizures are short, lasting less than a few minutes, but sometimes there are so many of 
them in a cluster that the child does not recover between seizures. Anti-epileptic drugs 
(AEDs) are used to stop the seizures and prevent further clusters. In some individuals, the 
AEDs do not work well and it is difficult to prevent seizures occurring. Fortunately, the 
epilepsy often improves over time, with seizures becoming less severe and less frequent 
during adolescence. Some individuals become seizure-free around this time. 
Development. Most, but not all, girls have normal development prior to the onset of 
seizures. Approximately 40% of females with GCE have normal intelligence throughout 
their lives. For the remaining 60% of girls, development slows during childhood and they 
ultimately develop ID, which can vary in severity from mild (i.e., will likely be able to 
attend mainstream education) to severe or profound (will need assistance in all areas of 
life). It is important to treat the clusters of seizures, as frequent and severe seizures can 
cause slowing of development. Many affected females have specific problems with 
planning and organisation, abstract reasoning, and the ability to control their behaviors 
(“executive functions”). 
Mental health and behavioural outcomes. Many children develop autistic features, as 
well as hyperactivity, attention-deficit disorder, and/or other behavioural disturbances. In 
adult life, some woman have psychiatric disorders, such as depression and psychosis. 
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Caregivers – Management 
The same text will be displayed as in Professionals – Management.  
Caregivers – Molecular Characteristics 
Many changes in the genetic code of the PCDH19 gene have been found to cause GCE. 
Changes which affect the gene’s ability to function (and therefore cause disease) are 
referred to as pathogenic variants or mutations. Every person has a unique genetic code and 
most changes to this code do not cause disease. These non-disease-causing changes are 
called benign variants. When a diagnosis of GCE is supported by the finding of a 
pathogenic variant by a molecular laboratory, the identified variation is recorded on the 
report from the testing laboratory. 
Most individuals with GCE have a pathogenic variant that is unique to their family, and 
therefore it can be difficult to determine if a variant is a benign (non-disease-causing) 
change or a pathogenic (disease-causing) change. More evidence may be required to be 
sure that the genetic change in PCDH19 is causing disease. Testing of other family 
members can be helpful and provide evidence for the variant being either benign or 
pathogenic. A clinical genetics service can advise on the next steps after a PCDH19 
pathogenic variant is identified. 
The international scientific and diagnostic community is working hard to build tools to 
improve our ability to determine whether a variant is disease-causing or not. 
Caregivers – Publications 
The same text will be displayed as in Professionals – Publications.  
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5.1 Preamble 
An interesting finding to emerge from the second study was the self-reported efficacy of 
the anti-epileptic medication levetiracetam. This independent finding was corroborated 
following discussions with our collaborators. Clinical evidence also suggested that 
levetiracetam was efficacious in ameliorating seizures and, in some cases, improving 
behavior. For this work, I collaborated with pediatric neurologists based in Melbourne 
and New Zealand to review the effect of levetiracetam as a treatment for GCE. The 
importance of this work is pivotal. Presently, there are no effective treatments available, 
as GCE is pharmaco-resistant. Our lab has been involved in a clinical trial of ganaxolone, 
a synthetic analogue of allopregnanolone. We had previously shown a deficiency in 
allopregnanolone in girls with PCDH19 variants.50 Data from my first two studies was 
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Abstract 
Background: GCE has a phenotypic spectrum that includes developmental and epileptic 
encephalopathy. GCE presents with clusters of seizures in the first years of life. Although 
patients typically outgrow their seizures, many are left with ID. Here we retrospectively 
assess the effect of levetiracetam in two independent cohorts of females with GCE. 
Methods: Cohort A was identified by searching our epilepsy genetics research database 
for girls with GCE who had trialled levetiracetam. Cohort B consisted of girls aged 2 
years or older, including women, participating in an international online questionnaire. 
Information regarding seizure frequency and levetiracetam use was obtained by in-person 
patient interview and review of clinical records for cohort A, and by patient report for 
cohort B. Results: Cohort A consisted of 17 females, aged 3-37 years, who had a trial of 
levetiracetam at an average age of 10.7 years. 13/17 females became seizure free for >12 
months; while 10/17 remained seizure free for >24 months. Cohort B comprised 62 
females, aged 1.5-41 years. 26/62 became seizure free for >12months, and 19/62 for >24 
months on levetiracetam therapy. Discussion: Levetiracetam was effective in two cohorts 
of females with GCE where 42% and 76% of females became seizure free for >12 
months, respectively. Levetiracetam is an effective therapy for females with GCE and 
should be considered early in the management of the highly refractory clusters of seizures 
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Introduction 
PCDH19 causes a distinctive epilepsy syndrome known as GCE.2, 3 This syndrome has a 
broad range of phenotypes ranging from a mild self-limited disorder to a highly refractory 
developmental and epileptic encephalopathy. A recent Scottish epidemiology study found 
an incidence of PCDH19 pathogenic variants of 1 in 20,500 live female births; it was the 
second most common cause of developmental and epileptic encephalopathy in girls.81 
PCDH19 is an X chromosome gene. It encodes a member of the delta-2 non-clustered 
protocadherins (d2-PCDHs), which belong to the cadherin super-family of cell-cell 
adhesion molecules with diverse roles in neuronal migration, neuronal cell specification, 
or synaptic function.82 In addition to its canonical role in brain wiring,51 PCDH19 protein 
has also been proposed to co-regulate gene expression with estrogen receptor alpha 
(ERa).50 While the fine detail of the underlying mechanism(s) of GCE is not yet fully 
understood, there is mounting evidence suggesting that cellular mosaicism, that is the 
presence of cells with and cells without functioning PCDH19 protein, is the fundamental 
disease driver.51 
Girls with GCE present at a mean age of 11.8 months (range 4-72) with clusters of FIAS 
and FBTCS.3, 8, 25, 47, 56, 61 Often triggered by fever, clusters can consist of up to 30 
seizures and last 1-14 days.8, 11, 22, 25, 28, 56, 83 Inter-cluster intervals last weeks to months.3, 
8, 11, 22, 25, 28, 56, 83 Typically, development is normal at onset of seizures and may regress 
with clusters.3, 8, 11, 25 Initially skills can be regained during the inter-cluster interval but 
eventually ID may be evident.8, 11, 25, 64 Seizures often cease in the second to third 
decade.3, 8, 11, 25, 28, 56, 63, 64 Two-thirds of women have ID, which ranges from mild to 
severe. A significant number have psychiatric comorbidities such as ASD and psychosis.8, 
11, 25, 28, 63, 64 Seizure onset before 12 months of age is associated with a poorer cognitive 
outcome.56, 64  
Preventing and aborting clusters of seizures is difficult and, despite trials of multiple 
AEDs, girls often require recurrent hospital admissions.56 Through clinical practice, we 
noted remarkable seizure control with levetiracetam for several girls with drug-resistant 
GCE. Here, we report the impact of levetiracetam on girls with GCE in two cohorts: a 
research cohort in which detailed historical clinical information was available and an 
international cohort of individuals with PCDH19 variants who were surveyed via an 
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online questionnaire 
Method 
We evaluated response to levetiracetam in two cohorts of patients with GCE. 
Cohort A 
We searched our Australian and New Zealand Epilepsy Genetics research database for 
individuals with epilepsy and pathogenic variants in PCDH19 who had received a trial of 
levetiracetam. The parents of each girl were interviewed using a standardized epilepsy 
questionnaire84 and seizure videos were reviewed where available. All medical records, 
EEGs, and neuroimaging were obtained. Seizures and epilepsy syndromes were 
diagnosed according to the 2017 International League Against Epilepsy classification.85, 86 
Clinical records were analyzed for seizure frequency and AED history.  
Cohort B 
We conducted a large online international survey of patients with PCDH19 pathogenic 
variants; only patients who had trialed levetiracetam were included in this study. We 
invited families with girls aged 2 years or older to participate. Patients were recruited via 
our international collaborators and PCDH19 family associations. The survey was carried 
out between April 2017 and March 2019 and was available in English, Italian, or French. 
Participants were proficient in one of these languages. The survey was completed by 
affected women of normal intellect, or a parent or carer in the case of minors or women 
with ID. Families provided their specific PCDH19 variant and results of any other genetic 
testing. Patients were excluded if they had any of the following: 
• an additional pathogenic variant(s) in another gene(s) 
• their PCDH19 variant was likely benign based on: frequency of their variant in 
gnomAD (http://gnomad.broadinstitute.org/) and in silico prediction tools 
CADDv1.3 (including Polyphen287, GPP88, MutPred89, Mutation Assessor90, 
PROVEAN91, and SIFT92) through the web-based ANNOVAR 
(http://wannovar.wglab.org/).  
For cohort B, participants were asked questions relating to seizure frequency and AED 
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history. Individuals were asked to list all the AEDs ever trialled, and to specify if any had 
resulted in seizure freedom and for how long.  
Written or online informed consent was obtained from all patients or their parents or legal 
guardians in the case of minors or those with ID. The study was approved by the New 
Zealand, Austin Health, and University of Adelaide Ethics committees.  
Results 
Cohort A 
We identified 40 females with epilepsy due to PCDH19 pathogenic variants from 19 
Australian and New Zealand families. 17/40 (43%) females had trialed levetiracetam. 
Adequate efficacy data were available for 14 girls (Table 5.1), and for 3, behavioral 
exacerbation meant that levetiracetam was discontinued before seizure efficacy could be 
assessed. The 14 girls who had an adequate trial of levetiracetam were previously drug-
resistant; they had an average of 5 AEDs prior to the introduction of levetiracetam. The 
average age at trial of levetiracetam was 10.7 years. Of the 17 girls that trialed 
levetiracetam, 13/17 (76%) became seizure free for 12 months or more; 10 (59%) were 
seizure free for at least 24 months. For nine girls, a detailed yearly analysis of seizure 
burden and AED history was available from the medical history and revealed a striking 
effect of levetiracetam (Fig. 5.1). For the remaining five girls, detailed yearly seizure 
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Table 5.1 Clinical information for cases who had adequate trial of levetiracetam 


























CP A A1 13y 10m FIAS Nil 3.3y Severe Y N CLB, CBZ, LTG, 
VPA, TPM 
5.1y 7.9y 5.2y None c.497_498insA 
p.Tyr166X 
JP A A2 13y 10m FIAS Nil 3.4y Mild N N CLB, CBZ, LTG, TPM 5.3y 7.7y 5.1y None c.497_498insA 
p.Tyr166X 
JR B B3 17.5y 16m FIAS FBTCS 3.7y Borderline N N CLB, CBZ, TPM, 
VPA, LTG 
4.8y 5.6y 11.8y None c.1919T>G 
p.Leu640Arg 
AB C C4 22y 19m TS FIAS, 
FBTCS 
1.5y Mild Y Y PRD, CLB, CBZ, 
VPA, ACTH, PB, PT, 
AZD 
20y 1y 21y None Exon 6 deletion 
SB C C5 31y 14m FBTCS FIAS 1.1y Mild Y Y PB, PHT, CLB, AZD, 
CBZ, LTG, VPA, 
TPM, CZP 
22y 9y 22y None Exon 6 deletion 
CJ D D6 8.9y 11m GTCS FIAS, FMS, 
FBTCS 
2.9y Normal N N VPA, CZP 2.9y 3.1y 7.5y None c.1031G>A 
p.Pro344Leu 
MK E E7 27y 8m FIAS GTCS 5y Moderate N Y CBZ, PHT, CZP, PHT, 
DZP, VPA, CLB 
Unknown 8y 19y None c.2534C>T 
p.Ser845Asn 
HK F F8 35y 9m FMS FIAS 9m Mild N Y VPA, NZP, VGB, 
LTG, GP, PHT, PB, 
TPM, TGB, CZP, CBZ 
28y 4y 31y None c.2123_2124del 
p.Lys708ArgfsX9 
KK F F9 3.3y 7m TS FIAS, FBTC 7m DD N N None 7m 1y Ongoing TPM c.2123_2124del 
p.Lys708ArgfsX9 
RV G G10 17.6y 8m TS FAS, GTCS 8m Moderate Y Y OX, CZP 12y 4.7y 13y None c.74T>C 
p.Leu25Pro 
AK H H11 32y 24m FMS FIAS Unknown Mild N N CBZ, LTG, VPA, TPM 16y 16y 16y None c.1671C>G 
p.Asn557Lys 
GS I H12 9.5y 9m GTCS TS, FBTCS, 
FIAS 
2.4y Mild Y N CLB, LTG, VPA, PRD 1.8y 1.2y Ongoing None c.1019A>G (het) 
p.Asn340Ser 
PC J J13 4.3y 18m FBTCS FIAS, TS, 
FMS 





TK K K14 17y 17m FIAS FIAS, FMS, 
FBTCS 
3y Borderline N Y VPA, CBZ, CLB 13y 2y Ongoing  c.498C>A 
p.Tyr166X 
In the Family column, the superscript number denotes the reference number of the paper in which this individual has been previously published. The ID denotes the specific patient identification number in that 
publication. ASD, autism spectrum disorder; AEDs, antiepileptic drugs; y, years; m, months; Y: yes; N, no; NA, not affective; PCDH19, protocadherin-19, DD, developmental delay; ID, intellectual disability; FIAS, 
focal impaired awareness seizure; FBTCS, focal to bilateral tonic-clonic seizure; TS, tonic seizure; GTCS, generalised tonic clonic seizure; FMS, focal motor seizure; LEV, Levetiracetam; CLB, clobazam; CBZ, 
carbamazepine; LTG, lamotrigine; VPA, sodium valproate; TPM, Topiramate; PRD, pyridoxine; ACTH, adrenocorticotropic hormone; PB, phenobarbital; AZD, acetazolamide; PHT, phenytoin; CZP, clonazepam; 
DZP, diazepam; VGB, vigabatrin; GP, gabapentin; NZP, nitrazepam; TGB, tiagabine; OX, oxcarbazepine; CBD; cannabidiol; ETX, ethosuximide. 
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Case example 
Patient 3 is an 18-year-old adolescent who presented at age 14 months with a cluster of 11 
focal seizures over 2 days. In retrospect she had had clusters of brief FIAS from age 9 
months that were thought to be day dreaming. She continued to have clusters of 11-60 
seizures over 2-11 days every 3 months. Her early development was normal. She walked 
at 14 months and her first words were at 9 months. During clusters her language and 
development would regress however, in her first 4 years, development would return to 
normal within 2 weeks of a cluster. By her fifth year, cognitive assessment showed that 
her verbal abilities were in the “low average” range and non-verbal abilities in the “mildly 
impaired” range (1st percentile). She was drug-resistant to clobazam, carbamazepine, 
topiramate, valproate, and lamotrigine, and her longest seizure-free period was 4 months. 
In the four years prior to levetiracetam, she had 245, 129, 202 and 259 seizures per year, 
respectively resulting in 12, 38, 34 and 27 days in hospital over 15 admissions. 
Levetiracetam was started just before her 5th birthday and controlled her seizures. She 
has not required any hospital admission subsequently. She had 4 seizures in her 6th year 
but after the levetiracetam dose reached 60 mg/kg/day she only had rare break-through 
seizures with growth at age 8 and 11 years. She has been seizure free since. 
Cohort B 
Eighty-nine females or their carers completed the online questionnaire. Of these, 82 had 
epilepsy and 62 had trialed levetiracetam. The average age when the survey was 
completed was 11.5 years (1.5 - 41 years). The average age of seizure onset was 10.3 
months (1.5 - 28 months). The majority (59/62, 95%) had been admitted to hospital at 
least twice with 68% (42/62) having at least 5 admissions. Nineteen cases (31%) had at 
least one episode of SE. 26/62 (42%) reported becoming seizure free for at least 12 
months with levetiracetam. This included 19 (31%) who were seizure free for 2-16 years. 
An additional 4 girls (6%) reported 4-12 months seizure freedom with levetiracetam. 
Duration of seizure freedom was associated with age at survey completion, with older 
girls more likely to report seizure freedom on levetiracetam (t(43.7) = 2.47, p = .018). 
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Figure 5.1 Seizure clusters (blue bars) for nine patients showing a marked reduction in cluster frequency with the 
introduction of levetiracetam (yellow bar). A) Girls younger than 14 years of age. B) Adolescent and adult patients. 
Length of X axis denotes the current age of the patient. Grey box indicates that no hospital records were available for 
this period. 
Discussion 
GCE has a characteristic clinical presentation where typically developing infant girls 
present with clusters of seizures, which often prove highly refractory.11, 25 Earlier age of 
seizure onset is associated with poorer cognitive outcome.56, 64 Although there are no 
studies to show that the seizure burden per se impacts negatively on their development, 
the regression of development associated with more severe clusters suggests that seizure 
load contributes independently to poor cognitive outcome. Initiating effective AEDs early 
is therefore likely to have a positive effect on developmental outcome. There are no 
published clinical trials of AEDs in females with GCE. A small series of 5 children with 
GCE reported a reduction in the duration of a cluster with the use of IV corticosteroid 
therapy however ongoing steroids did not prevent future clusters.83 A retrospective 
multicentre review of AED therapy in 58 females with GCE from 12 countries reported 
that the most effective AEDs were clobazam and bromide.93 Clinicians completed a 
questionnaire based on parental reports of seizure frequency. The age at trial of AEDs and 
the order of AED use was not reported. Here we report the effect of levetiracetam in two 
cohorts of females with GCE. Following independent recognition by two authors (LGS 
and IES) in clinical practice of the remarkable effect of levetiracetam in girls with GCE, 
we searched our epilepsy research database for all girls treated with levetiracetam (cohort 
   CHAPTER 5 
 
P a g e  | 82 
A) to ascertain if this was coincidental. Levetiracetam resulted in at least 12 months’ 
seizure freedom in 76% of cohort A. In an independent cohort (cohort B), 42% of females 
reported seizure freedom for 12 months or more with levetiracetam. Although the data 
from both cohorts is retrospective, the seizure freedom rates are considerably higher than 
those reported in ten randomised placebo-controlled trials of levetiracetam in focal 
epilepsies where only 2-18% of individuals became seizure free for 3-6 months.50, 94-104 In 
previous clinical series of GCE, a positive effect of levetiracetam has been reported in 
individual cases but was not systematically assessed.4, 28, 56 Delving into the effect of 
levetiracetam in the report by Lotte and colleagues, 38 cases had at least a 3 month trial of 
levetiracetam of which 13 (34%) had a 50% or more reduction in seizures and 5 (15%) 
became seizure free.93 Fourteen cases trialed levetiracetam for 12 months with 8 (57%) 
obtaining a 50% reduction in seizures and 3 (21%) being seizure free. Our cohort A, 
which was ascertained in a similar manner, demonstrated a much greater effect of 
levetiracetam (76% seizure free for12 months) than reported in the Lotte et al. study.93 A 
greater positive effect (42% seizure free for 12 months) was also seen independently in 
cohort B. Identifying AEDs that are effective in GCE is complicated as the natural history 
of this distinctive syndrome is that most girls become seizure free in adolescence.3, 4, 11, 56 
Therefore, retrospective reports of which AED controlled seizures are confounded by the 
age at which the AED was introduced, as it may have coincided with the age at which the 
girls would naturally outgrow their seizures. Seizure cessation may then be 
inappropriately attributed to the AED in use at that time. Age of specific AED 
introduction was not available for cohort B nor was it provided in the Lotte study.93 To 
definitively ascertain if an AED is effective, randomised, double-blind, trials of either 
placebo or proven alternative treatments are required. However, in our research cohort A, 
the average age at which levetiracetam was introduced was 10.7 years, which is younger 
than studies show most girls become seizure free.3, 8, 11, 25, 28, 56, 63, 64 Of the 7 cases in 
cohort A who trialed levetiracetam prior to their 6th birthday, six became seizure free for 
at least 1 year, and four only had break through seizures with iatrogenic reduction of the 
levetiracetam dose or when the girl grew (Fig. 5.1). This provides support to the effect 
being real and not due to natural seizure remission. 
   CHAPTER 5 
 
P a g e  | 83 
Why Levetiracetam may be beneficial in GCE can only be speculated. Evidence from 
iron-chloride induced epilepsy in rats suggests that levetiracetam leads to suppression of 
glutamate overflow and enhancement of GABAergic inhibition.105 While the suppression 
of the glutamate overflow effect could be explained through levetiracetam modulation of 
the synaptic vesicle glycoprotein 2A (SV2A) function, the modulation of GABAergic 
inhibition is less clear. The fact that the PCDH19 protein has recently been shown to 
physically interact with gamma aminobutyric acid alpha receptor (GABAAR)
106 may lead 
to testable hypotheses in this regard.  
In conclusion, the data from our two independent cohorts suggest that levetiracetam is an 
effective AED for GCE, rendering some girls seizure free. A randomized, double-blind, 
placebo-controled trial is required to prove the efficacy of levetiracetam in GCE but, 
given our promising data, levetiracetam should be considered early in the management of 
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6.1 Preamble 
When GCE (EFMR, at the time) was first described in 1971 by Juberg and Helman, a 
phenotype was only evident among females in the original family. Subsequent reports 
describe a “female-limited” disorder with “male-sparing”. It was not until 2009, that the 
first male was identified by Depienne and colleagues. Since then, only 12 males have 
been described with PCDH19 pathogenic variants and a GCE-like phenotype. In most 
cases, a single case is reported and no large cohorts have been presented. As such, males 
represent an under-recognized group. Using the information gleaned from the second 
study, I conduct a precise and comprehensive analysis of phenotypic abnormalities in the 
largest cohort of PCDH19-variant males to date. This work will facilitate the 
identification of males with GCE, useful to both families and clinicians. GCE can no 
longer be considered a disorder limited to females and has been re-named X-linked 
clustering epilepsy (XCE) to facilitate the growing number of affected male cases. 
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Abstract 
PCDH19 pathogenic variants cause an infantile onset epilepsy syndrome called GCE due 
to the vast majority of affected individuals being female. This syndromic name was 
developed to foster early recognition and diagnosis in infancy. It has, however, sparked 
debate, as, there are rare males with postzygotic somatic, and therefore, mosaic, PCDH19 
pathogenic variants with similar clinical features to females. Conversely, “transmitting” 
males with germline inherited PCDH19 variants are considered asymptomatic. To date, 
there has been no standardized neuropsychiatric assessment of males with PCDH19 
pathogenic variants. Here, we studied 15 males with PCDH19 pathogenic variants (nine 
mosaic and six transmitting) aged 2 to 70 years. Our families completed a survey 
including standardized clinical assessments: SRS-2, SDQ, BRIEF, and DOCS. We 
identified neuropsychiatric abnormalities in two males with germline PCDH19 possibly 
pathogenic variants. One had a prior history of a severe encephalopathic illness, which 
may have been unelated. We also describe a non-penetrant somatic mosaic male with 
mosaicism confirmed in blood, but not identified in skin fibroblasts. Our data suggest that 
transmitting hemizygous males are generally unaffected, in contrast to males with 
postzygotic somatic mosaic variants who show a similar neuropsychiatric profile to 
females who are naturally mosaic, due to XCI. The penetrance of PCDH19 pathogenic 
variants has been estimated to be 80%. Like females, not all mosaic males are affected. 
From our small sample, we estimate that males with mosaic PCHD19 pathogenic variants 
have a penetrance of 85%. With these insights into the male phenotypic spectrum of 
PCDH19 epilepsy, we propose the new term X-linked Clustering Epilepsy (XCE) to 
highlight the striking X-linked pattern of affected females with males being spared, unless 
they are mosaic. Both affected females and males typically present with infantile onset of 
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Introduction 
Pathogenic variants in PCDH19, encoding protocadherin-19, cause an infantile onset 
epilepsy syndrome called GCE, as it typically presents in girls with clusters of seizures. 
Affected females often have ID, executive dysfunction, and a range of psychiatric 
disorders including ASD, OCD, and ADHD.1, 3, 64 Mosaicism describes an individual with 
two or more populations of cells and can develop at any point following fertilization.107 
With regard to PCDH19 epilepsy, all females are effectively mosaic due to inactivation of 
one of their two X chromosomes, resulting in some cells containing wild-type PCDH19 
and some containing variant PCDH19. Males are typically hemizygous having only one 
X chromosome, however, when they have a postzygotic variant of PCDH19 they also 
become mosaic and are phenotypically similar to affected females. Twelve males with 
postzygotic somatic PCDH19 variants4-6, 17, 34, 108 and one male with Klinefelter syndrome 
and a heterozygous PCDH19 pathogenic variant109 have been identified with a similar 
phenotype to females. Although the reported clinical features of mosaic males are similar 
to affected females,64 there has been no standardized neuropsychiatric assessment of 
males with PCDH19 pathogenic variants. 
Males who inherit a germline loss-of-function PCDH19 variant are generally 
asymptomatic and referred to as “transmitting” males.1, 29, 30 However, there have been 
four transmitting males reported with neuropsychiatric abnormalities.16, 35, 36 One male 
with High Functioning ASD (previously known as Asperger’s syndrome), inherited his 
probably damaging missense variant from his asymptomatic mother,16 another male with 
ASD had unknown inheritance of his probably damaging missense variant,35 and two 
cases with ID.36 With such a small number of reported males, it is unclear if these clinical 
features are caused by the germline PCDH19 variant. Here, we report the phenotypic 
profile of 15 mosaic and transmitting males with PCDH19 pathogenic variants using 
standardized assessments conducted in conjunction with our PCDH19 survey.64   
Method 
Participants 
Our 15 male participants were ascertained through the international PCDH19 survey.110 
This cohort comprised 9 mosaic males (#1, #2, #3, #4, #5, #6, #7, #8, #9), with an age 
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range of 2 to 41 years (M =  9.67, SD = 12.2) and 6 transmitting males (#10, #11, #12, 
#13, #14, #15), with an age range of 16 to 70 years (M = 44.0, SD = 21.5). English 
speaking participants were from Ireland (1), Argentina (1), Republic of Moldova (1), 
United States (3), United Kingdom (1), Israel (1), Denmark (2), Netherlands (1), and 
Australia (1). Three participants from Italy spoke Italian and no English. Thirteen were 
Caucasian, with the remaining two Hispanic or Africana. Variant pathogenicity was 
determined by gnomAD (http://gnomad.broadinstitute.org/) frequency and in silico 
assessment through the web-based ANNOVAR (http://wannovar.wglab.org/). 
PCDH19 Survey  
The PCDH19 survey was developed and scored as previously described110 and 
incorporated the following: SRS-265 for the assessment of ASD-related symptoms, SDQ67 
for the assessment of ADHD-related symptoms, BRIEF111 for the assessment of executive 
dysfunction, and DOCS70 for the assessment of OCD-related symptoms. Demographic, 
development, variant, medication, and seizure information was captured using the EQ.110 
Participants or parents responding on behalf of their child were contacted to clarify or 
obtain additional information. Where possible, the treating clinician was also consulted to 
verify reported information. Italian translation of the EQ, survey scripts, and study 
material were performed and checked by either a professional translator or by an 
individual familiar with GCE and fluent in the relevant languages. Published authorized 
translations of the SRS-2, BRIEF, and DOCS were utilized. License agreements were 
obtained to reproduce assessments in an online format. The project was approved by the 
University of Adelaide Human Research Ethics Committee (H-2016-184). Electronic 
informed consent was obtained from all participants or their parents or legal guardians in 
the case of minors or those with ID. 
Results   
Males with mosaic PCDH19 variants 
Five of the nine mosaic males represented in the survey harbored novel PCDH19 variants 
(#2, #3, #5, #6, #8). These included two nonsense (p.Glu574*; p.Tyr516*) and three 
missense (p.Arg198Pro, p.Asp230His, p.Asn340Lys) variants affecting the EC domain, 
which is a highly conserved region of the PCDH19 protein.10 All five variants were 
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predicted to be likely pathogenic by in silico assessment.110 The remaining were 
previously published and included: nonsense (1), missense (2), and splice-site (1) 
PCDH19 pathogenic variants. Inheritance information showed that the PCDH19 variant 
arose de novo in eight males and was not available for one individual (Table 6.1). 
Seizures presented in clusters for eight of the nine mosaic males. For the eight mosaic 
males with seizures, the median age at seizure onset was 10 months. One male (#8) 
experienced seizure onset at 8 years of age. This is the latest seizure onset recorded for an 
individual with XCE. His seizures occurred in clusters for an average of 1 day, with 
approximately 5 seizures per day in a cluster, according to parent report. His seizures 
remain ongoing at 12 years of age. The mosaic nature of this variant was confirmed in 
saliva and predicted to be deleterious.  
One mosaic male (#9) had never had a seizure and no prior neuropsychiatric diagnoses. 
This male harbors a missense variant (c.1240G>A; p.Glu414Lys) that was transmitted to 
his daughter, who is affected (#28 in 110). We tested the blood DNA of this male and 
detected the PCDH19 variant allele in approximately the same ratio as the wild-type 
allele, that is 50:50. The daughter of #9 displayed the typical features associated with 
PCDH19 pathogenic variants, with seizure onset at 8 months of age, normal early 
development, autistic features, and mild ID. This variant is recurrent and has been 
reported in a female with seizures between 14 months and 5 years of age, aggression, and 
ID.24 The variant was inherited from an asymptomatic mother and was predicted to be 
deleterious by three independent in silico tools.24  
Transmitting males with a germline PCDH19 variant 
Six males with inherited PCDH19 variants were included. Four scored in the normal 
range on all neuropsychiatric measures (Table 6.1). Two males had neuropsychiatric 
abnormalities. The first male (#11) was a 23-year-old with mild ID, ASD, and impulsive 
behavior. His parent reported first behavioural concerns at 12 months. He had no seizures. 
His parent and physician report that, despite his severe ASD, he has well-developed 
language skills. Our assessment revealed a global executive composite score that was 
greater than 99% of scores from the standardization sample of 18-29 year-olds, indicative 
of an executive functions deficit. Although all domains were affected, the shift domain 
was especially elevated. Such inflexibility and rigidity is common in ASD and would 
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therefore be expected given his severe ASD. Scores on the SRS-2 supported the presence 
of ASD, with a total score in the moderate range. Elevation was also observed in the two 
DSM-5 equivalent domains; social communication and interaction and restricted interests 
and repetitive behavior. This male was reported to have a de novo frameshift variant 
(c.2341dup; p.Ile781Asnfs*3). This recurrent variant has been previously reported in a 
female with refractory seizure clusters and attention-deficit features.25, 31  
The second male was 16 years old. The following medical information was gained from 
parental report. He was a healthy boy with normal development until 9.5 years of age 
when he developed febrile infection-related epilepsy syndrome (FIRES).112 Following a 
prodromal illness he presented with rapidly escalating tonic-clonic seizures requiring a 
phenobarbital induced coma for a month. Serial MRI scans showed progressive atrophy. 
Investigations for infectious and autoimmune etiologies were negative. Following the 
acute illness, he was left with motor and cognitive neurological sequelae, as well as 
pharmaco-resistant focal epilepsy. It took more than a year for him to regain walking and 
he remains ataxic with foot drop. He has almost monthly focal seizures consisting of a 
visual aura which can progress to a bilateral tonic-clonic seizure despite felbamate and 
phenytoin. EEGs showed multifocal epileptiform discharges. Our neuropsychiatric 
assessment found normal executive functions, mild ASD symptoms, and no other 
behavioral disturbances. This profile is consistent with a diagnosis of FIRES and may not 
relate to the PCDH19 variant. This male was reported to have a missense PCDH19 
variant (c.1672 G>C; p.Asp558His) inherited from his unaffected mother. The variant is 
located in the calcium-binding domain (important for protein structure/folding). There is a 
previous report of this variant as likely pathogenic in a commercial gene company series 
(GeneDx) so this may be the same individual.74
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Table 6.1 Clinical characteristics of PCDH19 males 
 General Seizures  Neuropsychiatric comorbidities PCDH19 Variant 
Pt
. 
Age Zygosity Onset SE Clusters Isolated Hosp
. 
ICU ID ED EP CoP ADHD PP SD ASD OCD cDNA; Protein Type (loc) Inheritance Novel In silico 
Prediction 
1 2.5y Mosaic 22m - + - Once Yes No No Av Mild Mild Sev Sev No NC c.2656C>T; p.Arg886* Non (CP) De novo - Deleterious10, 16 
2 2y Mosaic 8m - + - Twic
e 
No No No Av Sev Mild Av Mild No NC c.1720G>T; p.Glu574* Non (EC6) De novo + Likely 
pathogenic 
3 5y Mosaic 5m - + + 5+ Yes Sev Sev Sev Mod Mod Sev Sev Sev NC c.593G>C; p.Arg198Pro Miss (EC2) De novo + Likely pathogenic 
4 10y Mosaic 11m - + - 5+ No Sev Sev Av Mild Mod Sev Sev Sev NC c.2147+2T>C; p.?  (Ex/Int1) De novo - Deleterious34 
5 5y Mosaic 8m - + - 5+ Yes No No Av Av Mild Mod Sev Mild NC c.688G>C; p.Asp230His Miss (EC2) De novo + Likely pathogenic 
6 2.5y Mosaic 5m - + - 5+ No Mild Mod Av Av Sev Mod Sev Sev NC c.1020T>A; p.Asn340Lys Miss (EC3) De novo + Likely pathogenic 
7 7y Mosaic 10m - + - 5+ Yes No No Av Av Av Av Mild No NC c.1352C>T; p.Pro451Leu Miss (EC4) De novo - Deleterious5 
8 12y Mosaic 96m - + + 5+ No Bord Mod Mod Av Av Sev Sev Mod NC c.1548C>A; p.Tyr516* Non (EC5) Unknown + Likely pathogenic 
9 41y Mosaic NA N
A 
NA NA NA NA No No NC NC NC NC NC Mod No c.1240G>A; p.Glu414Lys Miss (EC4) De novo - Deleterious24 
10 16y Hemi 114m - + + Once Yes No No Mod Av Av Mod Av Mild NC c.1672G>C; p.Asp558His Miss (EC5) Maternal - Deleterious74 
11 23y Hemi NA NA NA NA NA NA Mild Sev NC NC NC NC NC Mod NC c.2341dup; p.Ile781Asnfs*3 F/S (CP) Maternal - Deleterious25, 31 
12 63y Hemi NA NA NA NA NA NA No No NC NC NC NC NC No No c.1671C>G; p.Asn557Lys Miss (EC5) Unknown - Deleterious2, 56 
13 70y Hemi NA NA NA NA NA NA No No NC NC NC NC NC No *No c.370G>A; p.Asp124Asn Miss (EC1) Maternal - Deleterious24 
14 41y Hemi NA NA NA NA NA NA No No NC NC NC NC NC No No c.1683_1696del; p.Val562Thrfs*4 F/S (EC5) Unknown - Deleterious74 
15 51y Hemi NA NA NA NA NA NA No No NC NC NC NC NC No No c.1463T>A; p.Val488Asp Miss (EC5) Unknown + Likely pathogenic 
Abbreviations: ADHD, attention-deficit hyperactivity disorder; ASD; autism spectrum disorder; Av, average; Bord, borderline; CoP, conduct problems; CP, cytoplasmic domain; EC, extracellular cadherin domain; 
ED, executive dysfunction;  EP, emotional problems; Ex, exon; F/S, frameshift; Hemi, hemizygous; Hosp., hospitalizations; ICU, Intensive Care Unit admissions; ID, intellectual disability; Int, intron; isolated, 
presence of non-clustering seizures; loc, location; m, months; Miss, missense; Mod, moderate; NA, not applicable; NC, not covered; Non, nonsense; NP, not provided; OCD, obsessive compulsive disorder; PP, peer 
problems; Pt, participant; SD, social deficits; SE, status epilepticus; +, present; -, absent; Sev, severe 
*Score just below the clinical threshold (18 or higher)
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Neuropsychiatric profile 
Executive dysfunction occurred in 44% (4/9) mosaic males and one transmitting male 
(#11). All five individuals had a diagnosis of ID. As the SDQ is only available to 
individuals 18 years and younger, results from this measure were obtained for 8/9 mosaic 
and 1/6 transmitting males. This one transmitting male scored in the moderate range for 
emotional and peer problems and in the average range for all other measures. Emotional 
problems were recorded for 25% (2/8), conduct problems for 50% (4/8), 
inattention/hyperactivity for 75% (6/8), peer problems for 75% (6/8), and social deficits 
were recorded for all eight mosaic males. Sixty seven percent of mosaic males (6/9) 
including the non-penetrant male (#9) and two transmitting males (#10, #11) scored in the 
ASD clinical range. DOCS scores were all in the normal range, however, one male (#13) 
attained a total score just below the clinical threshold for OCD. Elevation in the harm, 
thoughts, and order domains were reported by this individual. The remaining transmitting 
males (#12, #14, and #15) scored within the normal range on all relevant measures. The 









Figure 6.1 Neuropsychiatric profile of males with PCDH19 pathogenic variants based on average (±2 SEM) SRS-2 
total and BRIEF total and subscale t scores. A) mosaic males B) males compared to the females from our previous 
publication,110 and C) hemizygous males. Green shaded region represents the normal range; yellow, mildly elevated; 
orange, moderately elevated; and red represents severely elevated t scores. ASD; autism spectrum disorder; ED, 
executive dysfunction; PO, plan/organize; WM, working memory. 
Our mosaic male (#9) without seizures had an SRS-2 score in the moderate range. Scores 
in this range indicate deficiencies in reciprocal social behavior that are clinically 
significant and lead to substantial interference with everyday social interactions. This 
finding was supported by an elevated score on the BRIEF shift domain and a slightly 
elevated score on the DOCS order domain, which indicates concerns in the area of mental 
flexibility and a need for order/symmetry, respectively. Sanger sequencing of blood-
derived DNA showed somatic mosaicism of his PCDH19 variant (c.1240G>A), however, 
PCDH19 mosaicism could not be detected in fibroblast-derived DNA (Fig. 6.1). 
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Figure 6.2 gDNA Sanger sequence illustrating the A) absence of mosaicism in skin fibroblasts and B) presence of 
mosaicism in blood for the non-penetrant mosaic male (#9). Sequences were generated using a reverse primer 
(CGTATATGTCGCCTGAGTT). 
Discussion 
We compared males with somatic and germline PCDH19 pathogenic variants and 
systematically describe their phenotypic spectrum. The clinical features of the mosaic 
males in our cohort concur with previous case reports.4-6 We describe five new cases, 
expanding the number of reported PCDH19 mosaic male cases to 18. We show that 
mosaic males have a neuropsychiatric profile that includes executive dysfunction, ADHD, 
and ASD; a clinical profile comparable to that reported for females who are naturally 
mosaic.64, 110 We also systematically assessed males with germline PCDH19 variants. 
Previous reports are limited, however, germline males are generally asymptomatic apart 
from four reported with ASD 16, 35 and ID.36 Here we describe two males with germline 
PCDH19 variants and neuropsychiatric abnormalities. However, one had FIRES at 9.5 
years, an acute encephalopathy with status epilepticus and fever which presents in 
previously normal children.112 Most patients have cognitive, motor, and behavioral 
sequelae and epilepsy. Based on molecular grounds alone, there is compelling evidence 
for his PCDH19 variant. However, when his clinical profile and family history are 
considered, it is more likely that FIRES explains the neuropsychiatric abnormalities we 
detected, and they are unrelated to his PCDH19 variant.  
We also describe a PCDH19 mosaic male with moderate ASD but no seizures. It is 
possible that his autistic features are due to other genetic or environmental factors; 
however, it may also be due to neuronal PCDH19 mosaicism. To our knowledge, there 
have only been two non-penetrant mosaic males reported.108 PCDH19 somatic mosaicism 
was confirmed in multiple tissues for both individuals. Interestingly, their skin fibroblasts 
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were not tested. Based on cellular interference, it was proposed that asymptomatic mosaic 
males have skewed neuronal mosaicism in favour of either wild-type or variant allele. 
Given that we were unable to identify mosaicism in the skin fibroblasts of our mosaic 
male, it is possible that a low level of mosaicism was present that was not detectable via 
Sanger Sequencing. Future studies should utilize more sensitive techniques (i.e., 
microdroplet PCR) for detection of PCDH19 mosaicism. The penetrance of PCDH19 
variants in females has been estimated to be 80%.64 There has been no estimate with 
respect to mosaic males. With the addition of our mosaic male, there have been three non-
penetrant males of the twenty reported mosaic males. Hence, we estimate the penetrance 
of PCDH19 variants in mosaic males to be 85%.  
Conclusion 
While PCDH19 variants predominantly affect females, it is important to recognize that 
PCDH19 variants also result in a spectrum of phenotypes in males, albeit less frequently. 
The phenotypic profile for somatic mosaic males resembles that of heterozygous affected 
females. We identified neuropsychiatric abnormalities in two males with germline 
PCDH19 variants, however, the PCDH19 variant in each case is likely serendipitous and 
our data suggest that transmitting males are generally unaffected. We also describe a non-
penetrant somatic mosaic male with mosaicism confirmed in blood, but not identified in 
skin fibroblasts. We propose microdroplet PCR for more sensitive detection of PCDH19 
somatic mosaicism.
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7.1 Preamble 
A unique feature of XCE is the phenotypic expression pattern of inherited PCDH19 
variants. Typically, X-linked inheritance leads to the condition in males, with females 
being spared. This is because females have two X chromosomes, the second of which 
conveys a degree of protection. The unique expression in XCE is such that heterozygous 
females are affected while hemizygous males are spared, contradicting classical X-
chromosome linked genetics. The identification of the first symptomatic “mosaic” male 
spurred the cellular interference hypothesis to explain this unique expression pattern. 
Cellular interference posits that co-existence of variant and wild-type PCDH19 cells (in 
the brain) leads to a disruption in cell-cell communications. The premise of this 
hypothesis is grounded in the idea that symptomatic females are cellular mosaics due to 
XCI of one copy of PCDH19 in each cell. This is supported by the existence of 
asymptomatic hemizygous males and symptomatic postzygotic somatic mosaic males. 
Differences in the degree of mosaicism (in females or in males) are speculated to explain 
variable penetrance, yet this has not yet been demonstrated. Here we test select biological 
factors for their association with the penetrance in XCE. These findings will form the 
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Abstract 
The clinical presentation of XCE is postulated to be underpinned by cellular mosaicism 
due to some cells expressing the wild-type and others loss-of-function or no PCDH19 
protein. XCE is an infantile onset epilepsy syndrome with unusual genetics whereby 
heterozygous females and postzygotic somatic mosaic males are affected, but hemizygous 
males are unaffected. The cellular mosaicism underpinning the XCE phenotype is driven 
by XCI in females and the developmental timing of the de novo variant in mosaic males. 
We have collected primary skin fibroblasts from clinically penetrant and non-penetrant 
XCE females and tested their XCI patterns, and relative levels of their wild-type and 
variant PCDH19 mRNA and protein expression. We investigated 13 females 
heterozygous for PCDH19 variants, including three discordant MZ twin pairs. Three out 
of four tested non-penetrant females showed completely wild-type PCDH19 expression. 
We show that the pattern of XCI in these cell lines does not correlate with the mRNA 
expression of the respective wild-type and variant PCDH19. This suggests that XCI does 
not predict the ratio of wild-type to variant PCDH19 mRNA expression. We suggest that 
the relative ratio of wild-type to variant PCDH19 expression, but not XCI, may provide a 
better molecular tool to assess the penetrance and the clinical severity of XCE. This may 
be beneficial for future diagnosis and prognosis of XCE. 
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Introduction 
PCDH19 pathogenic variants cause XCE; an infantile onset epilepsy syndrome with 
unusual genetics whereby heterozygous females and mosaic males are affected, but 
hemizygous males are unaffected. This is hypothesized to be a consequence of the 
presence of two neuronal populations; one expressing the wild-type and the other the 
variant PCDH19 protein. PCDH19 is a cell-cell adhesion molecule and, as such, this mix 
of neuronal cell populations results in a loss of or abnormal cell-cell interactions, referred 
to as cellular interference.4 Cellular mosaicism, either due to XCI in females or early 
somatic variant in males, is a unifying feature of XCE and the best hypothesis that can 
explain why PCDH19 variants are pathogenic in individuals with two different 
populations of neurons.   
The penetrance of XCE is predicted to be greater than 90%. However, our recent 
systematic review estimates this to be closer to 80% due to increased reports of 
asymptomatic carrier females.64 The first such report described two families with 
PCDH19 variants inherited from asymptomatic mothers (c.1700C>T and c.1852G>A, 
respectively).10 Following this, a mother with a novel PCDH19 variant (c.2705dupA) was 
reported to have an IQ of 98, no behavioral problems, and never manifested seizures.12 
Another report described an affected female with the recurrent PCDH19 variant 
(c.1019A>G) inherited from an asymptomatic mother.23 Importantly, this PCDH19 
variant has been identified in approximately 20 unrelated XCE cases, demonstrating that 
other modifying factors are affecting the variable penetrance of XCE. 
In mammals, XCI is a process of transcriptional silencing of one of the two female X 
chromosomes early in embryonic development.113 In X-linked disorders, XCI may act as 
a protective mechanism if skewed in favor of the chromosome with the wild-type 
allele.114 As PCDH19 hemizygous males are asymptomatic, skewing of XCI in females, 
whether in favor of the wild-type or the variant allele is speculated be protective in XCE. 
Several studies have examined XCI in XCE.2, 8, 9, 115-117 However, only two compared 
penetrant and non-penetrant individuals. In the first study examining XCI in a family with 
incomplete penetrance, a random XCI was observed in the proband and her asymptomatic 
sisters.28 In another study, the proband showed the same ratio of variant and wild-type 
alleles, however, her asymptomatic mother showed variability in the tested tissues (blood, 
saliva, hair), with complete wild-type expression detected in urinary cells.23 Accessible 
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ectodermal tissue would be expected to provide the best phenotypic correlate, as they 
share the same developmental origin as neuronal tissue. However, in the Terracciano et 
al. study, hair roots showed no genotype-phenotype correlation. As neuronal mosaicism 
has been demonstrated in a Pcdh19+/- mouse,51 it would be important to identify the most 
appropriate correlate for brain tissue in XCE, if at all possible. 
Here we analyzed penetrant and non-penetrant XCE females to determine XCI patterns, 
wild-type to variant PCDH19 mRNA expression, and PCDH19 protein levels. 
Specifically, we hypothesized that skewing in favor of one PCDH19 allele would be 
associated with non-penetrance or a milder phenotype and that XCI patterns observed in 
fibroblasts but not whole blood would provide a better correlate with the XCE phenotype.  
Method 
Patients 
Our cohort of 13 females with PDH19 variants, included a previously unpublished 
Danish sister pair (c.1469A>G, p.Tyr490Cys), an unpublished Danish family (c.370G>A, 
p.Asp124Asn), an Australian sister pair (c.1671C>G, p.Asn557Lys),2 a pair of MZ twins 
from Italy (c.1300_1301delCA, p.Gln434GlufsX11),9, 25 a MZ twin pair from Japan 
(c.1019A>G, p.Asn340Ser),26 and previously unpublished MZ twins from New Zealand 
(c.497_498insA, p.Tyr166X). All related individuals demonstrated a degree of 
phenotypic discordance, with the Danish sisters, family with the p.Asp124Asn variant, 
and the Italian MZ twins representing cases of complete discordance. The study was 
approved by the Women’s and Children’s Health Network Human Research Ethics 
Committee and written informed consent was obtained from the participating families. 
Clinical assessment 
Clinical information was previously collected via our PCDH19 survey.110 The PCDH19 
survey incorporated the following: SRS-265 for the assessment of ASD symptoms, the 
SDQ67 for the assessment of ADHD symptoms, the BRIEF109 for the assessment of 
executive dysfunction, the DOCS70 for the assessment of OCD symptoms, and the EQ110 
for demographic, development, variant, medication, and seizure information. 
Skin fibroblast cell culture 
   CHAPTER 7  
 
P a g e  | 107 
Established cultures were grown in RPMI-1640 medium (Sigma-Aldrich) supplemented 
with 10% FBS (Gibco; Thermo Fisher Scientific, Waltham, MA, USA), and 2 mM L-
glutaMAX (Sigma-Aldrich).  
Genomic DNA isolation 
gDNA was isolated from frozen fibroblast cell pellets as per the manufacturer’s 
instructions (DNeasy Blood & Tissue Kit; Qiagen, Hilden, Germany). We also had access 
to gDNA from blood cells, buccal mucosa, and saliva for the Japanese MZ twins.  
Expression Analysis 
X-chromosome inactivation assay. Five hundred nanograms of gDNA was digested 
overnight at 37°C in 25 µl with 1.5 µl HpaII enzyme (10 U/µl) (New England Biolabs, 
Beverly, MA, U.S.A.). Double digestion was performed with 1 µl DdeI enzyme (10 
U/µl).118 After digestion, the enzyme was inactivated at 80°C for 20 min, and PCR was 
performed on both digested and undigested DNAs (200 ng) with primers specific for the 
androgen receptor (AR) gene (5' -  TCC AGA ATC TGT TCC AGA GCG TGC - 3' and 
5' – FAM-GCT GTG AAG GTT GCT GTT CCT CAT - 3'). The PCR mixture contained 
5× GC-Rich Phusion PCR Buffer, 10mM dNTPs, primers (10 μM), 5% DMSO, and 
Phusion HiFi DNA Polymerase in 25 μl. Amplification was performed at 98°C for 3 min, 
followed by 98°C for 10 s, 60°C for 10 s, 72°C for 30 s for 27 cycles, and a final 
extension at 72°C for 10 min. Analysis of fluorescent samples was performed using ABI 
3100 Genetic Analyzer (Applied Biosystems). XCI was classified as random if the ratio 
between the two chromosomes was between 50:50 and 80:20 or skewed if the ratio was 
greater than 80:20. 
PCDH19 Relative Allelic Expression 
RNA isolation and cDNA synthesis. RNA was isolated from frozen cell pellets 
according to the manufacturer’s instructions (QIAshredder; RNAeasy Mini Kit; Qiagen, 
Hilden, Germany). cDNA synthesis was performed using SUPERSCRIPT IV Reverse 
Transcriptase (Invitrogen) according to the manufacturer’s instructions. 
cDNA PCR. PCDH19 was amplified from patient fibroblast cDNA with primers 5′- CTG 
CTG GTC ACC AAG CAG AAG ATT GA -3′ and 5′- AAC AGC CGA GGA GAC 
AAG TGA TGG -3′ or 5′- CTG CTG GTC ACC AAG CAG AAG ATT GA -3′ and 5′- 
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CCG AGA TGC AAT GCA GAC ACT TGC TG -3′. Amplified products were resolved 
on a 1% agarose gel, specific cDNA bands purified by gel extraction (QIAquick Gel 
Extraction Kit, Qiagen), and sequenced by Sanger sequencing. 
Sanger sequencing. Confirmation of variants and cDNA analysis was performed by 
Sanger sequencing using standard methods. Primer sequences (gDNA) included: 5′- ACC 
ACG AGT TCG GCA AA -3′ (#3, #4, #5, #12, and #13); 5′- CGT AGA TGT CGC CTG 
AGT T -3′ (#8, #9, #10, and #11); 5′- TGG GCA ATG TGC CCT TT -3′ (#1, #2, #6, and 
#7). Primer sequences (cDNA) included: 5′- TCG GAA GCT GTA GTG CGA CTG CGT 
C -3′ (#3, #4, #5, #12, and #13); 5′- AAC GGC ACT GCA CAC GTC CAT TGA -3′ 
(#10); 5′- CCA CCA GAA TAG TGG AGA AG -3′ (#11); 5′- GGA TCG CAG CGC 
GTA GAT GTC GCC T -3′ (#1 and #2); 5′- GAA CGC CTT GGT CTG CTC GTG GTT 
A -3′ (#8 and #9); and 5′- GTC ACC AGG TAG CCT ATG CCA GAG TT -3′ (#6 and 
#7). 
Cycloheximide assay. Approximately 3×106 early passage fibroblasts from two 
discordant MZ female twins (#8 and #9; #12 and #13) were cultured in presence of either 
100 μg/ml cycloheximide (Sigma-Aldrich) or DMSO (Sigma-Aldrich) at 37°C with 5% 
CO2 for 6 hours. Cells were harvested, washed once with 1×PBS (Sigma-Aldrich), and 
snap frozen until RNA isolation using QIAshredder and RNeasy Mini Kit (Qiagen) and 
generation of cDNA. An additional pellet of untreated cells from each individual was 
simultaneously harvested and gDNA isolated using DNeasy Blood and Tissue kit 
(Qiagen) for XCI analysis. 
PCDH19 Protein Analysis 
siRNA PCHD19 knockdown. MCF-7 cells were transfected with either PCDH19 ON-
TARGETplus SMARTpool (5′- GUU CCU AGC UUU ACG CAU U -3′, 5′- CAA UCA 
AGU GCA AGC GAG A -3′, 5′- UGG AGC UGA UAG CGA GAA A -3′, and 5′- AAU 
GGA AAU CUG CGU GAU A -3′) or scrambled (5′- UAG CGA CUA AAC ACA UCA 
A -3′) siRNAs (Dharmacon) using Lipofectamine RNAiMAX reagent according to the 
manufacturer's specifications (Life Technologies). MCF-7 cells were harvested 48 h after 
6 h of siRNA transfection at 37⁰C, washed once in 1×PBS (Sigma-Aldrich), and snap 
frozen until protein isolation. PCDH19 protein expression was determined by western 
blotting. 
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Western blot analysis. Protein lysates were prepared in lysis buffer (50 mM Tris-HCl, 
pH 7.5, 0.2% Triton X-100, 2 mM EDTA, 150 mM NaCl, 0.01% SDS, 50 mM NaF, 0.1 
mM Na3VO4, and 1× protease inhibitor/No EDTA, Roche Applied Sciences) followed 
by sonication and centrifugation. Protein concentration was determined by Pierce BCA 
Protein Assay Kit (Thermo Scientific). Lysates were resolved by 6% SDS-PAGE and 
transferred onto nitrocellulose membrane (Amersham Biosciences). Western blot was 
probed with rabbit anti-PCDH19 antibody (0.2 μg/ml; Bethyl Laboratories), detected with 
goat anti-rabbit horseradish peroxidase-conjugated secondary antibody (Dako) and 
visualized by enhanced chemiluminescence (GE Healthcare). β-Tubulin was employed as 
a loading control using rabbit anti-β-tubulin antibody (Abcam, Cambridge, UK). 
PCDH19 reference sequences 
All PCDH19 cDNAs and proteins were based on the following reference sequences, 
which represent the longest isoform of PCDH19 mRNA and protein: NM_001184880.2 
and NP_001171809.1 (https://www.ncbi.nlm.nih.gov/). 
Results 
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Table 7.1 Characteristics of PCDH19 females 















2 Denmark Yes 
15 months 
(GTCS) 












5 Denmark Yes 
6.5 months 
(GTCS) 



















































Abbreviations: ADHD, attention-deficit hyperactivity disorder; ASD, autism spectrum disorder; CP, conduct problems; 
EP, emotional problems; FeS, febrile seizure; FIAS, focal impaired awareness seizure; FS, focal seizure; GTCS, 
generalized tonic-clonic seizures; HCS, hemiclonic seizure; N/A, not applicable; OCD, obsessive compulsive disorder; 
PP, peer problems; SD, social deficits; #, isolated seizure 
Molecular analysis 
PCDH19 variants. All variants were located within exon 1, which corresponds to the EC 
repeat domain of the PCDH19 protein (Fig. 7.1).  













Figure 7.1 Lollipop plot illustrating all PCDH19 variants represented in the analysis (n = 13). 
Sanger sequence analysis confirmed the presence of a PCDH19 variant in the gDNA 
extracted from the relevant skin fibroblast cell line of all 13 females (Fig. 7.2). All 
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sequences demonstrated the presence of both the wild-type and the variant PCDH19 
sequence, as expected. 
 
Figure 7.2 gDNA sequences for all individuals grouped by family relationship included in the present study. A) Danish 
siblings (#1 and #2); B) Danish family (#3, #4, and #5); C) Australian siblings (#6 and #7); D) Italian MZ twins (#8 and 
#9); E) Japanese MZ twins (#10 and #11); and F) New Zealand MZ twins (#12 and #13). The variants are highlighted 
in blue. 
X-chromosome inactivation. XCI analysis was performed on fibroblast gDNAs from all 
13 patients. For six patients (#1, #2, #3, #4, #6, and #7) parental alleles could not be 
distinguished at the AR locus and were therefore not informative. Six of the seven 
patients who were informative at the AR locus had a skewed XCI (Table 7.2). For the 
Japanese MZ twins, we had additional tissue available for analysis. Whereas saliva and 
skin fibroblasts of the non-penetrant twin (#10) showed a completely skewed XCI 
pattern, a random XCI pattern was detected in her blood (27:73). A random XCI pattern 
was observed in blood (25:75) and saliva (28:72), and a skewed pattern in the skin 
fibroblasts (12:88) of the penetrant twin (#11). The buccal mucosa did not give a 
conclusive result for either twin, likely due to low DNA content.   
Relative PCDH19 cDNA expression. In an attempt to provide an independent and direct 
measure of XCI, we have measured relative PCDH19 mRNA expression in the skin 
fibroblasts of all these 13 females (Fig. 7.3). 
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Figure 7.3 cDNA sequences for all families. A) Danish siblings; B) Danish family; C) Australian siblings; D) Italian 
MZ twins; E) Japanese MZ twins; and F) NZ MZ twins. All sequences generated using reverse primers (see Methods 
for primer sequences). The variants are highlighted in blue. 
Between individual discordance in relative wild-type to variant PCDH19 mRNA 
expression was observed for all related individuals, except the Italian MZ twins (#8 and 
#9). Interestingly, three out of the four non-penetrant females (#1, #8, and #10) showed 
100% wild-type PCDH19 mRNA expression. However, the non-penetrant female from 
the Danish family (#3) exhibited 100% variant allele expression. Completely wild-type 
expression was also observed for mildly affected females #7 and #12. All remaining 
affected females showed either completely variant (#2, #4, #5, and #13) or an 
approximate 50:50 wild-type and variant mRNA expression (#6, #9, and #11). Taken 
together, these data suggest that: i) there is no correlation between XCI and penetrance in 
these individuals, ii) the wild-type and variant PCDH19 allele expression does not 
explain the phenotypic differences either, however, iii) there also appears to be no 
correlation between XCI and relative wild-type to variant PCDH19 mRNA expression.   
Of the six PCDH19 variants in the present study, two involve the introduction of a 
premature termination codon (PTC) into the PCDH19 mRNA (#8, #9, #12, & #13). PTC-
containing mRNA transcripts are typically eliminated by the nonsense mediated decay 
(NMD) pathway.119, 120 Of these individuals, only the Italian MZ twins (#8 and #9) 
provided a case of complete phenotypic discordance. Consequently, we treated the skin 
fibroblasts of these individuals with cycloheximide to inhibit NMD121 and were able to 
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rescue the PTC-containing mRNA transcript for one of the twins, that is the penetrant 






Figure 7.4 NMD of PCDH19 transcript in skin fibroblasts. Sequence chromatogram from A) non-penetrant female 
(patient 8) and B) penetrant female (patient 9) showing the absence of the mutant sequence in untreated cDNA; and C) 
minimal rescue of the variant transcript for the non-penetrant female and D) near complete rescue of the variant 
transcript for the penetrant female following cycloheximide treatment, which inhibits the pioneer round of translation 
and thus NMD. The position of the variant is highlighted in blue. 
Protein expression. PCDH19 has a molecular mass of 126kD122 and is weakly expressed 
in human fibroblasts. To confirm our ability to detect and specify the PCDH19 protein in 
fibroblasts via western blot, we used lysates from MCF-7 cells treated with PCDH19 or 
scrambled siRNA. PCDH19 was detectable in all patient and MCF-7 cells 
(Supplementary Fig. 7.1), confirming a very low PCDH19 expression in fibroblasts, 
therefore rendering subtle differences in expression levels between related individuals 
difficult to detect. Conversely, PCDH19 was easily detectable in MCF-7 cells. 
Genotype-phenotype associations. We obtained clinical information for eight patients 
(#2, #3, #4, #5, #6, #7, #12, and #13) via the PCDH19 survey.110 There was no consensus 
between the pattern of XCI and clinical outcomes when comparing related individuals or 
the group as a whole. However, relative PCDH19 cDNA expression demonstrated some 
agreement with phenotype (Table 7.2), such that complete variant expression or an 
approximate even expression of variant and wild-type was associated with more seizures 
(#6 and #13) and more severe psychiatric comorbidities (#2, #5, and #13). Conversely, 
wild-type expression was associated with no seizures (#1, #8, and #10), fewer seizures 
(#7) and no psychiatric comorbidities (#1, #7, #8, and #10). 
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Table 7.2 Genotype-phenotype associations 
General Molecular Seizures Neuropsychiatric comorbidities 













1 NI 100% WT - N/A No No No No No No No No 
2 NI 100% MT + 12 Mild Average Moderate Average Moderate Severe Mild Not tested 
3 NI 100% MT - N/A No No No No No No No No 
4 NI 100% WT + 20 Mild Not tested Not tested Not tested Not tested Not tested Moderate Not tested 
5 99:1 100% MT + 20 Moderate Average Mild Average Average Mild Severe Not tested 
6 NI 50:50 + 20 No Not tested Not tested Not tested Not tested Not tested No No 
7 NI 100% WT + 8 No Not tested Not tested Not tested Not tested Not tested No No 
8 84:16 100% WT - N/A No No No No No No No No 
9 25:75 100% MT + Unknown Not tested Not tested Not tested Not tested Not tested Not tested Not tested Not tested 
10 1:99 100% WT - N/A No No No No No No No No 
11 12:88 50:50 + Unknown No No No No No No No No 
12 100:0 100% WT + 30 Moderate Mild Mild Average Average Mild Moderate Not tested 
13 0:100 50:50 + 30 Moderate Average Mild Average Average Mild Moderate Not tested 
Abbreviations: ADHD, attention-deficit hyperactivity disorder; ASD; autism spectrum disorder; MT, mutant; NI, non-informative; OCD, obsessive compulsive disorder; WT, wild-type; XCI, X-
chromosome inactivation; - non-penetrant, + penetrant 
NB: “No” refers to information obtained from publications or clinicians indicating that the individual is unaffected/has no comorbidities whereas “average” refers to the results of the assessment 
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Discussion 
In this study, we show that the pattern of XCI in the skin fibroblasts of 13 females does 
not correlate with their PCDH19 allelic expression. As XCI analysis relies on the ability 
to distinguish between the alleles inherited from each parent at a given locus, there are 
limitations to this method. For the AR assay, parental alleles are distinguished by 
variation in the length of a CAG short tandem repeat located within the first exon of the 
AR gene.123 It is speculated that around 90% of the female population is heterozygous at 
this locus, however, this percentage is often lower in clinical settings.124, 125 For these 
reasons, we suggest using the ratio of wild-type to variant PCDH19 mRNA expression 
estimated/measured from sequence chromatograms of specific regions of cDNAs 
amplified by PCR. 
Three of four non-penetrant females represented in this analysis showed 100% wild-type 
PCDH19 mRNA expression however, there was no unanimous association between 
mRNA expression and penetrance. The Italian MZ twins with the p.1300_1301delCA 
variant had complete wild-type PCDH19 mRNA expression. When NMD was inhibited 
in their skin fibroblasts, we were only able to rescue the variant transcript for the 
penetrant twin. So, in one twin we were able to see the silenced transcript yet in the other 
we did not. This suggests that the mechanisms responsible for PCDH19 mRNA 
expression can differ between related individuals and that there is something else which is 
suppressing transcription of the variant allele in the tissue of the non-penetrant twin. Why 
we were unable to rescue the variant PCDH19 transcript in the skin fibroblasts for the 
non-penetrant twin remains unknown. Given the XCI pattern is approximately similar for 
both twins (so we assume there is expression of the variant allele), we speculate that the 
variant transcript is not subjected to NMD for the non-penetrant twin and that other 
transcriptional silencing factors are involved. Furthermore, the observed difference in 
relative wild-type to variant mRNA expression between related individuals may be due to 
transcriptional mechanisms inhibiting one of the two transcripts.  
Several hypotheses have been proposed to explain the unusual clinical phenotype in 
XCE.2, 4 One that has received considerable attention is that of cellular interference.4 This 
draws on the idea that neuronal populations expressing both wild-type and variant 
PCDH19 results in abnormal neuronal interactions and communication. A recent Pcdh19 
knockout mouse model showed that heterozygous Pcdh19 mice had elevated cortical 
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activity that was not present in mice completely lacking Pcdh19, reflecting the human 
condition.51 Furthermore, deletion of the wild-type Pcdh19 allele in heterozygous mice 
restored normal network activity.51 Here, we were unable to provide support for the 
mechanism of cellular interference through our finding clinical phenotypes in individuals 
with markedly skewed XCI. Conversely, the mouse model did not display an overt 
seizure or behavioral phenotype in heterozygous females. 
There are several limitations associated with our approach. First, we were unable to 
directly measure the ratio of wild-type to variant PCDH19 expression from the brain 
tissue, although post-mortem brain tissue as a source of mRNA for gene expression 
profiling remains a possibility. We were also unable to demonstrate a correlation between 
fibroblasts, blood, and saliva mRNA expression for individuals where additional tissue 
types were available. Secondly, later passage (>10) fibroblast cultures have been 
associated with XCI skewing in favor of the dominant X 126. To address this concern, we 
utilized early stage passage fibroblasts, however, the effect of passaging on skewing 
cannot be disregarded. Additional experiments comparing XCI in a primary biopsy with 
cultured cells at different passages from the same individual are required to determine if 
there are any effects of culture on XCI. Lastly, analysis on a small number of non-
penetrant females (n = 4) limited our ability to perform statistical analyses and draw firm 
conclusions. Given the limited number of non-penetrant females in XCE (penetrance 
~90%), this number may be representative, however, accessing additional non-penetrant 
female samples would increase the validity of these findings.  
Conclusion 
We have shown that XCI does not correlate with the ratio of the wild-type to variant 
PCDH19 mRNA expression, invalidating the use of this assay to predict relative 
PCDH19 mRNA expression. Without access to brain tissue, the ratio of the wild-type to 
variant PCDH19 mRNA expression may provide a better molecular tool to assess the 
penetrance and the clinical severity of XCE than XCI. This may benefit future diagnosis 
and prognosis of XCE. 
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This discussion begins with a brief overview of the thesis, and then discusses the key 
findings in a series of four outcomes. The first outcome is the statistical association between 
earlier seizure onset age and more severe ID. This association was first identified in Chapter 
2 and later validated in Chapter 3. In Chapter 3, we also identified an association between 
age at seizure onset and the severity of ASD symptoms, as well as an association between 
the frequency of seizures within a cluster and the severity of ASD symptoms. The second 
outcome involves the characterization of the neuropsychiatric profile associated with 
PCDH19 variants. These findings are discussed in terms of the entire cohort (Chapter 3) as 
well as a detailed analysis of PCDH9-variant males (Chapter 6). This outcome formed the 
basis of the PCDH19 website as part of the Human Disease Genes Website Series (Chapter 
4). The third outcome explores the efficacy of the AED Levetiracetam in the treatment of 
XCE (Chapter 5). The fourth outcome is the correlation between PCDH19 cDNA relative 
expression and clinical outcome (Chapter 7). Following is a discussion of the clinical 
implications. Finally, the strengths and limitations of the project are considered, as well as 
recommendations for future research.  
8.1 Overview 
This thesis examined the variable clinical and molecular expressivity associated with 
PCDH19 variants. Data used were obtained via a systematic review and meta-analysis of 
the PCDH19 literature, the PCDH19 survey, and patient gDNA, RNA, and protein derived 
from a variety of tissue. 
Five separate studies were conducted, with key results summarised below: 
Study 1 (Chapter 2) identified the comorbidities frequently associated with XCE in the 
literature and potential associations of clinical and molecular factors with neuropsychiatric 
outcomes. PCDH19 variants were associated with psychiatric comorbidities in 
approximately 60% of females, 80% of affected mosaic males, and reported in nine 
hemizygous males. Hyperactive, autistic, and obsessive-compulsive features were most 
frequently reported. We found that seizure onset ≤ 12 months was significantly associated 
(p = 4.127 x 10-7) with more severe ID compared with onset > 12 months. We identified 
two recurrent variants p.Asn340Ser and p.Tyr366Leufs*10, occurring in 25 (20 unrelated) 
and 30 (11 unrelated) cases, respectively. 
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Study 2 (Chapters 3 and 6) validated the prevalence of the comorbidities identified in 
Study 1 using standardized neuropsychiatric assessments that were administered as part of 
an online international survey (the PCDH19 survey). Executive dysfunction and ASD 
occurred in approximately 60% of individuals. The ASD profile included features of 
ADHD. In addition, 21% of individuals met criteria for OCD that appeared to be distinct 
from ASD. There were no phenotypic differences between heterozygous females and 
mosaic males. We describe a mosaic male and two hemizygous males with atypical clinical 
profiles. We also validated the association identified in Study 1 and identified additional 
associations. Earlier seizure onset age and increased number of seizures within a cluster 
were associated with more severe ASD symptoms, with seizure onset also predictive of 
executive dysfunction and prosocial behavior. We identified 35 novel variants, which 
included a newly identified recurrent variant Ile781Asnfs*3. 
In study 3 (Chapter 4) data collected from Study 1 and 2, as well as information gleaned 
directly from health professionals formed the basis of the PCDH19 gene website as part of 
the Human Disease Genes website series. This website connects families with clinicians 
and researchers and provides a platform where information can be shared or obtained 
regarding PCDH19 and XCE. As new information becomes available, it is uploaded to the 
site either by clinicians sharing data concerning a new patient or by the PCDH19 page 
moderators when new research findings are obtained. In this way, the website provides the 
latest data, statistics, information, and research opportunities for individuals wishing to 
learn more about this disorder.  
Study 4 (Chapter 5) evaluated the effectiveness of the AED levetiracetam in two 
independent cohorts of females with XCE. Cohort A consisted of 17 females, aged 3-37 
years, who had a trial of levetiracetam at an average age of 10.7 years. 13/17 females 
became seizure free for >12 months; while 10/17 remained seizure free for >24 months. 
Cohort B comprised 62 females, aged 1.5-41 years. 26/62 became seizure free for >12 
months, and 19/62 for >24 months on levetiracetam therapy. 
Study 5 (Chapter 7) explored biological factors associated with penetrance in XCE. We 
included 13 females with PCDH19 variants, including three discordant MZ twin pairs. We 
showed that XCE penetrance is not associated with the degree of relative wild-type to 
variant PCDH19 cDNA expression in skin fibroblasts. Three of four non-penetrant females 
showed completely wild-type PCDH19 cDNA expression. We showed that the pattern of 
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XCI does not correlate with relative PCDH19 cDNA expression, invalidating the use of 
this assay to infer PCDH19 wild-type to variant expression. 
8.2 Outcome 1: Predicting clinical outcomes 
Results across two studies, utilizing two independent cohorts support an association 
between the age an individual is when they have their first seizure and the severity of their 
clinical outcome. In addition, we showed that increased frequency of seizures within a 
cluster was associated with ASD symptom severity. This section discusses these 
associations and implications for clinical practice. 
8.2.1 Earlier seizure onset age is significantly associated with more severe 
cognitive impairment. 
The first study found that seizure onset ≤ 12 months was significantly associated with more 
severe ID compared with onset > 12 months. This finding derived from a meta-analysis of 
studies that included information about age at seizure onset and degree of ID. ID was then 
re-classified as a numeric variable to aid the analysis. This approach was limited due to the 
nature of the data collected. ID was reported categorically (borderline, mild, moderate, 
severe, or profound) and therefore differences that exist within categories are lost. 
Restrictions also exist with respect to the analyses that can be performed and the 
conclusions that can be drawn. This limitation was addressed in the second study through 
the use of standardized assessments. 
In our systematic review we identified that executive dysfunction was frequently reported 
in individuals with PCDH19 pathogenic variants. We also identified that EEG reports of 
abnormal activity in frontotemporal brain regions were relatively common in affected girls. 
The frontotemporal region of the brain is involved in executive functions such as decision 
making, inhibition, emotional regulation, as well as speech production.127 We also found 
that many girls appeared to have difficulties in these areas, such as inattention, aggression 
and other emotion regulation problems, and difficulties with speech, especially expressive 
language.  
To be better understand the specific cognitive deficits in XCE and validate the association 
identified in the first study, we examined the association between seizure onset and 
executive dysfunction in addition to ID. We validated the association between earlier 
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seizure onset age and more severe ID and expanded this to also include executive 
dysfunction (Study 2).  
8.2.2 Earlier seizure onset age and more frequent seizures within a cluster are 
significantly associated with more severe ASD symptoms. 
The second study also found that earlier seizure onset age and increased number of seizures 
within a cluster were associated with more severe ASD symptoms, with seizure onset also 
predictive of prosocial behavior. We found that executive dysfunction occurred in 63% of 
our cohort. Of these, 89% also met criteria for ASD. It has been posited that the social and 
non-social deficits observed in ASD stem from deficits in executive functions and might 
explain the co-occurrence of these disorders and why seizure onset and activity might be 
predictive of both outcomes.75 The prosocial behavior scale within the SDQ is a measure 
of social deficits. Social deficits are a core feature of ASD and therefore the association 
between seizure onset and prosocial behavior provides further validation for the impact of 
earlier seizures on behavior. 
8.2.3 Clinical implications. 
Developmental delay prior to seizure onset occurred in 18% of our cohort. The molecular 
diagnosis for many infantile neurodevelopmental disorders including epilepsy occurs at a 
mean age of 3 years, which represents delays of months to years for patients with 
pathogenic variants. Early clinical identification of XCE will result in earlier molecular 
diagnosis and may impact outcome by allowing optimization of both seizure management 
and developmental progress. 
We are the first to show that earlier seizure onset age predicts greater executive dysfunction, 
prosocial behavior, and ASD severity, and that increased seizure activity strengthens these 
associations. Clinicians are already using this information to inform prognosis. Prior to this, 
we had no information as to what an individual clinical outcome might entail. Through our 
work, we can now provide guidance and targeted intervention for patients and their 
families. 
8.3 Outcome 2: The neuropsychiatric profile of PCDH19 variants 
This section discusses the neuropsychiatric profile that was characterized for XCE and 
provides a brief description of the neuropsychiatric assessments that were utilized (Study 
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2). This section finishes with a discussion of the implications these findings have for 
families, as well as in clinical practice. 
8.3.1 The Social Responsiveness Scale, second edition and the Social 
Communication Questionnaire. 
The SRS-2 original parent form demonstrates very good test-retest reliability128, 129 and a 
moderate to strong positive correlation with the Autism Diagnostic Interview-Revised 
(ADI-R)129, which is the accepted gold-standard parent-report interview for the clinical 
diagnosis of ASD.130 The SRS-2 is based on DSM criteria with two subscales (Social 
Communication and Restricted Interests and Repetitive Behavior) that are combined to 
produce a total score. The SRS-2 total score is the most reliable measure for social deficits 
related to ASD. 
The SCQ is based on the ADI-R, which is very time intensive, taking upwards of two hours 
to complete.131 Conversely, the SCQ takes 10 minutes to complete.132 A total cutoff score 
of 15 is used for differentiating different pervasive developmental disorders from other 
diagnoses, with a sensitivity of 0.96 and a specificity of 0.80 (intellectual impairment 
excluded) and a sensitivity of 0.96 and a specificity of 0.67 (intellectual impairment 
included).133   
8.3.2 Autism spectrum disorder.  
For a diagnosis of ASD, there must be evidence of restricted, repetitive patterns of behavior, 
interests, or activity as well as deficits in social communication and interaction.57 Current 
prevalence estimates of ASD are around 2% of school-age children in the world,134 with 
this figure continuing to rise.57 Comparatively, we found an occurrence of ASD-like 
symptoms in approximately 60% of our cohort. This figure is well above the rates observed 
in the general population and suggests a possible common underlying mechanism in XCE 
and ASD. ASD also demonstrates significant overlap with other psychiatric disorders.57 
The ASD profile observed in our cohort included features of ADHD, and may represent a 
general deficit in executive functions that underlies these comorbidities. A targeted clinical 
assessment will help delineate these features and determine a differential diagnosis. 
8.3.3 The Strengths and Difficulties Questionnaire.  
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The SDQ has been used successfully in the screening and diagnosis of ADHD in 
community135 and clinical136 samples, respectively. All versions of the SDQ demonstrate 
very good psychometric properties, such as discriminant validity,137, 138 external validity,139 
internal consistency,140 and inter-rater reliability.141 
8.3.4 Attention-deficit hyperactivity disorder. 
ADHD is a neurodevelopmental disorder characterized by an inability to pay attention 
and control behavior.57 For a diagnosis of ADHD, symptoms must manifest before the 
age of 12, be age-inappropriate, remain for more than 6 months, and be apparent in more 
than one setting (i.e., home and school).57 ADHD is particularly difficult for the family; 
as troublesome behavior often involves anger and aggressive outbursts,142 in addition to 
inattention, hyperactivity, and disruptive behavior.57 According to the World Health 
Organization, ADHD is estimated to affect almost 40 million people,143 with a prevalence 
rate of around 5% in most cultures.57  
Neurological disorders (i.e., epilepsy) can lead to ADHD-like symptoms, such as deficits 
in attention and may explain the higher prevalence of ADHD observed in seizure 
disorders.144, 145 Therefore, the pathophysiology of ADHD likely involves a genetic 
predisposition. This is further supported by reports detailing the concordance for 
symptoms of ADHD among MZ and dizygotic (DZ) twins. There is greater concordance 
among MZ compared with DZ twins,146, 147 with some reports finding either complete148 
or near complete149 concordance among MZ twins. Similar findings have been observed 
across the lifespan, with higher concordance among MZ twins.150 Collectively, these 
findings suggest that ADHD is highly heritable and likely shares genetic vulnerabilities 
with other neurodevelopmental disorders and might explain the co-occurrence of ADHD 
features with ASD in our XCE cohort. 
8.3.5 The Dimensional Obsessive-Compulsive Scale. 
The DOCS demonstrates a stable factor structure, high total score (α = .93) and subscale (α 
= .83-.96) internal consistency, adequate test-retest reliability over a 12 week interval (r = 
.55-.66), good discriminant and convergent validity,70 and has been validated for internet 
administration.151 
8.3.6 Obsessive-compulsive disorder. 
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Obsessions and compulsions are the hallmark features of OCD and, for a clinical diagnosis, 
obsessive and compulsive behaviors must interfere with an individual’s life and cause them 
some degree of discomfort.57 OCD affects around 1.5% of the population, with females 
being affected at a slightly higher rate than males in adulthood.57 OCD is generally 
diagnosed in individuals during adolescence, though symptom onset is earlier in males, 
with 25% of males being diagnosed by the age of 10.57 For this reason, males are more 
commonly affected than females in childhood. OCD symptomology was observed in 21% 
of our cohort. This may be an accurate estimate or may reflect the similarities between 
OCD and other disorders, such as ASD. Only one of the six individuals meeting criteria for 
OCD also met criteria for ASD, suggesting that OCD is distinct from ASD and that later 
onset psychiatric comorbidities should be considered with a diagnosis of XCE. 
8.3.7 The Behavior Rating Inventory of Executive Function. 
All versions of the BRIEF demonstrate very good psychometric properties. Based on 
normative samples, test-retest reliabilities have been reported for the GEC of the parent (r 
= .86)111 and self-report (r = .89)152 forms, and, in general, the correlations between the 
parent and self-report ratings are moderate to high. The clinical utility of the BRIEF has 
also been established through convergent and ecological validity.153 The BRIEF is a 
particularly appropriate because it is written to capture the qualitative aspects of a child’s 
executive functions in a real world-setting, and has been used successfully in studies 
involving children with developmental and psychiatric disorders (for review, see154). 
8.3.8 Executive functions.  
Executive functions are a set of cognitive processes that include attention, working 
memory, inhibition, mental flexibility, problem-solving, planning, and reasoning.155 These 
processes are necessary for the cognitive control of behavior, that is, successfully 
monitoring and regulating behaviors in a goal-oriented manner.156 Cognitive control 
deficits underlie many psychiatric disorders, such as ADHD, ASD, and OCD. These 
disorders were shown to be associated with XCE in this thesis. The considerable overlap 
between executive dysfunction and ASD/ADHD symptomatology in our cohort, supports 
the notion that deficits in executive functions underlie the observed psychiatric features in 
XCE. 
8.3.9 Clinical implications.  
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SDQ impact assesses chronicity, distress, social impairment, and burden for others. 
Impact scores were in the very high range for approximately 75% of our cohort. This was 
further supported by 65% of respondents endorsing behavior as the most challenging 
aspect each day. To our knowledge, this is the first study to specifically incorporate a 
direct measure of burden on the individual and their family in the context of XCE. Impact 
scores have been shown to better discriminate community from clinical groups compared 
to symptom scores and may be a useful tool for determining caseness.157 Our findings 
afford a more comprehensive understanding of the caregiving context and its outcomes, 
and may lead to a practical application in devising effective support strategies for 
families, which still seem to be lacking. 
8.4 Outcome 3: Treatment efficacy in X-linked clustering epilepsy 
This section discusses levetiracetam and the implications our findings have for clinical 
practice. 
8.4.1 Levetiracetam. 
Levetiracetam (Keppra®, E Keppra®) is a second-generation AED. It is chemically 
unrelated to, and has low potential for clinically relevant pharmacokinetic interactions 
with, other currently available AEDs.158 The mechanism of action for levetiracetam is 
postulated to involve binding to SV2A, leading to inhibition of presynaptic 
neurotransmitter release;159 reducing calcium release;160 and activating GABA current by 
opposing the action of zinc and β-carbolines on GABA- and glycin-gated currents.161 
Levetiracetam has demonstrated therapeutic efficacy across a broad spectrum of 
epilepsies as an adjunctive therapy and as a monotherapy (see162 for a review). 
Interestingly, levetiracetam has been associated with an improvement in health-related 
quality of life.163, 164 This is important to note with respect to XCE, as the burden 
experienced by individuals and families affected by this disorder is high (refer Fig. 3.4). 
To date, the therapeutic efficacy of levetiracetam in XCE has not been systematically 
assessed. Several isolated cases have reported efficacy, and, in the Lotte study,93 seizure 
freedom was recorded for approximately a quarter of those trialling levetiracetam for 12 
months. Given the present pharmaco-resistant nature of XCE, levetiracetam should be 
considered early in the management seizure clusters. 
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There have been several isolated cases of adverse events following increased 
levetiracetam dosage,165, 166 however, levetiracetam is generally regarded as comparable 
to placebo.167 Cognition appears to be unaffected by levetiracetam administration, though 
an association with psychiatric and behavioral adverse events has been established.168 
This should be considered when administering levetiracetam for the treatment of seizures 
in XCE, given the high prevalence of late-onset psychosis.63 
8.4.2 Clinical implications.  
The mainstay of treatment of XCE is pharmacological therapy with AEDs. Identifying 
AEDs that are effective in XCE is complicated as the natural history of this disorder is 
that many females become seizure free in adolescence. Therefore, retrospective reports of 
which AED controlled seizures are confounded by the age at which the AED was 
introduced, as it may have coincided with the age at which patients would naturally 
outgrow their seizures. Seizure cessation may then be inappropriately attributed to the 
AED in use at that time. To definitively ascertain if an AED is effective randomized, 
double-blind, trials of either placebo or proven alternative treatments are required. 
8.5 Outcome 4: Penetrance of PCDH19 pathogenic variants 
In this section I discuss the major theory that has been proposed to explain penetrance in 
XCE, the association between cDNA expression and penetrance identified in Study 4, and 
how this can be interpreted with respect to theory.  
8.5.1 The cellular interference model. 
The current perspective accounting for the pathogenesis of XCE is the cellular 
interference model, which posits an alteration of cell-cell interactions. Here, PCDH19 
loss-of-function at the cellular level would result in a gain of (or altered) function at the 
tissue level due to altered interactions between wild-type and variant cells.22 The co-
existence of both cell types in the brain may result in a skewing of cell-cell 
communication due to the formation of separate cellular networks (e.g. wild-type and 
wild-type) or deregulation of the networks from altered cell-cell signalling (Fig. 8.1).4 
Normal individuals, hemizygous males with PCDH19 variants or highly skewed females, 
whom are essentially homogeneous for either wild-type cells or variant cells will be 
asymptomatic or “non-penetrant”.  
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Figure 8.1 Cellular interference model as an explanation of pathogenesis in XCE: A) Interaction of wild-type cells or 
B) variant cells both have a normal phenotype; (C) A mosaic population of wild-type and variant cells are unable to 
communicate correctly resulting in the disease expression. Modified from4. 
8.5.2 Association between PCDH19 cDNA expression and clinical outcomes. 
No clear association was observed between penetrance in XCE and the degree of variant 
and wild-type PCDH19 mRNA expression in skin fibroblasts. The precise mechanism by 
which penetrance is determined is yet to be elucidated; however, is likely to involve a 
complex interplay of post-transcriptional regulatory factors. Cellular interference posits 
that skewing in favour of complete, or near-complete, wild-type or variant expression 
would be associated with a milder phenotype or absence of symptoms. Although we were 
able to identify three non-penetrant females with 100% wild-type PCDH19 expression, 
we were unable to provide support for the mechanism of cellular interference through our 
finding clinical phenotypes in individuals with markedly skewed XCI. Our cohort 
consisted of six individuals with 100% wild-type expression, of whom three had seizures 
with varying neuropsychiatric profiles and three were non-penetrant. There were four 
with 100% variant expression, of whom one was non-penetrant and three had seizures, 
two with neuropsychiatric comorbidities and one with no information in this regard. 
There were three individuals with 50:50 expression, all with seizures but two with no 
neuropsychiatric comorbidities. These unexpected findings suggest that a new model of 
pathogenesis in this condition may be needed. While males with mosaic PCDH19 
pathogenic variants provide support for cellular interference, the identification of tissue 
mosaicism in the brain and asymptomatic females with homozygous PCDH19 variants 
would lend further support to this model. 
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8.6 Strengths and limitations  
A limitation that was identified in this research thesis was a lack of consensus with 
respect to how comorbidities are identified and assessed. As an initial step, standardized 
clinical assessments will address this discrepancy and is a strength of this research thesis. 
Standardized measures are particularly useful in contexts such as these, as they minimize 
any potential confounds that are likely to emerge as a result of different time points of 
administration, different administrators, and differences in the assessments themselves. 
Such differences render any comparisons across studies less meaningful and can lead to 
variation in results.  
Moreover, research settings are often constrained by available resources and time, 
therefore highlighting the need for tools that can be administered quickly and easily.169 
The self-report is a type of assessment whereby respondents respond to questions about 
their personal circumstances (i.e., psychiatric symptoms) without researcher involvement. 
A written questionnaire is an example of a highly structured self-report that can be 
systematically administered by different researchers in different contexts, thus reducing 
the influence of potential confounds. They are also able to be administered online, which 
makes them a very quick and easy way to obtain information, particularly if respondents 
are spread geographically, as is the case in XCE. Variations to the self-report include the 
“parent” or “other” report, which are completed by someone on behalf of the individual 
being assessed. These reports are particularly useful if the individual demonstrates poor 
insight into their circumstances or is unable to comprehend instructions, such is the case 
among young children170, 171 or individuals with ID.172   
While the use of standardized assessments was a major strength of this study, limitations 
also exist with relation to this methodology. Surveys such as the PCDH19 survey, involve 
the collection of data at a given time point thus limiting the ability to demonstrate causal 
associations. Biases also exist with self-reported data.73, 173 Validity checks within the 
BRIEF addressed these biases to some extent. Retrospective accounts are inherently less 
reliable than direct observation of behavior or events.174 The overwhelming gap in the 
literature is empirical evaluation and data on neuropsychiatric comorbidities in XCE. 
Longitudinal studies of the comorbidities in XCE are required to assess which early 
symptoms are markers for increased severity and chronicity, as well as long-term impact 
on functioning and wellbeing. Understanding the progression of neuropsychiatric 
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comorbidities and the role they play in future physiological and psychological health will 
determine if early intervention of neuropsychiatric comorbidities can prevent disease 
progression.  
Participation bias is a concern in all survey studies. Non-response bias may limit the 
ability to generalize the study’s findings. The response rate for the PCDH19 survey of 
65% is very high.175 Additionally, responses were obtained primarily from the primary 
caregivers of affected individuals. Contact with many survey respondents was ongoing 
and clarification or additional information could be sought around survey responses. A 
notable strength of this thesis is the large representative sample of the population of 
interest. Having access to an international cohort comprising the parents of affected 
individuals (male and female), as well as asymptomatic carriers of a PCDH19 variant 
provided the most comprehensive overview of the phenotypic spectrum associated with 
PCDH19 variants to date. 
This thesis has made several novel contributions to the field. The first is the 
characterization of the neuropsychiatric profile associated with PCDH19 variants. This is 
the first study to provide a comprehensive, standardized assessment of neuropsychiatric 
comorbidities, of which families identify as an area of major concern. This information 
provides a foundation for future longitudinal studies and will lead to the development of 
targeted intervention and guidance for patients and their families. The second contribution 
is the identified statistical associations between seizure onset age, frequency, and clinical 
outcome. This information is already being used by clinicians to inform prognosis and 
sheds light on possible mechanisms that underlie these clinical features. Lastly, we 
identify levetiracetam as an effective pharmaco-therapy in the management of the highly 
refractory clusters of seizures that characterize this genetic disease. 
8.7 Recommendations for further research 
Our comprehensive assessment of the neuropsychiatric comorbidities may provide an 
understanding of the pathological mechanisms involved. We identified significant overlap 
with relation to features of executive dysfunction and ASD, suggesting a common pathway 
underlying the neuropsychiatric comorbidities in this disorder. Of importance is an 
understanding of the neurobiological mechanisms of both epileptic seizures and 
neuropsychiatric comorbidities and to identify the contribution of these features to disease 
pathophysiology. The identification of blood biomarkers (in addition to skin biopsies) will 
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lead to more accurate and earlier diagnosis, which in turn has implications for early 
intervention. 
ID is formally diagnosed based on the following criteria: deficits in intellectual and 
adaptive functioning, and an onset of intellectual and adaptive deficits during the 
developmental period.57 Almost 75% of the reviewed cases reported individual FSIQ scores 
as a way of classifying ID. While FSIQ is an effective and accurate way to measure global 
intelligence, it does not adequately explain where specific deficits in cognition occur. It 
also fails to take an individual’s adaptive functioning into account. Adaptive functioning is 
a measure of how well an individual is able to meet acceptable standards of personal 
independence and social responsibility when compared to others of similar age and 
sociocultural background.57 Adaptive functioning is assessed via a combination of clinical 
and standardized assessments, the latter of which are generally administered to a 
knowledgeable informant (e.g., parents). Therefore, FSIQ assessments that also incorporate 
adaptive functioning measures will more accurately reflect the level of dysfunction that 
exists for the individual. 
The development of a framework for the assessment of neuropsychiatric comorbidities in 
XCE (including those identified in this thesis) could improve research, management, and 
outcomes. To validate the patient’s experience and that experienced by their families, as 
well as explain symptoms to patients, such frameworks should incorporate all dimensions 
of distress suffered by individuals. This can be achieved through more comprehensive 
assessments of impact and distress (similar to that employed by the impact supplement in 
the SDQ). In doing so, perhaps we can tailor interventions to meet the needs of patients and 
their families, thereby improving treatment adherence and outcomes.  
Besides the mechanism of cellular interference, sex-specific differences likely contribute 
to the heterogeneity and variable expressivity associated with PCDH19 pathogenic 
variants. Sex hormones, in particular those associated with the menstrual cycle and 
menopause, can trigger gender specific epilepsy.176, 177 Genes regulated by steroid hormone 
receptors, such as aldo-keto reductase family 1 member C3 (AKR1C3), are dysregulated in 
individuals with PCDH19 pathogenic variants.50 AKR1C3 converts androstenedione 
to testosterone, which is involved in the epigenetic modulation of gene expression. Taken 
together, these data raise the possibility that, in addition to or in conjunction with alterations 
   CHAPTER 8 
 
P a g e  | 131 
in cell-cell interactions, epigenetic dysregulation – specifically of genes regulated by 
steroid hormone receptors – underlies the pathogenesis in XCE.  
Treatment options for both seizures and neuropsychiatric comorbidities in XCE require 
further research, particularly the exploration of neuropsychiatric treatment options. 
Presently, Marinus Pharmaceuticals are running a phase III clinical trial for the treatment 
of epileptic seizures in XCE using ganaxolone. In phase II of this clinical trial, it was 
identified that treatment outcomes included an improvement in behaviour. This effect on 
behavior has been incorporated into the phase III clinical trial, which has been informed by 
this thesis.  
8.8 Conclusions 
We have shown that XCI patterns do not correlate with relative PCDH19 cDNA expression 
in fibroblasts, thus invalidating use of this assay to infer PCDH19 expression. We were 
also unable to provide support for cellular interference through our finding clinical 
phenotypes in individuals with markedly skewed XCI, suggesting that a new model of 
pathogenesis in this condition may be required. 
We identified three recurrent variants p.Asn340Ser, p.Tyr366Leufs*10, and 
Ile781Asnfs*3, as well as 35 novel PCDH19 pathogenic variants, thus significantly 
expanding the number of cases in the PCDH19 literature. This represents the largest cohort 
reported and allowed for the characterization of the clinical profile associated with 
PCDH19 variants. Executive dysfunction and ASD occurred in approximately 60% of 
individuals. The ASD profile included features of ADHD. OCD symptomology was 
observed in 21% individuals. There were no phenotypic differences between heterozygous 
females and mosaic males. Neuropsychiatric disorders can be very responsive to early 
intervention;58-60 therefore, a better understanding of these comorbidities may help to 
inform treatment and ultimately lead to better developmental outcomes for individuals 
affected by XCE. 
We show that both seizure onset age and activity are associated with clinical outcomes. 
Clinicians can use this information to inform prognosis and provide targeted intervention 
and guidance for patients and their families. 
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Appendix A:  Survey Assessments 
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A2 Social Communication Questionnaire (SCQ) 
Lifetime Form SCQTM 
 
Social Communication Questionnaire 
Michael Rutter, MD, FRS,  Anthony Bailey, MD,  Sibel Kazak Berument, PhD,  
Catherine Lord, PhD, and Andrew Pickles, PhD 
Name of Subject   Gender 
        Male   Female 
Date of Interview Date of Birth  Chronological Age 
    
Name of Respondent  Relation to Subject 
   
Clinician Name  School/Clinic 
   
Directions 
Thank you for taking the time to complete this questionnaire. Please answer each question by circling yes or no.  A few questions ask about several 
related types of behavior; please circle yes if any of these behaviors have ever been present. Although you may be uncertain about whether some 
behaviors were ever present or not, please answer yes or no to every question on the basis of what you think. 
1. Is she/he now able to talk using short phrases or sentences? If no, skip to question 8. Yes No 
2. Can you have a to and fro “conversation” with her/him that involves taking turns or building on  what you have 
said? 
Yes No 
3. Has she/he ever used odd phrases or said the same thing over and over in almost exactly the same way (either phrases 
that she/he has heard other people use or ones that she/he has made up)? 
Yes No 
4. Has she/he ever used socially inappropriate questions or statements? For example, has she/he  ever regularly asked 
personal questions or made personal comments at awkward times? 
Yes No 
5. Has she/he ever got her/his pronouns mixed up (e.g., saying you or she/he for I)? Yes No 
Response Sheet 
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6. Has she/he ever used words that she/he seemed to have invented or made up her/himself; put things in odd, indirect 
ways; or used metaphorical ways of saying things (e.g., saying hot rain for steam)? 
Yes No 
7. Has she/he ever said the same thing over and over in exactly the same way or insisted that you say the same thing 
over and over again? 
Yes No 
Continued on next page 
8. Has she/he ever had things that she/he seemed to have to do in a very particular way or order or rituals that she/he 
insisted that you go through? 
Yes No 
9. Has her/his facial expression usually seemed appropriate to the particular situation, as far as you could tell? Yes No 
10. Has she/he ever used your hand like a tool or as if it were part of her/his own body   
(e.g., pointing with your finger, putting your hand on a doorknob to get you to open the door)? 
Yes No 
11. Has she/he ever had any interests that preoccupy her/him and might seem odd to other people (e.g., traffic lights, 
drainpipes, or timetables)? 
Yes No 
12. Has she/he ever seemed to be more interested in parts of a toy or an object (e.g., spinning the wheels of a car), 
rather than using the object as it was intended? 
Yes No 
13. Has she/he ever had any special interests that were unusual in their intensity but otherwise appropriate for her/his 
age and peer group (e.g., trains, dinosaurs)? 
Yes No 
14. Has she/he ever seemed to be unusually interested in the sight, feel, sound, taste, or smell of things or 
people? 
Yes No 
15. Has she/he ever had any mannerisms or odd ways of moving her/his hands or fingers, such as flapping or moving 
her/his fingers in front of her/his eyes? 
Yes No 
16. Has she/he ever had any complicated movements of her/his whole body, such as spinning or repeatedly bouncing 
up and down? 
Yes No 
17. Has she/he ever injured her/himself deliberately, such as by biting her/his arm or banging  her/his head? Yes No 
18. Has she/he ever had any objects (other than a soft toy or comfort blanket) that she/he had  to carry around? Yes No 
19. Does she/he have any particular friends or a best friend? Yes No 
For the following behaviors, please focus on the time period between the child’s fourth and fifth birthdays. You may find it easier to remember 
how things were at that time by focusing on key events, such as starting school, moving house, Christmastime, or other specific events that are 
particularly memorable for you as a family. If your child is not yet 4 years old, please consider her or his behavior in the past 12 months. 
20. When she/he was 4 to 5, did she/he ever talk with you just to be friendly (rather than to  get something)? Yes No 
21. When she/he was 4 to 5, did she/he ever spontaneously copy you (or other people) or what  you were doing 
(such as vacuuming, gardening, or mending things)? 
Yes No 
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22. When she/he was 4 to 5, did she/he ever spontaneously point at things around her/him just to  show you things 
(not because she/he wanted them)? 
Yes No 
23. When she/he was 4 to 5, did she/he ever use gestures, other than pointing or pulling your hand,  to let you know 
what she/he wanted? 
Yes No 
24. When she/he was 4 to 5, did she/he nod her/his head to mean yes? Yes No 
25. When she/he was 4 to 5, did she/he shake her/his head to mean no? Yes No 
26. When she/he was 4 to 5, did she/he usually look at you directly in the face when doing things  with you or talking 
with you?  
Yes No 
27. When she/he was 4 to 5, did she/he smile back if someone smiled at her/him? Yes No 
28. When she/he was 4 to 5, did she/he ever show you things that interested her/him to engage  your attention? Yes No 
29. When she/he was 4 to 5, did she/he ever offer to share things other than food with you? Yes No 
30. When she/he was 4 to 5, did she/he ever seem to want you to join in her/his enjoyment  of something? Yes No 
31. When she/he was 4 to 5, did she/he ever try to comfort you if you were sad or hurt? Yes No 
32. When she/he was 4 to 5, when she/he wanted something or wanted help, did she/he look at you  and use gestures 
with sounds or words to get your attention? 
Yes No 
33. When she/he was 4 to 5, did she/he show a normal range of facial expressions? Yes No 
34. When she/he was 4 to 5, did she/he ever spontaneously join in and try to copy the actions in social games, such as 
The Mulberry Bush or London Bridge Is Falling Down? 
Yes No 
35. When she/he was 4 to 5, did she/he play any pretend or make-believe games? Yes No 
36. When she/he was 4 to 5, did she/he seem interested in other children of approximately the same  age whom 
she/he did not know? 
Yes No 
37. When she/he was 4 to 5, did she/he respond positively when another child approached her/him? Yes No 
38. When she/he was 4 to 5, if you came into a room and started talking to her/him without calling  her/his name, did 
she/he usually look up and pay attention to you? 
Yes No 
39. When she/he was 4 to 5, did she/he ever play imaginative games with another child in such a way that you could 
tell that they each understood what the other was pretending? 
Yes No 
40. When she/he was 4 to 5, did she/he play cooperatively in games that required joining in with  a group of other 
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A3 Strengths and Difficulties Questionnaire (SDQ)  
A3.1 Parent Form (2-4) 
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A3.2 Parent Form (5-10) 
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A3.3 Parent Form (11-17) 
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A3.4 Self-Report Form (11-17) 
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A4 Dimensional Obsessive-Compulsive Scale (DOCS)  
This questionnaire asks you about 4 different types of concerns that you might or might not experience. For each type there is 
a description of the kinds of thoughts (sometimes called obsessions) and behaviors (sometimes called rituals or compulsions) 
that are typical of that particular concern, followed by 5 questions about your experiences with these thoughts and behaviors. 
Please read each description carefully and answer the questions for each category based on your experiences in the last month.   
  




 -Thoughts or feelings that you are contaminated because you came into contact with (or were nearby) a certain object or 
person.  
-The feeling of being contaminated because you were in a certain place (such as a bathroom).  
-Thoughts about germs, sickness, or the possibility of spreading contamination.  
-Washing your hands, using hand sanitizer gels, showering, changing your clothes, or cleaning objects because of 
concerns about contamination.  
-Following a certain routine (e.g., in the bathroom, getting dressed) because of contamination 
-Avoiding certain people, objects, or places because of contamination.  
  
The next questions ask about your experiences with thoughts and behaviors related to contamination over the last month. 
Keep in mind that your experiences might be different than the examples listed above. Please circle the number next to your 
answer:  
  
1. About how much time have you spent each day thinking about contamination and engaging in washing 
or cleaning behaviors because of contamination?  
0 None at all  
1 Less than 1 hour each day  
2 Between 1 and 3 hours each day  
3 Between 3 and 8 hours each day  
4 8 hours or more each day  
  
2. To what extent have you avoided situations in order to prevent concerns with contamination or having to 
spend time washing, cleaning, or showering?  
0 None at all  
1 A little avoidance  
2 A moderate amount of avoidance  
3 A great deal of avoidance  
4 Extreme avoidance of nearly all things  
  
3. If you had thoughts about contamination but could not wash, clean, or shower (or otherwise remove the 
contamination), how distressed or anxious did you become?  
0 Not at all distressed/anxious  
1 Mildly distressed/anxious  
2 Moderately distressed/anxious   
3 Severely distressed/anxious  
4 Extremely distressed/anxious  
  
4. To what extent has your daily routine (work, school, self-care, social life) been disrupted by 
contamination concerns and excessive washing, showering, cleaning, or avoidance behaviors?  
0 No disruption at all.  
1 A little disruption, but I mostly function well.  
2 Many things are disrupted, but I can still manage.  
3 My life is disrupted in many ways and I have trouble managing.  
4 My life is completely disrupted and I cannot function at all.  
  
5. How difficult is it for you to disregard thoughts about contamination and refrain from behaviors such as 
washing, showering, cleaning, and other decontamination routines when you try to do so?  
0 Not at all difficult  
1 A little difficult  
2 Moderately difficult  
3 Very difficult  
4 Extremely difficult 
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-A doubt that you might have made a mistake that could cause something awful or harmful to happen.  
-The thought that a terrible accident, disaster, injury, or other bad luck might have occurred and you weren’t careful 
enough to prevent it.  
-The thought that you could prevent harm or bad luck by doing things in a certain way, counting to certain numbers, or 
by avoiding certain “bad” numbers or words.  
-Thought of losing something important that you are unlikely to lose (e.g., wallet, identify theft, papers).  
-Checking things such as locks, switches, your wallet, etc. more often than is necessary.  
-Repeatedly asking or checking for reassurance that something bad did not (or will not) happen.  
-Mentally reviewing past events to make sure you didn’t do anything wrong.  
-The need to follow a special routine because it will prevent harm or disasters from occurring.  
-The need to count to certain numbers, or avoid certain bad numbers, due to the fear of harm.  
  
The next questions ask about your experiences with thoughts and behaviors related to harm and disasters over the last month. 
Keep in mind that your experiences might be slightly different than the examples listed above. Please circle the number next 
to your answer:  
  
1. About how much time have you spent each day thinking about the possibility of harm or disasters and 
engaging in checking or efforts to get reassurance that such things do not (or did not) occur?  
0 None at all  
1 Less than 1 hour each day  
2 Between 1 and 3 hours each day  
3 Between 3 and 8 hours each day  
4 8 hours or more each day  
  
2. To what extent have you avoided situations so that you did not have to check for danger or worry about 
possible harm or disasters?  
0 None at all  
1 A little avoidance  
2 A moderate amount of avoidance  
3 A great deal of avoidance  
4 Extreme avoidance of nearly all things   
  
3. When you think about the possibility of harm or disasters, or if you cannot check or get reassurance 
about these things, how distressed or anxious did you become?  
0 Not at all distressed/anxious  
1 Mildly distressed/anxious  
2 Moderately distressed/anxious   
3 Severely distressed/anxious  
4 Extremely distressed/anxious  
  
4. To what extent has your daily routine (work, school, self-care, social life) been disrupted by thoughts 
about harm or disasters and excessive checking or asking for reassurance?  
0 No disruption at all.  
1 A little disruption, but I mostly function well.  
2 Many things are disrupted, but I can still manage.  
3 My life is disrupted in many ways and I have trouble managing.  
4 My life is completely disrupted and I cannot function at all.  
  
5. How difficult is it for you to disregard thoughts about possible harm or disasters and refrain from 
checking or reassurance-seeking behaviors when you try to do so?  
0 Not at all difficult  
1 A little difficult  
2 Moderately difficult  
3 Very difficult  
4 Extremely difficult    
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-Unpleasant thoughts about sex, immorality, or violence that come to mind against your will.  
-Thoughts about doing awful, improper, or embarrassing things that you don’t really want to do.  
-Repeating an action or following a special routine because of a bad thought.  
-Mentally performing an action or saying prayers to get rid of an unwanted or unpleasant thought.   
-Avoidance of certain people, places, situations or other triggers of unwanted or unpleasant thoughts  
  
  
The next questions ask about your experiences with unwanted thoughts that come to mind against your will and behaviors 
designed to deal with these kinds of thoughts over the last month. Keep in mind that your experiences might be slightly 
different than the examples listed above. Please circle the number next to your answer:  
  
1. About how much time have you spent each day with unwanted unpleasant thoughts and with behavioral 
or mental actions to deal with them?  
0 None at all  
1 Less than 1 hour each day  
2 Between 1 and 3 hours each day  
3 Between 3 and 8 hours each day  
4 8 hours or more each day  
  
2. To what extent have you been avoiding situations, places, objects and other reminders (e.g., numbers, 
people) that trigger unwanted or unpleasant thoughts?  
0 None at all  
1 A little avoidance  
2 A moderate amount of avoidance  
3 A great deal of avoidance  
4 Extreme avoidance of nearly all things  
  
3. When unwanted or unpleasant thoughts come to mind against your will how distressed or anxious did 
you become?  
0 Not at all distressed/anxious  
1 Mildly distressed/anxious  
2 Moderately distressed/anxious   
3 Severely distressed/anxious  
4 Extremely distressed/anxious  
  
4. To what extent has your daily routine (work, school, self-care, social life) been disrupted by unwanted 
and unpleasant thoughts and efforts to avoid or deal with such thoughts?  
0 No disruption at all.  
1 A little disruption, but I mostly function well.  
2 Many things are disrupted, but I can still manage.  
3 My life is disrupted in many ways and I have trouble managing.  
4 My life is completely disrupted and I cannot function at all.  
  
5. How difficult is it for you to disregard unwanted or unpleasant thoughts and refrain from using 
behavioral or mental acts to deal with them when you try to do so?  
0 Not at all difficult  
1 A little difficult  
2 Moderately difficult  
3 Very difficult  






   APPENDIX A 
 
P a g e  | 147 




-The need for symmetry, evenness, balance, or exactness.  
-Feelings that something isn’t “just right.”  
-Repeating a routine action until it feels “just right” or “balanced.”  
-Counting senseless things (e.g., ceiling tiles, words in a sentence).   
-Unnecessarily arranging things in “order.”  
-Having to say something over and over in the same way until it feels “just right.”   
  
  
The next questions ask about your experiences with feelings that something is not “just right” and behaviors designed to 
achieve order, symmetry, or balance over the last month. Keep in mind that your experiences might be slightly different than 
the examples listed above. Please circle the number next to your answer:  
  
1. About how much time have you spent each day with unwanted thoughts about symmetry, order, or balance and 
with behaviors intended to achieve symmetry, order or balance?  
0 None at all  
1 Less than 1 hour each day  
2 Between 1 and 3 hours each day  
3 Between 3 and 8 hours each day  
4 8 hours or more each day  
  
2. To what extent have you been avoiding situations, places or objects associated with feelings that something is not 
symmetrical or “just right?”  
0 None at all  
1 A little avoidance  
2 A moderate amount of avoidance  
3 A great deal of avoidance  
4 Extreme avoidance of nearly all things  
  
3. When you have the feeling of something being “not just right,” how distressed or anxious did you become?  
0 Not at all distressed/anxious  
1 Mildly distressed/anxious  
2 Moderately distressed/anxious   
3 Severely distressed/anxious  
4 Extremely distressed/anxious  
  
4. To what extent has your daily routine (work, school, self-care, social life) been disrupted by the feeling of things 
being “not just right,” and efforts to put things in order or make them feel right?  
0 No disruption at all.  
1 A little disruption, but I mostly function well.  
2 Many things are disrupted, but I can still manage.  
3 My life is disrupted in many ways and I have trouble managing.  
4 My life is completely disrupted and I cannot function at all.  
  
5. How difficult is it for you to disregard thoughts about the lack of symmetry and order, and refrain from urges to 
arrange things in order or repeat certain behaviors when you try to do so?  
0 Not at all difficult  
1 A little difficult 
2 Moderately difficult 
3 Very difficult 
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A6 Epilepsy Questionnaire (EQ) 
DEMOGRAPHICS 
 
YOUR DETAILS: Please enter your details, as outlined below.  
YOUR CHILD’S DETAILS: Please enter your child’s details, as outlined below. 
THE INDIVIDUAL’S DETAILS: Please enter the details of the individual you are responding on behalf 
of, as outlined below. 
 




*Date of birth: dd/mm/yyyy 
 
*Sex: 






☐ Caucasian  
☐ Indigenous 
☐ Other (please specify) 
 
Country of birth: 
 
Mother’s age (in years): 
 
Father’s age (in years): 
 
Age of other parent (in years): 
 
Relationship to individual: 
 
Age (in years) of mother (if known/applicable): 
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DEVELOPMENTAL DETAILS 
 
The following questions relate to your development. 
The following questions relate to your child’s development. 
The following questions relate to the development of the individual you are responding on behalf of. 
 
*Have you had a neurocognitive assessment?  
*Has your child had a neurocognitive assessment?  





If you are happy to share your neurocognitive assessment, please attach it here. 





The following questions relate to your child’s previous development. 
 





At what age (in months) did you first notice they were not developing as they should? 
 
What aspects of their development were affected? 
 





How many times did this happen? 
☐ Once 
☐ Twice 
☐ Three times 
☐ Four times 
☐ Five times or more 
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CURRENT DEVELOPMENT 
 
The following questions relate to your development at the present time.  
The following questions relate to your child’s development at the present time.  
The following questions relate to the individual’s development at the present time.  
 
What year/grade are you in at school?  
What year/grade is your child in school?  
☐ Preschool/Nursery school/Day care 
☐ Kindergarten/Reception 
☐ Year 1 
☐ Year 2 
☐ Year 3 
☐ Year 4 
☐ Year 5 
☐ Year 6 
☐ Year 7 
☐ Year 8 
☐ Year 9 
☐ Year 10 
☐ Year 11 
☐ Year 12 
☐ Not currently attending school 
☐ Never attended school 
 
What is the highest level of education you have attained?  
What is the highest level of education they attained?  
☐ Attended some school 
☐ Graduated high/secondary school 
☐ Diploma 
☐ Undergraduate degree 
☐ Postgraduate degree 
☐ Have never attended school 
 
Are they able to do age appropriate work?  





Do they require assistance/help with completing age-appropriate work? 





*Have you been diagnosed with an intellectual disability? 
*Has your child been diagnosed with an intellectual disability? 
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*What level of intellectual disability have you been diagnosed with? 
*What level of intellectual disability has your child been diagnosed with? 








Which of these most accurately describes your child’s language proficiency?  
Which of these most accurately describes the individual’s language proficiency?  
☐ Pre-verbal (e.g., coos and makes pleasure sounds) 
☐ Distinct consonant/vowel sounds (e.g., babbles in a speech-like way) 
☐ Single word utterances (e.g., "Hi", "dog", "Dada", or "Mama") 
☐ Two word utterances (e.g., "Where kitty?" or "more cookie") 
☐ Two or three word phrases (i.e., speaks in a way that is understood by family members and friends) 
☐ Four or more word sentences (i.e., speaks easily without having to repeat syllables or words) 




The next questions relate to your diagnosed mutation. 
The next questions relate to your child’s diagnosed mutation. 
The next questions relate to the individual’s diagnosed mutation. 
 
*What is your diagnosed mutation? E.g., c.1019A>G or p.D340N 
*What is your child’s diagnosed mutation? E.g., c.1019A>G or p.D340N 
*What is their diagnosed mutation? E.g., c.1019A>G or p.D340N 
If you are unsure, just type “unsure.”  
 
*Please select the option that reflects the inheritance of your mutation.  
☐ Only I have the mutation 
☐ I have the mutation but neither parent has been tested 
☐ Both my mother and I have the mutation 
☐ Both my father and I have the mutation 
☐ Unsure 
 
*Please select the option that reflects the inheritance of your child’s mutation.  
☐ Only my child has the mutation 
☐ My child has the mutation but neither parent has been tested 
☐ My child and I have the mutation 
☐ My child and his/her other parent have the mutation 
☐ Unsure 
 
*Please select the option that reflects the inheritance of their mutation.  
☐ Only the individual has the mutation 
☐ The individual has the mutation but neither parent has been tested 
☐ The individual and their mother have the mutation 





   APPENDIX A 
 
P a g e  | 153 
*Have you been diagnosed with any additional mutations?  
*Has your child been diagnosed with any additional mutations?  





Please provide details of any additional mutations that you have been diagnosed with. E.g., SCN1A, c.2837A>G 
or p.R466H 
Please provide details of any additional mutations that your child has been diagnosed with. E.g., SCN1A, 
c.2837A>G or p.R466H 
Please provide details of any additional mutations the individual has been diagnosed with. E.g., SCN1A, 




Has your child ever had a seizure? 
Has the individual ever had a seizure? 






The next questions relate to your seizure medication. 
The next questions relate to your child’s seizure medication. 
The next questions relate to the individual’s seizure medication. 
 
Please select all the medication that you have previously taken for your seizures. 
Please select all the medication that your child has previously taken for their seizures. 
Please select all the medication that the individual has previously taken for their seizures. 
 
Please select all the medication that you are currently taking for your seizures. 
Please select all the medication that your child is currently taking for their seizures. 
Please select all the medication that the individual is currently taking for their seizures. 
 
☐ Acetazolamide (e.g., Diamox) 
☐ Carbamazepine (e.g., Tegretol) 
☐ Cannabidiol (e.g., Sativex) 
☐ Clobazam (Onfi, Frisium) 
☐ Clonazepam (e.g., Klonotin) 
☐ Clorazepate (Tranxene) 
☐ Ethosuximide (Zarontin) 
☐ Gabapentin (e.g., Neurontin) 
☐ Lacosamide (Vimpat) 
☐ Lamotrigine (e.g., Lamictal) 
☐ Levetiracetam (Keppra) 
☐ Nitrazepam (e.g., Alodorm) 
☐ Oxcarbazepine (Oxtellar, Trileptal) 
☐ Perampanel (Fycompa) 
☐ Phenytoin (e.g., Dilantin) 
 
☐ Piracetam (e.g., Nootropil) 
☐ Potassium Bromide (Dibro-Be mono) 
☐ Primidone (Mysoline) 
☐ Pyridoxine/Vitamin B6 (e.g., Neuro-K) 
☐ Retigabine/Ezogabine (Potiga, Trobalt) 
☐ Rufinamide (Banzel, Inovelon) 
☐ Stiripentol (Diacomit) 
☐ Sultiame/Sulthiame (Ospolot) 
☐ Tiagabine (Gabitril) 
☐ Topiramate (Topamax) 
☐ Valproate/Valproic Acid (e.g., Depakote) 
☐ Vigabatrin/Gamma Vinyl GABA (Sabril) 
☐ Zonisamide (Zonegran) 
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*Have your seizures been controlled with medication for a period of time? 
*Have your child’s seizures been controlled with medication for a period of time? 




Are you currently seizure-free? 
Is your child currently seizure-free? 




Please provide details of the medication or medications that have been successful in controlling your seizures. 
Please provide the duration (in months) that you have remained seizure free in brackets following each medication 
listed. E.g., Valproate (13 months), Lamotrigine (5 months) 
 
Please provide details of the medication or medications that have been successful in controlling your child’s 
seizures. Please provide the duration (in months) that your child remained seizure free in brackets following each 
medication listed. E.g., Valproate (13 months), Lamotrigine (5 months) 
 
Please provide details of the medication or medications that have been successful in controlling the individual’s 
seizures. Please provide the duration (in months) that they remained seizure free in brackets following each 




The next questions relate to your seizures. 
The next questions relate to your child’s seizures. 
The next questions relate to the individual’s seizures. 
 
*At what age (in months) did you begin having seizures?  
*At what age (in months) did your child begin having seizures?  
*At what age (in months) did they begin having seizures?  
If you are unsure, just type “unsure.” 
 
How many hospital admissions for seizures have you had?  
How many hospital admissions for seizures has your child had?  









Have you been admitted to ICU as a result of seizures? 
Has your child been admitted to ICU as a result of seizures? 
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*Have you ever had a seizure lasting longer than 30 minutes? 
*Has your child ever had a seizure lasting longer than 30 minutes? 





How often do you have seizures that last longer than 30 minutes? 
How often does your child have seizures that last longer than 30 minutes? 





☐ Other (please specify)  
 
How long do these seizures last? Multiple options may be selected. 
☐ 30-40 minutes 
☐ 40-50 minutes 
☐ 50-60 minutes 
☐ 60+ minutes 
 










*Do your seizures cluster (many seizures occur together then there are long periods of time with no seizures)? 
*Do your child’s seizures cluster (many seizures occur together then there are long periods of time with no 
seizures)? 





What is the average number of days a cluster lasts?  
 
What is the average number of seizures per day in a cluster?  
 
How many seizure clusters have you had in the last 12 months?  
How many seizure clusters has your child had in the last 12 months? 
How many seizure clusters have they had in the last 12 months?  
 
* Do you ever experience isolated seizures (not in a cluster)? 
*Does your child ever experience isolated seizures (not in a cluster)? 
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When you have experienced isolated seizures, how often did they occur?  





☐ Other (please specify)  
 
When was your last seizure? 
When was your child’s last seizure? 




What do you find to be most challenging each day? 
As a parent, what do you find to be most challenging each day? 
As someone who is close to this individual, what do you find to be most challenging each day? 
 
What do you find to be the most helpful in responding to these challenges?  
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Appendix B:  Scripts 
B1 Survey 
 
UNDERSTANDING INDIVIDUAL DIFFERENCES ASSOCIATED WITH 
PROTOCADHERIN-19 (PCDH19) MUTATIONS 
 
Page 1: WELCOME TO THE SURVEY 
 
Thank you for taking the time to access this survey for a Doctor of Philosophy student 
research project. 
 
It should take no more than 45 minutes to complete. 
 
Your responses will not be individually identifiable. 
Your honesty in providing your responses would be greatly appreciated. 
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Page 2: Human Research Ethics Committee (HREC) consent form 
 
(This project has been approved by HREC: H-2016-184). Any concerns or queries can be 
directed to the HREC Secretariat - hrec@adelaide.edu.au). 
 
1. I have read the Participant Information Sheet provided via email and agree to take part in 
the following research project: 
Understanding individual differences associated with PCDH19 mutations. 
2. I am aged 18 years or older and am able to give consent freely. 
3. I have had the project, so far as it affects me, fully explained to my satisfaction by the 
researcher via the Participant Information Sheet (attached to the original email invite). My 
consent is given freely. 
4. I understand the purpose of the research project and understand that my involvement will 
not be of any benefit to me directly. 
5. I understand that information gained during the study may be published, and I will not be 
identified, nor will my personal results be shared. 
6. I understand that I am free to withdraw from the project without consequence. 
7. I am aware that I should keep a copy of this consent form (can take a screen shot) and the 
Participant Information Sheet provided previously. 
8. I understand that by submitting my survey response I consent to my data being used for 
this project.  
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Page 3: Screening 
 
*Are you completing this survey on behalf of yourself or someone else? 
☐ Yourself 
☐ Someone else 
 
Page 4: Screening 
 
*How old are you? 
☐ Younger than 11 years old 
☐ 11 – 14 years old 
☐ 15 – 17 years old 
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Page 5: Assent 
 
We are from the University of Adelaide in Australia and we are asking you to be in our 
research. We do research to learn more about how the world works and why people act the 
way they do. In this study, we want to learn more about epilepsy. 
 
What we are asking you to do: 
We would like to ask you to take a 30-minute online survey about your feelings, thoughts, 
and the things you do.   
 
Do I have to be in this study? 
You do not have to participate in this study. It is up to you. You can say no now or you can 
even change your mind later. No one will be upset with you if you decide not to be in this 
study.  
 
Will being in this study hurt or help me in any way? 
Being in this study will bring you no harm. There are no direct benefits to you for 
participating in this study. It will hopefully help us learn more about epilepsy. 
 
What will you do with information about me? 
We will be very careful to keep your answers to the survey questions private. Before and 
after the study we will keep all information we collect about you locked up and password 
protected and no individual will be identified in any report of the findings. 
 
If you have questions about the study, contact: kristy.kolc@adelaide.edu.au 
 
If you have questions about your rights in the study, contact: Human Research Ethics 
Committee, hrec@adelaide.edu.au  
 
If you become upset during the survey or would like to talk to someone about how you are 
feeling, contact: rachel.roberts@adelaide.edu.au 
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Page 6: Screening 




Page 7: Screening 
*How old is your child? 
☐ Between 2 and 4 years old 
☐ Between 5 and 10 years old 
☐ Between 11 and 17 years old 
☐ 18 years old or older 
 
Page 8: Screening 
*How old is the individual you are responding on behalf of? 
☐ Under 18 years of age 
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Page 9: Thank you 
 
We’re sorry. You do not meet the requirements for this survey. We sincerely thank you and 
appreciate your time and effort. 
 
If you have or know a parent willing to complete this survey, please kindly forward them the 
survey link. 
 
Again, thank you and have a nice day. 
 
Page 267: THIRD PARTY CONSENT 
 
*If you are unable to provide mutation and/or seizure details, and/or (where applicable) 
neurocognitive/developmental details, are you happy for the researchers in this study to 
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Page 268: THIRD PARTY CONSENT 
 




☐ Other (please specify) 
 
Contact name:   
Contact email: 
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Page 271: COMPLETION: THANK YOU 
 
This completes the survey  
Thank you for your participation  
Information collected in this research project may be used to answer similar questions in the 
future, such as to investigate the potential benefits of a given treatment. Please indicate 
whether or not you consent for the information you have provided being used in the future by 
selecting one of the boxes below: 




Please note that no individual will be personally identifiable in any reporting of future results 
This information may also be compared to existing medical data that we have if, for instance, 
you or the individual you are responding on behalf of, has provided a skin or saliva sample. 
Please indicate whether or not you consent for the information you have provided being 
compared to existing data by selecting one of the boxes below: 
*Consent for data to be compared to existing information: 
☐ YES 
☐ NO 
Once you have indicated your response above, please click on the DONE button located at 
the bottom of this page to submit your survey. 
(This project has been approved by HREC: H-2016-184. Any concerns or queries 
can be directed to the HREC Secretariat - hrec@adelaide.edu.au)   
*Indicates a required field 
 
PREV/DONE 
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B2 Neuropsychiatric Assessment 
Page 10: Questionnaire 1 
SRS-2 AutoScore Form (Preschool) 
John N. Constantino, MD 
Instructions 
For each question, please select the response that best describes your child's behavior over 
the past 6 months. 
1 = NOT TRUE   2 = SOMETIMES TRUE   3 = OFTEN TRUE   4 = ALMOST ALWAYS TRUE 
Strengths and Difficulties Questionnaire (P 2-4; © Robert Goodman, 2005) 
For each item, please select the option for Not True, Somewhat True or Certainly True. It 
would help us if you answered all items as best you can even if you are not absolutely certain. 
Please give your answers on the basis of your child's behaviour over the last six months. 
Please give your answers on the basis of your child's behaviour over the last six months. 
BRIEF-P: Behavior Rating Inventory of Executive Function- Preschool Version 
RATING FORM 
Gerard A. Gioia, PhD, Kimberly Andrews Espy, PhD, and Peter K. Isquith, PhD 
Instructions to Parents 
Below is a list of statements that describe young children. We would like to know if your 
child has had problems with these behaviors during the past 6 months. Please answer all the 
items the best that you can. Please do not skip any items. Think about your child as you read 
these statements and select: 
N   if the behavior is   Never   a problem 
S   if the behavior is   Sometimes   a problem 
O   if the behavior is   Often   a problem 
 
For example, if having tantrums when told "No" is never a problem, you would select N for 
this item: 
 
Has tantrums when told "No"      N      S      O 
During the past 6 months, how often has each of the following behaviors been a problem? 
N = NEVER 
S = SOMETIMES  
O = OFTEN 
 
(School-Age) 
(P 5-10; © Robert Goodman, 2005) 
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BRIEF: Behavior Rating Inventory of Executive Function PARENT FORM 
Gerard A. Gioia, PhD, Peter K. Isquith, PhD, Steven C. Guy, PhD, and Lauren Kenworthy, 
PhD 
 
Below is a list of statements that describe children. We would like to know if your child has 
had problems with these behaviors over the past 6 months. Please answer all the items the 
best that you can. Please DO NOT SKIP ANY ITEMS. Think about your child as you read 
each statement and select your response: 
 
For example, if your child never has trouble completing homework on time, you would 
select N for this item: 
 
Has trouble completing homework on time      N      S      O 
 
Over the past 6 months, how often has each of the following behaviors been a problem? 
 
(P 11-17; © Robert Goodman, 2005) 
 
(Adult Relative/Other Report) 
 
For each question, please select the response that best describes this individual's 
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BRIEF-A: Behavior Rating Inventory of Executive Function-Adult Version 
INFORMANT REPORT FORM 
Robert M. Roth, PhD, Peter K. Isquith, PhD, and Gerard A. Gioia, PhD 
 
Below is a list of statements that may describe your child/parent/spouse/sibling or another 
person with whom you are familiar. We would like to know if he/she has had problems with 
these behaviors over the past month. Please answer all the items the best that you can. Please 
DO NOT SKIP ANY ITEMS. Think about him/her as you read each statement and then 
indicate your response by selecting: 
 
For example, if he/she never has trouble making decisions, you would select N for this item: 
 
Has trouble making decisions      N      S      O 
 
During the past month, how often has each of the following behaviors been a problem? 
(S 11-17; © Robert Goodman, 2005) 
 
For each item, please select the response for Not True, Somewhat True or Certainly True. It 
would help us if you answered all items as best you can even if you are not absolutely certain. 
Please give your answers on the basis of how things have been for you over the last six 
months. 
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BRIEF-SR: Behavior Rating Inventory of Executive Function- Self-Report Version 
RATING FORM 
Steven C. Guy, PhD, Peter K. Isquith, PhD, and Gerard A. Gioia, PhD  
 
Below is a list of statements that describe young people. We would like to know if you have 
had any problems with these behaviors over the past 6 months. Please answer all of the 
items the best that you can, even if they don't seem to apply to you. Please think about 
yourself as you read these statements and respond by selecting: 
 
For example, if you never have trouble completing homework on time, you would 
select N for this item: 
 
I have trouble completing homework on time      N      S      O 
 
Dimensional Obsessive-Compulsive Scale (© Jonathan S. Abramowitz, 2009) 
 
This questionnaire asks you about 4 different types of concerns that you might or might not 
experience. For each type there is a description of the kinds of thoughts (sometimes 
called obsessions) and behaviors (sometimes called rituals or compulsions) that are typical of 
that particular concern, followed by 5 questions about your experiences with these thoughts 
and behaviors. Please read each description carefully and answer the questions for each 
category based on your experiences in the last month. 
(Adult Self Report) 
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BRIEF-A: Behavior Rating Inventory of Executive Function- Adult Version SELF-
REPORT FORM 
Robert M. Roth, PhD, Peter K. Isquith, PhD, and Gerard A. Gioia, PhD 
 
Below is a list of statements. We would like to know if you have had problems with these 
behaviors over the past month. Please answer all the items the best that you can. Please DO 
NOT SKIP ANY ITEMS. Indicate your response by selecting: 
 
 
For example, if you never have trouble making decisions, you would select N for this item: 
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Appendix C:  Survey Materials 
C1 Advertisement 
 
Protocadherin-19 (PCDH19) Research  
(H-2016-184) 
 
The research team at the University of Adelaide, led by Professor Jozef Gecz, are looking for 
people who have a protocadherin-19 (PCDH19) mutation or are able to report on behalf of 
someone with a PCDH19 mutation to participate in their research project. Their project aims 
to understand the types of symptoms associated with PCDH19 mutations, as well as the 
challenges faced by affected individuals and their families. 
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Professor Jozef Gecz is an Australian 
NH&MRC Senior Principal Research Fellow 
and Professor of Human Genetics at the 
University of Adelaide. He is the founding 
head of the Neurogenetics Research 
Program located at the Adelaide Women's 
and Children's Hospital.  
Protocadherin-19 
(PCDH19) Research  
(H-2016-184) 
The research team at the University of 
Adelaide in Australia, led by Professor 
Jozef Gecz, are looking for people who 
have a PCDH19 mutation or are able to 
report on behalf of someone with a 
PCDH19 mutation to participate in their 
research project. Their project aims to 
understand the types of symptoms 
associated with PCDH19 mutations, as 
well as the challenges faced by affected 
individuals and their families. 
For more information, please email     
kristy.kolc@adelaide.edu.au 
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C3 Invitation 
 
Dear [insert name], 
 
I am contacting you on behalf of Professor Jozef Gecz, who is the head of Neurogenetics 
Research at the University of Adelaide, Australia and a leading researcher in Protocadherin-
19 (PCDH19) epilepsy. Professor Gecz and his team are looking for people who have a 
PCDH19 mutation or are able to report on behalf of someone with a PCDH19 mutation to 
participate in their research project (H-2016-184). 
Their research project aims to improve our understanding of the types of symptoms 
associated with PCDH19 mutations, as well as the challenges faced by affected individuals 
and their families. Their project also aims to provide a clear picture of how these symptoms 
change over time by looking at different age groups. This information will help us to better 
understand PCDH19 mutations, which will help to build upon existing treatment and support 
programs for affected individuals and their families. 
Participation would involve responding to a number of online questionnaires, which should 
take no more than 45 minutes of your time. The survey can be completed by parents or 
knowledgeable informants of individuals affected by PCDH19 mutations or, where 
applicable, the individuals themselves (this also includes unaffected carriers of the mutation). 
If you would like to know more about this research or are interested in participating, please 
contact kristy.kolc@adelaide.edu.au  
Your decision will not impact the services you currently or may receive in any way, and you 
are under no obligation to participate in this research.  
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Thank you for your interest in our study. I would like to introduce myself. My name is Kristy 
Kolc and I am a PhD student working under the supervision of Professor Jozef Gecz, who is 
the head of Neurogenetics Research at the University of Adelaide and a leading researcher in 
Protocadherin-19 (PCDH19) epilepsy. 
 
Also attached to this email you will find a participant information sheet, which outlines all 
the details related to this research project and what your participation or your child’s 
participation will entail. Please kindly read this information sheet and if you are interested in 
participating/your child participating please click on the link at the end of the information 
sheet, which will take you to the consent page and the start of the survey. 
 
Please note that progress may be saved and the survey returned to at any time. Should you 
decide not to participate/for your child not to participate, we thank you for your time and 
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C5 Reminder Email 
 
Dear [insert name], 
 
 
This is just a friendly reminder regarding your participation in our research project that aims 
to improve our understanding of the types of symptoms associated with PCDH19 mutations, 
as well as the challenges faced by affected individuals and their families. If you have decided 
not to participate in this research, please disregard this message. 
 
We realize that it is often hard to find time in our busy lives, which is why we have made it 
possible for you to save your survey progress and come back to it later. We have also tried to 
minimize the amount of time needed to complete the questionnaires by only asking those 
questions that we believe to be directly relevant. We expect that it should take no more than 
45 minutes of your time. 
 
We have attached the participant information sheet. Once you have read this and decide that 
you wish to participate, please click on the link at the end of the information sheet to take you 
to the consent page and the start of the survey.  
 
Please be advised that the survey closing date is [insert date]. Following this, you will no 
longer be able to access the survey. 
 
 
Thank you again and we wish you all the best, 
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Appendix D:  Consent Forms 
D1 Participant Information Sheet (Parent) 
PROJECT TITLE: Understanding individual differences associated with protocadherin-19 (PCDH19) 
mutations  
HUMAN RESEARCH ETHICS COMMITTEE APPROVAL NUMBER: H-2016-184 
PRINCIPAL INVESTIGATOR: Professor Jozef Gecz 




You are invited to participate in the research project described below. 
What is the project about? 
The research project aims to understand the symptoms associated with protocadherin-19 (PCDH19) mutations. 
The project also aims to provide a clear picture of how these symptoms change over time by looking at different 
age groups. This information will help us to better understand PCDH19 mutations, which will help to build upon 
existing treatment and support programs for affected individuals and their families. 
 
Who is undertaking the project? 
This project is being conducted by Kristy Kolc. This research will form the basis for the degree of Doctor of 
Philosophy at the University of Adelaide, Australia under the supervision of Prof Jozef Gecz, Dr Duyen Pham, 
and Dr Rachel Roberts. This project is supported by an NHMRC grant and international philanthropic funding. 
Why am I being invited to participate? 
This research is to be undertaken amongst males and females who have a PCDH19 mutation and those who are 
able to report on behalf of someone with a PCDH19 mutation.  
What will I be asked to do? 
Participants will be asked to complete three questionnaires on behalf of their child that measure autism spectrum 
symptoms (e.g., “has an unusually narrow range of interests”), attention-deficit/hyperactivity symptoms (e.g., “I 
think before I do things”), and executive function (e.g., problem-solving skills). They will also be asked to provide 
general (e.g., age, sex, country of residence) and (if applicable) clinical (e.g., medication, mutation, and seizure 
details) information. 
 
How much time will the project take? 
Your participation in the project will take between 30-45 minutes. 
Are there any risks associated with participating in this project? 
The questionnaires are not intended to cause distress in any way, although responding to questions about personal 
experiences may cause distress for some participants. Please note that if you experience distress at any point, you 
do not need to continue your participation. Some people may feel they could benefit from speaking to someone 
about how they are feeling. There are a number of people you can contact in this event, such as a doctor, 
counsellor, or the PCDH19 Alliance (http://pcdh19info.org/). Additionally, Dr Rachel Roberts is a clinical 
psychologist and is available to be contacted at rachel.roberts@adelaide.edu.au. 
What are the benefits of the research project? 
This research will allow participants to share information about their personal experiences, which will potentially 
improve our understanding of the types of symptoms associated with PCDH19 mutations, as well as the challenges 
faced by affected individuals and their families.  
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Can I withdraw from the project? 
Participation in this project is completely voluntary. If you agree to participate, you can withdraw from the study 
up until the submission of the PhD thesis. Findings from this research will be shared through publications and 
presentations. If material you have contributed has already been published, it will not be possible to withdraw it 
from that publication. However, you may withdraw your contribution from the research data and, in that case it 
will not be used in any further publications.  
What will happen to my information? 
The information collected from this project will be confidentially stored on password protected university 
computers, and will only be accessible to the researchers listed on this form. This information will be kept for a 
minimum of five years and all responses are confidential and only group responses will be reported so that no 
individual will be identified in any report of the findings. With your additional consent, the information collected 
may be used in future research addressing similar questions or linked to existing molecular data (through provision 
of saliva or skin samples, for example). Again, no individual will be identified in any future use of the results. 
The disposal of any data or personal records will be carried out in accordance with the requirements of the State 
Records Act 1997 and the University Records Management Policy.  
Who do I contact if I have questions about the project? 
Any questions regarding this project should be addressed to: 
 
Professor Jozef Gecz  or  Dr Duyen Pham   
Email: jozef.gecz@adelaide.edu.au  Email: duyen.pham@adelaide.edu.au 
Phone: +618 8313 2453    Phone: +618 8313 7955 
 
Dr Rachel Roberts  or  Ms Kristy Kolc 
Email: rachel.roberts@adelaide.edu.au  Email: kristy.kolc@adelaide.edu.au 
Phone: +618 8313 5228    Phone: +618 8313 7984 
What if I have a complaint or any concerns? 
The study has been approved by the Human Research Ethics Committee (HREC) at the University of Adelaide 
(approval number H-2016-184). If you have questions or problems associated with the practical aspects of your 
participation in the project, or wish to raise a concern or complaint about the project, then you should consult the 
Principal Investigator. If you wish to speak with an independent person regarding a concern or complaint, the 
University’s policy on research involving human participants, or your rights as a participant, please contact the 
HREC Secretariat on:  
 
Phone:  +61 8 8313 6028    Email: hrec@adelaide.edu.au  
Post: c/- Research Services, The University of Adelaide, SA 5005 AUSTRALIA 
 
Any complaint or concern will be treated in confidence and fully investigated. You will be informed of the 
outcome. 
If I want to participate, what do I do? 
If you wish to participate, please click on the link https://www.research.net/r/PCDH19- and enter password 
PCDH19- (for your first child) and https://www.research.net/r/PCDH19- and enter password PCDH19- (for your 
second child, if applicable) to take you to the consent page and the start of the survey. Completion and submission 




Prof Jozef Gecz  Dr Duyen Pham   Dr Rachel Roberts Ms Kristy Kolc 




   APPENDIX D 
 
P a g e  | 177 
D2 Participant Information Sheet (Informant) 
PROJECT TITLE: Understanding individual differences associated with protocadherin-19 (PCDH19) 
mutations 
HUMAN RESEARCH ETHICS COMMITTEE APPROVAL NUMBER: H-2016-184 
PRINCIPAL INVESTIGATOR: Professor Jozef Gecz 




You are invited to participate in the research project described below. 
What is the project about? 
The research project aims to understand the symptoms associated with protocadherin-19 (PCDH19) mutations. 
The project also aims to provide a clear picture of how these symptoms change over time by looking at different 
age groups. This information will help us to better understand PCDH19 mutations, which will help to build upon 
existing treatment and support programs for affected individuals and their families. 
Who is undertaking the project? 
This project is being conducted by Kristy Kolc. This research will form the basis for the degree of Doctor of 
Philosophy at the University of Adelaide, Australia under the supervision of Prof Jozef Gecz, Dr Duyen Pham, 
and Dr Rachel Roberts. This project is supported by a NHMRC grant and international philanthropic funding. 
Why am I being invited to participate? 
This research is to be undertaken amongst males and females who have a PCDH19 mutation and those who are 
able to report on behalf of someone with a PCDH19 mutation.  
What will I be asked to do? 
Participants will be asked to complete two questionnaires on behalf of the individual with a PCDH19 mutation 
that measure autism spectrum symptoms (e.g., “has an unusually narrow range of interests”) and executive 
function (e.g., problem-solving skills). They will also be asked to provide general (e.g., age, sex, country of 
residence) and (if applicable) clinical (e.g., medication, mutation, and seizure details) information. 
 
How much time will the project take? 
Your participation in the project will take between 25-40 minutes. 
Are there any risks associated with participating in this project? 
The questionnaires are not intended to cause distress in any way, although responding to questions about personal 
experiences may cause distress for some participants. Please note that if you experience distress at any point, you 
do not need to continue your participation. Some people may feel they could benefit from speaking to someone 
about how they are feeling. There are a number of people you can contact in this event, such as a doctor, 
counsellor, or the PCDH19 Alliance (http://pcdh19info.org/). Additionally, Dr Rachel Roberts is a clinical 
psychologist and is available to be contacted at rachel.roberts@adelaide.edu.au. 
What are the benefits of the research project? 
This research will allow participants to share information about their personal experiences, which will potentially 
improve our understanding of the types of symptoms associated with PCDH19 mutations, as well as the challenges 
faced by affected individuals and their families.  
Can I withdraw from the project? 
Participation in this project is completely voluntary. If you agree to participate, you can withdraw from the study 
up until the submission of the PhD thesis. Findings from this research will be shared through publications and 
presentations. If material you have contributed has already been published, it will not be possible to withdraw it 
from that publication. However, you may withdraw your contribution from the research data and, in that case it 
will not be used in any further publications.  
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What will happen to my information? 
The information collected from this project will be confidentially stored on password protected university 
computers, and will only be accessible to the researchers listed on this form. This information will be kept for a 
minimum of five years and all responses are confidential and only group responses will be reported so that no 
individual will be identified in any report of the findings. With your additional consent, the information collected 
may be used in future research addressing similar questions or linked to existing molecular data (through provision 
of saliva or skin samples, for example). Again, no individual will be identified in any future use of the results. 
The disposal of any data or personal records will be carried out in accordance with the requirements of the State 
Records Act 1997 and the University Records Management Policy.  
Who do I contact if I have questions about the project? 
Any questions regarding this project should be addressed to: 
 
Professor Jozef Gecz  or  Dr Duyen Pham   
Email: jozef.gecz@adelaide.edu.au  Email: duyen.pham@adelaide.edu.au 
Phone: +618 8313 2453    Phone: +618 8313 7955 
 
Dr Rachel Roberts  or  Ms Kristy Kolc 
Email: rachel.roberts@adelaide.edu.au  Email: kristy.kolc@adelaide.edu.au 
Phone: +618 8313 5228    Phone: +618 8313 7984 
What if I have a complaint or any concerns? 
The study has been approved by the Human Research Ethics Committee (HREC) at the University of Adelaide 
(approval number H-2016-184). If you have questions or problems associated with the practical aspects of your 
participation in the project, or wish to raise a concern or complaint about the project, then you should consult the 
Principal Investigator. If you wish to speak with an independent person regarding a concern or complaint, the 
University’s policy on research involving human participants, or your rights as a participant, please contact the 
HREC Secretariat on:  
 
Phone:  +61 8 8313 6028    Email: hrec@adelaide.edu.au  
Post: c/- Research Services, The University of Adelaide, SA 5005 AUSTRALIA  
 
Any complaint or concern will be treated in confidence and fully investigated. You will be informed of the 
outcome. 
If I want to participate, what do I do? 
If you wish to participate, please click on the link https://www.research.net/r/PCDH19- and enter password 
PCDH19- to take you to the consent page and the start of the survey. Completion and submission of the survey 




Prof Jozef Gecz  Dr Duyen Pham   Dr Rachel Roberts Ms Kristy Kolc 
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D3 Participant Information Sheet (Adult Self-Report) 
PROJECT TITLE: Understanding individual differences associated with protocadherin-19 (PCDH19) 
mutations 
HUMAN RESEARCH ETHICS COMMITTEE APPROVAL NUMBER: H-2016-184 
PRINCIPAL INVESTIGATOR: Professor Jozef Gecz 




You are invited to participate in the research project described below. 
What is the project about? 
The research project aims to understand the symptoms associated with protocadherin-19 (PCDH19) mutations. 
The project also aims to provide a clear picture of how these symptoms change over time by looking at different 
age groups. This information will help us to better understand PCDH19 mutations, which will help to build upon 
existing treatment and support programs for affected individuals and their families. 
Who is undertaking the project? 
This project is being conducted by Kristy Kolc. This research will form the basis for the degree of Doctor of 
Philosophy at the University of Adelaide, Australia under the supervision of Prof Jozef Gecz, Dr Duyen Pham, 
and Dr Rachel Roberts. This project is supported by an NHMRC grant and international philanthropic funding. 
Why am I being invited to participate? 
This research is to be undertaken amongst males and females who have a PCDH19 mutation and those who are 
able to report on behalf of someone with a PCDH19 mutation.  
What will I be asked to do? 
Participants will be asked to complete three questionnaires that measure autism spectrum symptoms (e.g., “people 
think I am interested in too few topics, or that I get too carried away with those topics”), obsessive-compulsive 
symptoms (e.g., about how much time have you spent each day with unwanted unpleasant thoughts and with 
behavioral or mental actions to deal with them?), and executive function (e.g., problem-solving skills). They will 
also be asked to provide general (e.g., age, sex, country of residence) and (if applicable) clinical (e.g., medication, 
mutation, and seizure details) information. 
 
How much time will the project take? 
Your participation in the project will take between 30-45 minutes. 
Are there any risks associated with participating in this project? 
The questionnaires are not intended to cause distress in any way, although responding to questions about personal 
experiences may cause distress for some participants. Please note that if you experience distress at any point, you 
do not need to continue your participation. Some people may feel they could benefit from speaking to someone 
about how they are feeling. There are a number of people you can contact in this event, such as a doctor, 
counsellor, or the PCDH19 Alliance (http://pcdh19info.org/). Additionally, Dr Rachel Roberts is a clinical 
psychologist and is available to be contacted at rachel.roberts@adelaide.edu.au. 
What are the benefits of the research project? 
This research will allow participants to share information about their personal experiences, which will potentially 
improve our understanding of the types of symptoms associated with PCDH19 mutations, as well as the challenges 
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Can I withdraw from the project? 
Participation in this project is completely voluntary. If you agree to participate, you can withdraw from the study 
up until the submission of the PhD thesis. Findings from this research will be shared through publications and 
presentations. If material you have contributed has already been published, it will not be possible to withdraw it 
from that publication. However, you may withdraw your contribution from the research data and, in that case it 
will not be used in any further publications.  
What will happen to my information? 
The information collected from this project will be confidentially stored on password protected university 
computers, and will only be accessible to the researchers listed on this form. This information will be kept for a 
minimum of five years and all responses are confidential and only group responses will be reported so that no 
individual will be identified in any report of the findings. With your additional consent, the information collected 
may be used in future research addressing similar questions or linked to existing molecular data (through provision 
of saliva or skin samples, for example). Again, no individual will be identified in any future use of the results. 
The disposal of any data or personal records will be carried out in accordance with the requirements of the State 
Records Act 1997 and the University Records Management Policy.  
Who do I contact if I have questions about the project? 
Any questions regarding this project should be addressed to: 
 
Professor Jozef Gecz  or  Dr Duyen Pham   
Email: jozef.gecz@adelaide.edu.au  Email: duyen.pham@adelaide.edu.au 
Phone: +618 8313 2453    Phone: +618 8313 7955 
 
Dr Rachel Roberts  or  Ms Kristy Kolc 
Email: rachel.roberts@adelaide.edu.au  Email: kristy.kolc@adelaide.edu.au 
Phone: +618 8313 5228    Phone: +618 8313 7984 
What if I have a complaint or any concerns? 
The study has been approved by the Human Research Ethics Committee (HREC) at the University of Adelaide 
(approval number H-2016-184). If you have questions or problems associated with the practical aspects of your 
participation in the project, or wish to raise a concern or complaint about the project, then you should consult the 
Principal Investigator. If you wish to speak with an independent person regarding a concern or complaint, the 
University’s policy on research involving human participants, or your rights as a participant, please contact the 
HREC Secretariat on:  
 
Phone:  +61 8 8313 6028    Email: hrec@adelaide.edu.au  
Post: c/- Research Services, The University of Adelaide, SA 5005 AUSTRALIA 
 
Any complaint or concern will be treated in confidence and fully investigated. You will be informed of the 
outcome. 
If I want to participate, what do I do? 
If you wish to participate, please click on the link https://www.research.net/r/PCDH19- and enter password 
PCDH19- to take you to the consent page and the start of the survey. Completion and submission of the survey 




Prof Jozef Gecz  Dr Duyen Pham   Dr Rachel Roberts Ms Kristy Kolc 
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D4 Participant Information Sheet (Youth Self-Report) 
PROJECT TITLE: Understanding individual differences associated with protocadherin-19 (PCDH19) 
mutations 
HUMAN RESEARCH ETHICS COMMITTEE APPROVAL NUMBER: H-2016-184 
PRINCIPAL INVESTIGATOR: Professor Jozef Gecz 




Your child is invited to participate in the research project described below. 
What is the project about? 
The research project aims to understand the symptoms associated with protocadherin-19 (PCDH19) mutations. 
The project also aims to provide a clear picture of how these symptoms change over time by looking at different 
age groups. This information will help us to better understand PCDH19 mutations, which will help to build upon 
existing treatment and support programs for affected individuals and their families. 
Who is undertaking the project? 
This project is being conducted by Kristy Kolc. This research will form the basis for the degree of Doctor of 
Philosophy at the University of Adelaide, Australia under the supervision of Prof Jozef Gecz, Dr Duyen Pham, 
and Dr Rachel Roberts. This project is supported by an NHMRC grant and international philanthropic funding. 
Why am I being invited to participate? 
This research is to be undertaken amongst males and females who have a PCDH19 mutation and those who are 
able to report on behalf of someone with a PCDH19 mutation.  
What will I be asked to do? 
Participants will be asked to complete three questionnaires that measure obsessive-compulsive symptoms (e.g., 
about how much time have you spent each day with unwanted unpleasant thoughts and with behavioral or mental 
actions to deal with them?), attention-deficit/hyperactivity symptoms (e.g., “I think before I do things”), and 
executive function (e.g., problem-solving skills). They will also be asked to provide general (e.g., age, sex, country 
of residence) and (if applicable) clinical (e.g., medication, mutation, and seizure details) information.  
 
How much time will the project take? 
Your child’s participation in the project will take between 20-30 minutes. 
Are there any risks associated with participating in this project? 
The questionnaires are not intended to cause distress in any way, although responding to questions about personal 
experiences may cause distress for some participants. Please note that if your child experiences distress at any 
point, they do not need to continue their participation. Some people may feel they could benefit from speaking to 
someone about how they are feeling. There are a number of people you can contact in this event, such as a doctor, 
counsellor, or the PCDH19 Alliance (http://pcdh19info.org/). Additionally, Dr Rachel Roberts is a clinical 
psychologist and is available to be contacted at rachel.roberts@adelaide.edu.au. 
What are the benefits of the research project? 
This research will allow participants to share information about their personal experiences, which will potentially 
improve our understanding of the types of symptoms associated with PCDH19 mutations, as well as the challenges 
faced by affected individuals and their families.  
Can I withdraw from the project? 
Participation in this project is completely voluntary. If you agree for your child to participate, they can withdraw 
from the study up until the submission of the PhD thesis. Findings from this research will be shared through 
publications and presentations. If material they have contributed has already been published, it will not be possible 
to withdraw it from that publication. However, you may withdraw their contribution from the research data and, 
in that case it will not be used in any further publications.  
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What will happen to my information? 
The information collected from this project will be confidentially stored on password protected university 
computers, and will only be accessible to the researchers listed on this form. This information will be kept for a 
minimum of five years and all responses are confidential and only group responses will be reported so that no 
individual will be identified in any report of the findings. With your additional consent, the information collected 
may be used in future research addressing similar questions or linked to existing molecular data (through provision 
of saliva or skin samples, for example). Again, no individual will be identified in any future use of the results. 
The disposal of any data or personal records will be carried out in accordance with the requirements of the State 
Records Act 1997 and the University Records Management Policy.  
Who do I contact if I have questions about the project? 
Any questions regarding this project should be addressed to: 
 
Professor Jozef Gecz  or  Dr Duyen Pham   
Email: jozef.gecz@adelaide.edu.au  Email: duyen.pham@adelaide.edu.au 
Phone: +618 8313 2453    Phone: +618 8313 7955 
 
Dr Rachel Roberts  or  Ms Kristy Kolc 
Email: rachel.roberts@adelaide.edu.au  Email: kristy.kolc@adelaide.edu.au 
Phone: +618 8313 5228    Phone: +618 8313 7984 
What if I have a complaint or any concerns? 
The study has been approved by the Human Research Ethics Committee (HREC) at the University of Adelaide 
(approval number H-2016-184). If you have questions or problems associated with the practical aspects of your 
child’s participation in the project, or wish to raise a concern or complaint about the project, then you should 
consult the Principal Investigator. If you wish to speak with an independent person regarding a concern or 
complaint, the University’s policy on research involving human participants, or your child’s rights as a participant, 
please contact the HREC Secretariat on:  
 
Phone: +61 8 8313 6028     Email: hrec@adelaide.edu.au  
Post: c/- Research Services, The University of Adelaide, SA 5005 AUSTRALIA 
 
Any complaint or concern will be treated in confidence and fully investigated. You will be informed of the 
outcome. 
If I want to participate, what do I do? 
If you wish to participate, please click on the link https://www.research.net/r/PCDH19- and enter password 
PCDH19- to take you to the consent page and the start of the survey. Completion and submission of the survey 




Prof Jozef Gecz  Dr Duyen Pham   Dr Rachel Roberts Ms Kristy Kolc 
Neurogenetics Head Postdoctoral Fellow  Senior Lecturer  PhD Candidate 
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Appendix E:  Further Information 
 
If you would like to learn more about PCDH19, you can do so via the:  
1. Human Disease Genes Website Series: https://humandiseasegenes.nl/pcdh19 
2. PCDH19 Registry: https://www.pcdh19info.org/pcdh19-patient-registry 
 
Additionally, there are several community groups dedicated to sharing information and 
connecting families affected by PCDH19 pathogenic variants: 
1. USA (PCDH19 Alliance): https://www.pcdh19info.org/ 
2. Italy (Insieme per la Ricerca PCDH19): http://www.pcdh19research.org/ 
3. France (Association PCDH19 France): https://pcdh19france.fr/ 
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Supplementary Tables 
S2.1 Seizure onset precipitate 
 Frequency Percent 
Valid Not applicable 3 1.1 
Afebrile 16 5.9 
Fever 86 31.7 
Not reported 49 18.1 
Unclear 111 41.0 
Unknown 2 .7 
Vaccination 4 1.5 
Total 271 100.0 
Missing  0  
Total 271  
 
S2.2 Variant location 
 Frequency Percent 
Valid EC1 32 11.7 
EC2 38 13.9 
EC3 55 20.1 
EC4 63 24.8 
EC5 17 6.2 
EC5-EC6 1 .4 
EC6 29 10.6 
Cytoplasmic 20 7.3 
Not applicable 16 6.2 
Total 271 100.0 
Missing  0  
Total 271  
 
S2.3 Type of variant 
 Frequency Percent 
Valid Frameshift 74 27.3 
In-frame deletion 1 .4 
In-frame duplication 3 1.1 
In-frame insertion 1 .4 
Missense substitution 122 45.0 
Nonsense substitution 52 19.2 
Nonsense; Missense 1 .4 
Silent substitution 1 .4 
Splice-site 5 1.8 
Whole/partial gene deletion 11 4.0 
Total 271 100.0 
Missing  0  
Total 271  
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S2.4 PCDH19 cDNA 
cDNA Protein Correct Annotation Frequency cDNA Protein Correct Annotation Frequency 
1017delC N340Mfs*28  1 1522_1528delATCAATC I508Pfs*59  1 
1019A>G (17 recurrent) N340S  25 152dupT A51Rfs*37  1 
1022A>G D341G  1 1537G>C G513R  1 
1023C>G D341E  1 1615G>C G539R  1 
1026_1027delinsAA N342_P343delinsKT  1 1628T>C L543P  1 
1031C>G (unrel.) P344R  2 1649G>A R550P R550Q 1 
1031C>T P344L  1 1671C>G (sibs) N557K  2 
1036_1040dup N347Kfs*23  1 1681G>A P561S 1681C>T 1 
1048C>G S350* 1049C>G 1 1682C>G (sibs+unrel.) P561R  3 
1091_1092insC (recurrent*) Y366Lfs*10  2 1700C>T (unrel.) P567L  2 
1091delC (DZ twins+unrel.) P364fs P364Rfs*4 3 1765_1766delTG V589Cfs*8 1765_1766delGT 1 
1091dupC (9 recurrent*) Y366Lfs*10  28 1780G>C D594H  1 
1098C>G Y366*  1 1786G>C D596H  1 
1123G>T D375Y  1 1787A>T D596V  1 
1129G>A D377N  1 1802G>A G601D  1 
1129G>C  D377H  1 1804C>T (unrel.) R602*  2 
1131C>A D377E  1 1825G>T E609*  1 
1143dupT G381Wfs*19  1 1852G>A D618N  1 
1178C>T P393L  1 1863dupT G622Wfs*18  1 
1183C>T R395*  1 1864G>C G622R  1 
1184G>C R395P  1 1924G>A V642M  1 
1192G>T E398*  1 1955T>C L652P  1 
1211C>T T404I  1 1956_1959delCTCT S653Pfs*6  1 
1240G>C E414Q  1 2012C>G (rel.+1 unrel.) S671*  7 
1240G>A E414K  1 2019delC S674Lfs*2  1 
1298T>C L433P  1 2030_2031insT (rel.) L677fs*717 L677Ffs*41 7 
1300_1301delCA (MZ twins) Q434Efs*11  2 2147+2T>C p.? (exon/intron 1)  1 
1322T>A (rel.) V441E  10 2156T>G L719*  1 
134_135ACdel (sibs) D45Gfs*43  2 215T>G V72G  1 
1347_1348insAAC N449_H450insN  1 2341dupA I781Nfs*3  1 
1352C>T P451L  1 2359C>T R787C  1 
1375C>T Q459*  1 241dupC L81Pfs*8  1 
1408_1417delGCCTATCTGC A470Sfs*96  1 242T>G (recurrent) L81R  4 
142G>T (sibs) E48*  2 253C>T (rel. + 1 unrel.) Q85*  5 
1456G>C G486R  1 2567delCGGCACT Not provided 2567delAGGGGCC, Q856Pfs*6 1 
1464_1466delCTC S489delS  1 2568C>T# S856S 2563C>T, S855S 1 
1521dupC I508Hfs*15  1 2617-1G>A p.? (intron 3/exon 4)  1 
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cDNA Protein Correct Annotation Frequency cDNA Protein Correct Annotation Frequency 
2631_2634delTTTT F878Tfs*5  1 617T>A F206Y  1 
2656C>T (5 recurrent) R886*  8 695A>G (recurrent) N232S  4 
2675-6A>G  p.? (intron 4/exon 5)  1 697_700delinsTAAC (sibs) D233*  2 
2675+1G>C (unrel.) p.? (exon/intron 4)  2 701A>G N234S  1 
2697dupA  E900Rfs*8  1 706C>T P236S  1 
269A>T D90V  1 718G>T E240*  1 
2705dupA (rel.) D902Kfs*6 N902Kfs*6 2 729C>A Y243*  1 
2873C>T R958Q 2873G>A  1 730dupG A244Gfs*76  1 
2903dupA D968Efs*18  1 746A>G E249G  1 
2926G>A# D976N 3070G>A, D1024N 1 747A>T E249D  1 
339C>A C113*  1 74T>C (sibs) L25P  2 
352G>T E118*  2~ 772_773delAT I258Pfs*61  1 
357delC (unrel.) K120Rfs*3  2 785C>A A262D  1 
361G>A D121N  1 78delG K26Nfs*4  1 
370G>A (sibs) D124N  2 790G>C (unrel.) D264H  2 
415_423dup (rel.) S139_A141dup  3 799G>T E267*  1 
416C>A S139*  1 823T>A Y275N  1 
416C>T S139L  1 824A>C Y275S  1 
424delG A142Pfs*70  1 826T>C S276P  1 
437C>G (rel.) T146R  3 83C>A  S28*  1 
445C>T P149S  1 83C>A & 90A>G S28* & E90E  1 
457G>A A153T  1 840C>G Y280*  1 
462C>A Y154*  1 859G>T E287*  1 
462C>G Y154*  1 859G>T & 3319C>G E287* & R1107G  1 
469G>A D157N  1 918C>G Y306*  1 
471C>A D157E  1 919G>A E313K E307K 1 
473C>G S158*  1 91G>A E31K  1 
488T>G V163G  1 937G>A E307K E313K 1 
497_498insA Y166*  1 949C>T Q317*  1 
506delC (unrel.) T169Sfs*43  2 958dupG D320Gfs*22  1 
514dupG E172Gfs*54  1 964G>C G322R  1 
569T>G L190R  1 C>G H146Q 1935C>G, H645Q 1 
571G>C V191L  1 T>C V91A 1770T>C, V590A 1 
593G>T R198L  1 Total   145 
595G>C E199Q  1     
605C>A S202*  1 Partial gene deletion   1 
608A>C & 617T>G H203P & F206C  1 Whole gene deletion   10 
NB: del = deletion, dup = duplication, DZ = dizygotic, ins = insertion, sibs = siblings, unrel/rel. = unrelated/related individuals, *same mutation, ~ possible repeated case, #unlikely to be clinically relevant 
All corrections based on NM_001184880.1 
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S2.5 Inheritance 
 Frequency Percent 
Valid #Maternal 9 3.3 
De novo 110 40.6 
De novo; Paternal 1 .4 
Familial 3 1.1 
Maternal 32 11.8 
Not the father 1 .4 
Not the mother 2 .7 
Not reported 10 3.7 
Paternal 64 23.6 
Unknown 39 14.4 
Total 271 100.0 
Missing  0  
Total 271  
 
 
S2.6 Cognitive function 
 Frequency Percent 
Valid Normal 55 28.2 
Borderline 10 5.1 
Mild ID 53 27.2 
Moderate ID 43 22.1 
Severe/Profound ID 34 17.4 
Total 195 100.0 
Missing  76  
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S3.1 Reliability coefficients for SDQ Parent-Report scores 
 Cronbach α  
SDQ scale Total difficulties .71 
Emotional symptoms .77 
Conduct problems .63 
Hyperactivity-inattention .67 
Peer problems .66 
Prosocial behavior .83 
 Impact .86 
SDQ Strengths and Difficulties Questionnaire 
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S3.2 In silico assessment of all novel PCDH19 variants in our cohort 
           


























c.496_498AAA; p.Tyr166Lys De novo NC Absent NC 0.896 NC -8.199 D NC Likely Pathogenic 
16 Moldova 99663003 c.593G>C; p.Arg198Pro (mosaic)  De novo 31 Absent 0.4938962 0.927 0.987 -6.44 D Del Likely Pathogenic 
23 USA 99662127 c.1469A>C; p.Tyr490Ser De novo 25.6 Absent 0.9081805 0.919 0.991 -8.43 D Del Likely Pathogenic 
26,56 Denmark 99662797 c.799G>A; p.Glu267Lys Maternal, Paternal 33 Absent 0.1402426 0.887 0.771 -3.59 D Del Likely Pathogenic 
27 Denmark 99662127 c.1469A>G; p.Tyr490Cys Paternal 24.5 Absent 0.8659184 0.908 0.978 -8.43 D Del Likely Pathogenic 
30 UK 99662908 c.688G>C; p.Asp230His (mosaic) De novo 27.5 Absent 0.9995749 0.888 0.999 -6.19 D Del Likely Pathogenic 
40 New Zealand 99661677 c.1919T>G; p.Leu640Arg De novo 25.1 Absent 0.0750358 0.87 0.972 -5.26 D Del Likely Pathogenic 
44 USA 99662994 c.602A>C; p.Gln201Pro De novo 24.4 Absent 0.1126678 0.686 0.897 -4.9 D Del Likely Pathogenic 
67 Italy 99662576 c.1020T>A; p.Asn340Lys (mosaic) De novo 23.9 Absent 0.5263762 0.915 0.998 -5.51 D Del Likely Pathogenic 
69 Italy 99661654 c.1942G>C; p.Gly648Arg De novo 28.6 Absent 0.9850428 0.866 0.913 -7.06 D Del Likely Pathogenic 
73 Italy 99662925 c.671T>A; p.Leu224His De novo 24.5 Absent 0.9962677 0.81 0.94 -5.3 D Del Likely Pathogenic 
78 Italy 99551837 c.2885G>A; p.Arg962Gln Unknown 32 0.0000056 0.0001695 0.657 0.758 -1.92 D Del Likely Pathogenic 
85 Italy 99662817 c.779T>G; p.Leu260Arg De novo 25.8 Absent 0.9746687 0.959 0.959 -5.53 D Del Likely Pathogenic 
89,97, 
98,99 
Italy 99661623 c.1973T>G; p.Val658Gly 
Maternal (3) 
Unknown 
23.4 Absent 0.8591691 0.587 0.819 -4.08 P Del Likely Pathogenic 
90,96 Italy 99662133 c.1463T>A; p.Val488Asp Paternal, Unknown 26 Absent 0.3091389 0.912 0.987 -5.88 D Del Likely Pathogenic 
91 Italy 99663460 c.136G>C; p.Ala46Pro Paternal 25.3 Absent 5.81E-05 0.884 0.355 -1.5 D Tol Likely Pathogenic 
111 France 99662628 c.968C>T; p.Pro323Leu Paternal 26.1 Absent 0.5317213 0.803 0.132 -8.44 D Del Likely Pathogenic 
Ex USA 99658583 c.2227T>A; p.Ser743Thr 
Maternal (2),  
Unknown 







 11 Argentina 99661876 c.1720G>T; p.Glu574* (mosaic) De novo 37 Absent NC NC NC NC NC NC Likely Pathogenic 
59 Netherlands 99657726 c.2412C>A; p.Cys804* Unknown 38 Absent NC NC NC NC NC NC Likely Pathogenic 
70 Italy 99662844 c.752C>A; p.Ser251* De novo 41 Absent NC NC NC NC NC NC Likely Pathogenic 
107 France 99663544 c.52C>T; p.Gln18* De novo 36 Absent NC NC NC NC NC NC Likely Pathogenic 









3 Russia 99662500 c.1095_1096insG; .Tyr366Valfs*10 De novo NC Absent NC NC NC NC NC NC Possibly Damaging 




c.518_525del; p.Leu173Profs*50 De novo NC Absent NC NC NC NC NC NC Possibly Damaging 




c.1710_1716del; p.Asn570Lysfs*12 De novo NC Absent NC NC NC NC NC NC Possibly Damaging 
87 Italy 99662437 c.1159delC; p.Arg387Valfs*135 Unknown NC Absent NC NC NC NC NC NC Possibly Damaging 




c.1958_1959del; p.Ser653Cysfs*64 De novo NC Absent NC NC NC NC NC NC Possibly Damaging 
104 Canada 99657637 c.2501dup; p.Asn834Lysfs*13 Unknown NC Absent NC NC NC NC NC NC Possibly Damaging 












Maternal (2),  
Unknown 







22 UK 99551874 c.2849-1G>C; p.? Unknown 33 Absent NC NC NC NC NC NC Likely Pathogenic 
B, benign; D, probably damaging; Del, deleterious; Dup, duplication; H, high; L, low; M, medium; N, neutral; NC, not covered; P, possibly damaging; Tol, tolerated  
NB: red text highlights benign scores, Ex refers to the excluded variant 
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S3.3 In silico assessment of all non-PCDH19 variants in our cohort 
 




























STRADA: c.1144-1G>A; p.? 63703741 Unknown NC Absent NC  NC  NC  NC  NC  Possibly Damaging 
TPK1: 
c.337G>A:p.Glu113Lys 
















79245505 De novo 23.3 0.00001206 0.71 NC -1.72 P Tol Likely Benign 



















61981052 Unknown 15.1 0.0002254 0.15 0.646 -0.8 D Tol Likely Benign 
B, benign; CADD, Combined Annotation Dependent Depletion; D, probably damaging; Del, deleterious; N, neutral; NC, not covered; P, possibly damaging; Polyphen2, Polymorphism Phenotyping v2; 
PROVEAN, Protein Variation Effect Analyzer; SIFT, Sorting Intolerance from Tolerance; Tol, tolerated 
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S3.4 PCDH19 variant list  
# Group Variant Inheritance Novel Relatives 
1 Heterozygous female c.1091dup; p.Tyr366Leufs*10 Unknown 
  
2 Heterozygous female c.1335C>G; p.Asp445Glu Unknown 
  
3 Heterozygous female c.1095_1096insG; p.Tyr366Valfs*10 De novo Yes 
 
4 Heterozygous female c.614del; p.Ser205Thrfs*7 Maternal Yes Yes (52) 
5 Heterozygous female c.445_450dup; p.Pro149_Leu150dup Maternal Yes Yes (10,64) 
6 Mosaic male c.2656C>T; p.Arg886* De novo 
  
7 Heterozygous female c.1810A>C; p.Thr604Pro De novo Yes 
 
8 Heterozygous female c.496_498AAA; p.Tyr166Lys De novo Yes 
 
9 Heterozygous female c.370G>A; p.Asp124Asn  Maternal 
 
Yes (42,45,53,61,62) 
10 Heterozygous female c.445_450dup; p.Pro149_Leu150dup Maternal Yes Yes (5,64) 
11 Mosaic male c.1720G>T; p.Glu574* De novo Yes 
 
12 Heterozygous female c.1019A>G; p.Asn340Ser Maternal 
 
Yes (54) 
13 Heterozygous female c.1335C>A; p.Asp445Glu Maternal 
 
Yes (49) 
14 Heterozygous female c.1091dup; p.Tyr366Leufs*10 Paternal 
  
15 Heterozygous female c.1873A>G; p.Arg625Gly Maternal 
 
Yes (51) 
16 Mosaic male c.593G>C; p.Arg198Pro De novo Yes 
 
17 Heterozygous female WGD De novo 
  
18 Mosaic male c.2147+2T>C; p.? De novo 
  
19 Heterozygous female c.2113C>T; p.Arg705* De novo 
  
20 Heterozygous female c.2146dup; p.Ser716Lysfs*2 Paternal 
  
21 Heterozygous female c.1114C>T; p.Arg372Trp De novo 
  
22 Heterozygous female c.2849-1G>C; p.? Unknown Yes 
 
23 Heterozygous female c.1469A>C; p.Tyr490Ser De novo Yes 
 
24 Heterozygous female c.498C>G; p.Tyr166* Maternal 
 
Yes (58) 
25 Heterozygous female c.2341dup; p.Ile781Asnfs*3 De novo 
  
26 Heterozygous female c.799G>A; p.Glu267Lys  Maternal Yes Yes (56) 
27 Heterozygous female c.1469A>G; p.Tyr490Cys Paternal Yes 
 
28 Heterozygous female c.1240G>A; p.Glu414Lys Paternal 
 
Yes (63) 
29 Heterozygous female c.1091dup; p.Tyr366Leufs*10 De novo 
  
30 Mosaic male c.688G>C; p.Asp230His De novo Yes 
 
31 Heterozygous female c.1683_1696del; p.Val562Thrfs*4 Paternal 
 
Yes (65) 
32 Heterozygous female WGD De novo 
  
33 Heterozygous female WGD De novo 
  
34 Heterozygous female WGD Unknown 
  
35 Heterozygous female c.518_525del; p.Leu173Profs*50 De novo Yes 
 
36 Heterozygous female c.497dup; p.Tyr166* De novo 
 
Yes (37) 
37 Heterozygous female c.497dup; p.Tyr166* De novo 
 
Yes (36) 
38 Heterozygous female c.593G>T; p.Arg198Leu De novo 
  
39 Hemizygous male (with 
epilepsy) 
c.1672G>C; p.Asp558His  Maternal 
  
40 Heterozygous female c.1919T>G; p.Leu640Arg De novo Yes 
 
41 Heterozygous female c.1091dup; p.Tyr366Leufs*10 Paternal 
  
42 Heterozygous female c.370G>A; p.Asp124Asn  Maternal 
 
Yes (9,45,53,61,62) 
43 Heterozygous female c.361G>C; p.Asp121His De novo 
  
44 Heterozygous female c.602A>C; p.Gln201Pro De novo Yes 
 
45 Heterozygous female c.370G>A; p.Asp124Asn  Paternal 
 
Yes (9,42,53,61,62) 
46 Heterozygous female c.74T>C; p.Leu25Pro Maternal 
 
Yes (48) 
47 Hemizygous male (no 
epilepsy) 
c.2341dup; p.Ile781Asnfs*3 Maternal 
  
48 Heterozygous female c.74T>C; p.Leu25Pro Maternal 
 
Yes (46) 
49 Non-penetrant female c.1335C>A; p.Asp445Glu Unknown 
 
Yes (13) 
50 Heterozygous female c.437C>G; p.Thr146Arg Paternal 
 
Yes (108,109) 
51 Heterozygous female c.1873A>G; p.Arg625Gly Unknown 
 
Yes (15) 
52 Heterozygous female c.614del; p.Ser205Thrfs*7 De novo Yes Yes (4) 
53 Heterozygous female c.370G>A; p.Asp124Asn  Paternal 
 
Yes (9,42,45,61,62) 
54 Heterozygous female c.1019A>G; p.Asn340Ser Unknown 
 
Yes (12) 
55 Heterozygous female c.1671C>G; p.Asn557Lys Paternal 
 
Yes (57,60) 
56 Non-penetrant female c.799G>A; p.Glu267Lys  Paternal Yes Yes (26) 
57 Heterozygous female c.1671C>G; p.Asn557Lys Paternal 
 
Yes (55,60) 
58 Non-penetrant female c.498C>G; p.Tyr166* Unknown 
 
Yes (24) 
59 Heterozygous female c.2412C>A; p.Cys804* Unknown Yes 
 
60 Transmitting male c.1671C>G; p.Asn557Lys Unknown 
 
Yes (55,57) 
61 Transmitting male c.370G>A; p.Asp124Asn  Maternal 
 
Yes (9,42,45,53,62) 
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62 Non-penetrant female c.370G>A; p.Asp124Asn  Paternal 
 
Yes (9,42,45,53,61) 
63 Non-penetrant mosaic male c.1240G>A; p.Glu414Lys De novo 
 
Yes (28) 
64 Heterozygous female c.445_450dup; p.Pro149_Leu150dup Unknown Yes Yes (5,10) 
65 Transmitting male c.1683_1696del; p.Val562Thrfs*4 Unknown 
 
Yes (31) 
66 Heterozygous female c.1457del; p.Gly486Alafs*83 De novo Yes 
 
67 Mosaic male c.1020T>A; p.Asn340Lys De novo Yes 
 
68 Heterozygous female c.2338A>T; p.Lys780* De novo 
  
69 Heterozygous female c.1942G>C; p.Gly648Arg De novo Yes 
 
70 Heterozygous female c.752C>A; p.Ser251* De novo Yes 
 
71 Heterozygous female c.1710_1716del; p.Asn570Lysfs*12 De novo Yes 
 
72 Mosaic male c.1352C>T; p.Pro451Leu De novo 
  
73 Heterozygous female c.671T>A; p.Leu224His De novo Yes 
 
74 Heterozygous female c.1098C>G; p.Tyr366* De novo 
  
75 Heterozygous female c.2873G>A; p.Arg958Gln Maternal 
 
Yes (93) 
76 Heterozygous female c2617-1G>A; p.? De novo 
  
77 Heterozygous female c.1178C>T; p.Pro393Leu  De novo 
  
78 Heterozygous female c.2885G>A; p.Arg962Gln Unknown Yes 
 
79 Heterozygous female WGD De novo 
  
80 Heterozygous female c.1091dup; p.Tyr366Leufs*10 De novo 
  
81 Heterozygous female c.1019A>G; p.Asn340Ser De novo 
  
82 Heterozygous female c.1129G>C; p.Asp377His De novo 
  
83 Heterozygous female c.2675-6A>G; p.? De novo 
  
84 Heterozygous female WGD De novo 
  
85 Heterozygous female c.779T>G; p.Leu260Arg De novo Yes 
 
86 Heterozygous female c.958dup; p.Asp320Glyfs*22 De novo 
  
87 Heterozygous female c.1159delC; p.Arg387Valfs*135 Unknown Yes 
 
88 Heterozygous female c.706C>T; p.Pro236Ser De novo 
  
89 Heterozygous female c.1973T>G; p.Val658Gly Maternal Yes Yes (97,98,99) 
90 Heterozygous female c.1463T>A; p.Val488Asp Paternal Yes Yes (96) 
91 Heterozygous female c.136G>C; p.Ala46Pro Paternal Yes 
 
92 Heterozygous female c.1298T>C; p.Leu433Pro De novo 
  
93 Non-penetrant female c.2873G>A; p.Arg958Gln Unknown 
 
Yes (75) 
94 Heterozygous female c.1019A>G; p.Asn340Ser De novo 
 
Yes (95) 
95 Heterozygous female c.1019A>G; p.Asn340Ser Maternal 
 
Yes (94) 
96 Transmitting male c.1463T>A; p.Val488Asp Unknown Yes Yes (90) 
97 Non-penetrant female c.1973T>G; p.Val658Gly  Maternal Yes Yes (89,98,99) 
98 Heterozygous female c.1973T>G; p.Val658Gly  Maternal Yes Yes (89,97,99) 
99 Non-penetrant female c.1973T>G; p.Val658Gly Unknown Yes Yes (89,97,98) 
100 Heterozygous female c.971del; p.Asn324Ilefs*44 Maternal Yes 
 
101 Heterozygous female c.1958_1959del; p.Ser653Cysfs*64 De novo Yes 
 
102 Heterozygous female c.1091del; p.Pro364Argfs*4 De novo 
  
103 Heterozygous female c.2656C>T; p.Arg886* De novo 
  
104 Heterozygous female c.2501dup; p.Asn834Lysfs*13 Unknown Yes 
 
105 Heterozygous female c.1091dup; p.Tyr366Leufs*10 De novo 
  
106 Heterozygous female c.2019del; p.Ser674Leufs*2 De novo 
  
107 Heterozygous female c.52C>T; p.Gln18* De novo Yes 
 
108 Heterozygous female c.437C>G; p.Thr146Arg Paternal 
 
Yes (50,109) 
109 Heterozygous female c.437C>G; p.Thr146Arg Paternal 
 
Yes (50,108) 
110 Heterozygous female c.745del; p.Glu249Lysfs*56 De novo Yes 
 
111 Heterozygous female c.968C>T; p.Pro323Leu Paternal Yes 
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S3.5 Development frequencies (and percentages) 
 
a. Early development based on parent/caregiver-report (n = 83) 
 
 Heterozygous 
females (%) n = 73 
Mosaic  
males (%) n = 8 
Hemizygous 
 males (%) n = 2 
Developmental delay 43/73 (59) 6/8 (75) 1/2 (50) 
    -Prior to seizure onset 13/43 (30) 2/6 (33) N/A 
Regression 31/73 (42) 4/8 (50) 2/2 (100) 
    - ≥5 episodes of regression 17/31 (55) 3/4 (75) 1/2 (50) 
    -Following seizure cluster 27/31 (87) 2/4 (50) 1/2 (50) 
    -Following status epilepticus 5/31 (16) 0/4 (0) 0/2 (0) 
 
b. Intellect based on self- or patient/caregiver-report (n = 111) 
 Heterozygous females Mosaic males Hemizygous males 
 
 Affected 
 (n = 89) 
Non-penetrant 
 (n = 7) 
Affected 
(n = 8) 
Non-penetrant  
(n = 1) 
Affected  
(n = 2) 
Transmitting 
(n = 4)  
Normal intelligence 45 7 4 1 1 4 
Borderline intelligence 3 0 1 0 0 0 
Mild ID 18 0 1 0 1 0 
Moderate ID 9 0 0 0 0 0 
Severe ID 12 0 2 0 0 0 
Profound ID 2 0 0 0 0 0 
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S3.6 Seizure details 
Participant Seizures Status Epilepticus Clustered Seizures Isolated seizures 
ID Group Age Presence Onset (m) Hosp. adm. ICU admission Presence Freq. Dur. Conv. NC Presence Dur. (days) Seiz/day (av.) Last 12m Last seiz Presence Freq. 
1 AF 1.5 YES 8 3 YES NO N/A N/A N/A N/A YES 5 24 3 4/07/2018 NO N/A 
2 AF 3 YES 15.5 2 YES NO N/A N/A N/A N/A YES 4 50 3 14/08/2018 YES Yearly 
3 AF 2.5 YES 5.5 5 YES NO N/A N/A N/A N/A YES 1 42 14 09/07/2018 NO N/A 
4 AF 2 YES 9 3 YES NO N/A N/A N/A N/A UNSURE N/A N/A N/A 1/10/2018 NO N/A 
5 AF 2 YES 22 0 NO NO N/A N/A N/A N/A YES 2 4 2 25/02/2018 YES Weekly 
6 MM 2.5 YES 22 1 YES NO N/A N/A N/A N/A YES 13 7 1 17/06/2017 NO N/A 
7 AF 4 YES 6 5 YES YES Mon 50-60min YES YES YES 3 15 6 8/06/2018 NO N/A 
8 AF 2.5 YES 17 4 YES NO N/A N/A N/A N/A YES 10 24 4 Ongoing YES Twice 
9 AF 4 YES 10 5 YES NO N/A N/A N/A N/A YES 3 17 15 24/05/2018 NO N/A 
10 AF 3 YES 14 5 YES YES Yearly 30-50min NO YES YES 5 15 3 17/07/2017 YES Yearly 
11 MM 2 YES 8 2 NO NO N/A N/A N/A N/A YES UNSURE UNSURE 0 1/06/2016 NO N/A 
12 AF 2.5 YES 28 3 NO NO N/A N/A N/A N/A YES 3 8 1 10/01/2018 YES Yearly 
13 AF 8 YES 6 5 YES YES Yly 40-50min YES NO YES 4 25 12 1/01/2019 YES Infrequent 
14 AF 9 YES 4 5 NO YES Rarely 30-40min YES NO YES 3 40 30 6/10/2018 YES Yearly 
15 AF 7 YES 6 5 NO YES Yearly 30-40min YES NO YES 3 40 15 30/07/2018 YES Yearly 
16 MM 5 YES 5 5 YES NO N/A N/A N/A N/A YES 2 2 5 26/08/2018 YES Monthly 
17 AF 10 YES 15 5 YES NO N/A N/A N/A N/A YES 2 15 0 1/09/2014 NO N/A 
18 MM 10 YES 11 5 NO NO N/A N/A N/A N/A YES 7 30 2 1/12/2017 NO N/A 
19 AF 8 YES 12 4 YES NO N/A N/A N/A N/A YES 1 3 0 1/05/2015 YES Infrequent 
20 AF 6 YES 11 4 YES NO N/A N/A N/A N/A YES 2 10 0 1/09/2017 YES Infrequent 
21 AF 5 YES 6.5 4 YES NO N/A N/A N/A N/A YES 16 14 0 19/02/2017 YES Monthly 
22 AF 7 YES 11 5 YES YES Rarely 30-40min YES NO YES 10 45 0 1/08/2017 YES Yearly 
23 AF 10 YES 12 5 YES YES Bi-mon 30-60+min NO YES YES 5 5 6 17/07/2017 NO N/A 
24 AF 6 YES 10 3 YES NO N/A N/A N/A N/A YES 6 8 26 30/12/2017 YES Infrequent 
25 AF 8 YES 14 3 YES NO N/A N/A N/A N/A YES 2 13 0 14/12/2015 YES Monthly 
26 AF 10 YES 13 5 YES YES Mon-yearly 30-40min YES NO YES 2 100 8 21/06/2018 NO N/A 
27 AF 7 YES 15 5 NO YES Yearly 50-60min YES NO YES 3 12 0 1/02/2016 YES Yearly 
28 AF 9 YES 8 5 YES NO N/A N/A N/A N/A YES 7 10 0 1/04/2017 NO N/A 
29 AF 8 YES 3 5 YES YES Weekly 30-60+min YES YES YES 4 30 1000 Ongoing YES Monthly 
30 MM 5 YES 8 5 YES NO N/A N/A N/A N/A YES 3 10 24 1/03/2018 NO N/A 
31 AF 6 YES 11 2 NO NO N/A N/A N/A N/A YES 3 5 0 6/10/2015 NO N/A 
32 AF 6 YES 28 1 YES NO N/A N/A N/A N/A YES 14 5 0 1/01/2013 NO N/A 
33 AF 8 YES 10 5 YES YES Daily 30-40min NO YES YES 3 7 5 15/06/2006 NO N/A 
34 AF 13 YES 8 3 YES NO N/A N/A N/A N/A YES 14 20 0 1/10/2008 NO N/A 
35 AF 11 YES 9 5 YES YES No pattern 30-50min NO YES YES 5 12 0 19/08/2016 NO N/A 
36 AF 11 YES 8 5 NO YES Rarely 30-40min YES YES YES 4 30 0 1/09/2011 YES Monthly 
37 AF 11 YES 8 5 NO YES Rarely 30-40min YES YES YES 4 30 0 1/11/2011 YES Monthly 
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38 AF 11 YES 6 5 YES UNSURE N/A N/A N/A N/A YES 7 8 6 18/02/2018 YES Monthly 
39 AM(S) 16 YES 114 1 YES NO N/A N/A N/A N/A YES 5 2 12 1/12/2018 YES Infrequent 
40 AF 15 YES 14 5 YES NO N/A N/A N/A N/A YES 12 28 0 1/10/2008 YES Infrequent 
41 AF 12 YES 10 5 YES YES Once 30-40min YES NO YES 5 16 1 1/08/2015 YES Yearly 
42 AF 15 YES 6.5 5 YES NO N/A N/A N/A N/A YES 2 20 11 13/01/2018 NO N/A 
43 AF 12 YES 13 5 YES NO N/A N/A N/A N/A YES 1 10 100 4/04/2018 YES Yearly 
44 AF 16 YES 8 5 YES YES Daily 30-40min YES YES YES 4 19 12 12/08/2017 YES Unsure 
45 AF 41 YES 7 2 NO NO N/A N/A N/A N/A YES 2 20 0 1/01/2002 NO N/A 
46 AF 22 YES 8 5 NO YES Yearly 40-50min YES YES YES 5 8 0 1/01/2007 YES Yearly 
47 AM(NS) 23 NO N/A 0 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
48 AF 28 YES 7 5 YES YES Mon 30-60+min YES YES YES 7 10 0 1/01/2009 YES Yearly 
49 NP 35 NO N/A 7 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
50 AF 30 YES 60 5 YES NO N/A N/A N/A N/A YES 3 10 0 1/01/1997 NO N/A 
51 AF 36 YES 6 6 NO NO N/A N/A N/A N/A YES 1 10 0 1/01/1989 YES Yearly 
52 AF 38 YES 21 6 NO NO N/A N/A N/A N/A YES 2 3 0 In childhood YES Infrequent 
53 AF 35 YES 2 5 YES YES Once 30-40min YES NO NO N/A N/A N/A 1/01/1988 YES Yearly 
54 AF 36 YES 3 2 NO NO N/A N/A N/A N/A YES 2 3 8 13/03/2018 YES Yearly 
55 AF 35 YES 18 2 NO NO N/A N/A N/A N/A YES 3 20 0 1/01/1994 YES Twice 
56 NP 46 NO N/A 7 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
57 AF 32 YES 24 2 YES YES 3 times 60+ min YES YES YES 2 8 0 1/01/2002 YES Infrequent 
58 NP 33 YES 60 1 YES NO N/A N/A N/A N/A NO N/A N/A N/A 1/01/1989 YES Once 
59 AF 41 YES 10 5 NO NO N/A N/A N/A N/A YES 2 5 0 1/01/2002 NO N/A 
60 TM 63 NO N/A 7 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
61 TM 70 NO N/A 7 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
62 NP 47 NO N/A 7 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
63 MM(U) 41 NO N/A 7 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
64 AF 31 YES 55 1 NO NO N/A N/A N/A N/A YES 1 7 0 1/08/1998 YES Yearly 
65 TM 41 NO N/A 7 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
66 AF 2 YES 11 4 NO NO N/A N/A N/A N/A YES 15 5 1 8/06/2018 YES Weekly 
67 MM 2.5 YES 5 5 NO NO N/A N/A N/A N/A YES 1 7 20 8/07/2018 NO N/A 
68 AF 3 YES 24 5 NO NO N/A N/A N/A N/A YES 7 10 30 1/06/2018 NO N/A 
69 AF 3 YES 8 4 NO NO N/A N/A N/A N/A YES 2 20 5 12/01/2018 YES Infrequent 
70 AF 2.5 YES 10 1 YES NO N/A N/A N/A N/A YES 6 14 6 1/02/2018 NO N/A 
71 AF 6 YES 27 1 NO NO N/A N/A N/A N/A YES 1 10 0 1/02/2015 NO N/A 
72 MM 7 YES 10 5 YES NO N/A N/A N/A N/A YES 3 15 1 1/02/2018 NO N/A 
73 AF 6 YES 14 4 YES NO N/A N/A N/A N/A YES 3 6 0 24/06/2015 YES Once 
74 AF 7 YES 11 3 NO NO N/A N/A N/A N/A YES 4 8 0 1/02/2015 YES Infrequent 
75 AF 6 YES 9 1 NO NO N/A N/A N/A N/A YES 3 4 0 1/08/2017 YES Monthly 
76 AF 10 YES 11 2 YES NO N/A N/A N/A N/A YES 2 14 0 1/08/2014 YES Twice 
77 AF 8 YES 13 5 NO NO N/A N/A N/A N/A YES 2 10 2 24/05/2016 YES Once 
78 AF 8 YES 8 5 YES NO N/A N/A N/A N/A YES 15 20 40 10/03/2018 NO N/A 
79 AF 9 YES 8 5 NO YES 3-4m 60+ min YES YES YES 4 20 4 1/01/2018 NO N/A 
80 AF 8 YES 6 5 NO NO N/A N/A N/A N/A YES 24 10 3 1/03/2018 YES Yearly 
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81 AF 17 YES 5 5 NO NO N/A N/A N/A N/A YES 2 8 0 1/02/2016 YES Infrequent 
82 AF 17 YES 7 5 YES YES Once 40-50min YES NO YES 5 30 0 1/04/2015 YES Yearly 
83 AF 16 YES 6 5 YES YES Twice 30-40min YES NO YES 6 30 2 1/10/2017 YES Yearly 
84 AF 17 YES 15 5 YES NO N/A N/A N/A N/A YES 2 4 21 1/10/2018 YES Infrequent 
85 AF 13 YES 7 4 NO NO N/A N/A N/A N/A YES 1 25 6 21/03/2018 YES Monthly 
86 AF 15 YES 2.5 5 NO NO N/A N/A N/A N/A YES 14 8 0 1/01/2012 YES Yearly 
87 AF 27 YES 7 5 NO NO N/A N/A N/A N/A NO N/A N/A N/A 30/09/2018 YES Weekly 
88 AF 43 YES 9 5 NO NO N/A N/A N/A N/A YES 1 5 0 1/01/2013 YES Monthly 
89 AF 21 YES 5 5 YES NO N/A N/A N/A N/A YES 1 7 2 1/10/2017 NO N/A 
90 AF 21 YES 16 5 YES NO N/A N/A N/A N/A YES 2 10 0 24/07/2003 NO N/A 
91 AF 18 YES 11 5 NO NO N/A N/A N/A N/A YES 3 30 0 19/02/2008 NO N/A 
92 AF 25 YES 9 5 YES NO N/A N/A N/A N/A NO N/A N/A N/A 1/03/2008 YES Infrequent 
93 NP 45 YES 3 0 NO NO N/A N/A N/A N/A NO N/A N/A N/A 1/08/1972 YES Once 
94 AF 52 YES 8 6 NO UNSURE N/A N/A N/A N/A YES   0 UNSURE UNSURE N/A 
95 AF 23 YES 8 6 YES YES Yearly 60+ min YES YES YES 4  0 9/05/2016 YES Once 
96 TM 51 NO N/A 7 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
97 NP 54 NO N/A 7 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
98 AF 25 YES 30 5 NO NO N/A N/A N/A N/A YES 15 20 0 1/01/2004 NO N/A 
99 NP 57 NO N/A 7 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
100 AF 10 YES 11 5 YES NO  N/A N/A N/A N/A YES 1 3 0 1/01/2016 YES Daily 
101 AF 6 YES 16 5 NO  NO  N/A N/A N/A N/A YES 5 30 0 1/10/2017 NO  N/A 
102 AF 6 YES 7 5 YES NO  N/A N/A N/A N/A YES 2 7 5 26/08/2018 NO  N/A 
103 AF 7 YES 3.5 5 YES NO  N/A N/A N/A N/A YES 3 15 10 1/08/2018 YES Yearly 
104 AF 5 YES 14 5 YES YES Twice 50-60min YES NO  YES 2 10 5 1/03/2018 NO  N/A 
105 AF 7 YES 10 5 YES NO  N/A N/A N/A N/A YES 5 10 3 16/07/2018 YES Infrequent 
106 AF 14 YES 4 5 YES NO  N/A N/A N/A N/A YES 2 6 2 1/05/2018 NO  N/A 
107 AF 12 YES 22 5 YES NO  N/A N/A N/A N/A YES 7 5 0 1/01/2010 NO  N/A 
108 AF 32 YES 1.5 0 NO  NO  N/A N/A N/A N/A YES 4 20 0 1/02/2010 NO  N/A 
109 AF 23 YES 22 5 YES NO  N/A N/A N/A N/A YES 3  0 19/12/2008 YES Twice 
110 AF 23 YES 18 5 YES NO  N/A N/A N/A N/A YES 1 Many 0 1/01/2006 NO  N/A 
111 AF 33 YES 18 5 NO  YES Yearly 30-40min YES UNSURE YES 1 3 0 1/01/2002 NO  N/A 
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S3.7 Frequencies (and percentage) of SDQ domain and impact scores for 
affected individuals 
a. Heterozygous females (n = 65) 
 SDQ Domains 











Average 35 (54) 25 (38.5) 22 (34) 19 (29.5) 17 (26) 
Mild 12 (18) 13 (20) 15 (23) 6 (9) 9 (14) 
Moderate 7 (11) 16 (24.5) 11 (17) 6 (9) 7 (11) 
Severe 11 (17) 11 (17) 17 (26) 34 (52.5) 32 (49) 
 
b. Mosaic males (n = 8) 
 SDQ Domains 











Average 6 (75) 4 (50) 2 (25) 2 (25) 0 (0) 
Mild 0 (0) 2 (25) 3 (37.5) 0 (0) 2 (25) 
Moderate 1 (12.5) 1 (12.5) 2 (25) 2 (25) 0 (0) 
Severe 1 (12.5) 1 (12.5) 1 (12.5) 4 (50) 6 (75) 
 
c. Impact scores (n = 73) 
SDQ score classification 
Heterozygous 
females (n = 65) 
Mosaic 
males (n = 8) 
Average 9 (14) 1 (12.5) 
Mild 6 (9) 1 (12.5) 
Moderate 3 (5) 0 (0) 
Severe 47 (72) 6 (75) 
 
S3.8 Descriptive statistics for all neuropsychiatric measures 
Group Measure N Min Max Mean SD 
Heterozygous females SRS-2 82 35 107 69.5* 18.6 
SCQ 8 8 32 18.5* 8.12 
SDQ 65 3 31 17.6* 6.68 
BRIEF 89 34 98 67.8* 15.8 
DOCS 17 0 33 11.4 10.7 
Mosaic males SRS-2 8 46 86 68.8* 15.1 
SDQ 8 8 29 16.5* 6.28 
BRIEF 8 51 80 63.9* 11.7 
Non-penetrant females SRS-2 7 41 70 47.7 10.1 
BRIEF 7 39 75 47.6 12.5 
DOCS 7 0 46 11.1 16.3 
Transmitting males SRS-2 4 41 51 46.3 4.99 
BRIEF 4 38 53 45.3 6.19 
DOCS 4 0 15 5.25 6.70 
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S3.9 Average scores on measures of executive dysfunction, ASD, and 
prosocial behavior based on seizure onset and activity 
 





N SDQ Prosocial 
behavior 
Late / Mild 22 61.0 -0.35 16 6.31 
Late / Severe 6 63.7 0.01 5 4.60 
Early / Mild 33 71.8 0.17 28 5.32 
Early / Severe 24 75.3 0.85 21 3.52 
 
 
S3.10 Genotype-phenotype associations 
Dependent variable Independent 
variable N Mean Std. deviation Significance 
BRIEF t score Non-truncating 59 61.8 16.1 
p = .067 
Truncating 38 68.1 17.0 
ASD z score (SRS-2 & SCQ) Non-truncating 59 -0.12 0.98 
p = .738 
Truncating 38 -0.05 1.04 
SCQ emotional problems Non-truncating 29 3.62 2.77 
p = .128 
Truncating 32 2.63 2.27 
SCQ conduct problems Non-truncating 29 3.41 2.01 
p = .941 
Truncating 32 3.38 2.03 
SCQ hyperactivity-
inattention 
Non-truncating 29 6.52 2.23 
p = .491 
Truncating 32 6.06 2.83 
SCQ peer problems Non-truncating 29 4.48 2.17 
p = .190 
Truncating 32 3.66 2.70 
SCQ prosocial behavior Non-truncating 29 5.21 2.87 
p = .545 
Truncating 32 4.75 2.98 
 Age at seizure onset Non-truncating 48 10.3 6.35 
p = .506 
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Figure S2.1 Distribution of age at seizure onset for males and females 
 
 
Figure S3.1 Boxplots illustrating average total BRIEF t scores (blue) for females (n = 89) and males (n = 8) and average 
total SRS-2 t scores (orange) for females (n = 82) and males (n = 8). 
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Figure S3.2 Average (±2 SEM) BRIEF total GEC and subscale t scores. Darkening shades of red correspond to increasing 
degrees of severity. WM, working memory; PO, plan/organize; GEC, global executive composite. 
 
 
Figure S3.3 Association between seizure onset, seizure activity, and clinical outcome: a) executive dysfunction measured by 
the BRIEF and b) ASD outcome measured by the SRS-2 or SCQ (scores converted to z scores for the analysis). Early = ≤12 























































































































































































Figure S7.1 PCDH19 protein expression for all patients represented in the analysis (n = 13). All protein levels compared to 
age-matched controls (n = 4). PCDH19 is weakly expressed in skin fibroblasts and easily detectable in MCF-7 cells (dilution 
factor 1:3).
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